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Endothelial cells (ECs) have a well-established role in the maintenance of 
vascular physiology. Moreover, ECs participate in many physiological 
processes such as angiogenesis, blood homeostasis, inflammatory response, 
lipid metabolism and many more. Angiogenesis is one of the most studied 
functions of endothelium, where ECs participate in the formation of the new 
blood vessels. Additionally, ECs can also exhibit a form of plasticity called 
endothelial-to-mesenchymal transition (EndMT), which is characterized by 
the loss of endothelial-specific morphology and markers and acquisition of 
mesenchymal-like phenotype. Both angiogenesis and EndMT can be regulated 
by physiological cues, such as inflammation and haemodynamic forces, as 
well as number of molecular stimuli, such as TGF-β. Interestingly, recent 
evidence suggests that angiogenesis and EndMT can be orchestrated by 
miRNAs. This thesis aims to address the hypothesis that miR-148b is a 
modulator of angiogenesis and endothelial cell plasticity in the form of 
EndMT. 
The preliminary high-throughput miRNA screen has identified miR-148b as a 
strong enhancer of HUVEC proliferation. Subsequent bioinformatic analysis 
and validation demonstrated that TGFB2 and SMAD2 are direct targets of 
miR-148b in ECs. Further experiments using gain- and loss-of-function 
approaches demonstrated that miR-148b regulates EC function. Specifically, 
overexpression of miR-148b enhanced EC migration, proliferation and in vitro 
angiogenesis, whereas its inhibition promoted EndMT, decreasing the 
expression of CD31 and VE-Cadherin and elevating collagen 1. Furthermore, 
inflammatory cytokine challenge decreased miR-148b levels in ECs, 
promoting EndMT, via upregulation of SMAD2, and enhancing reactive 
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oxygen species production, all of which were abrogated by exogenous miR-
148b. Finally, in a mouse model of skin wound healing, delivery of miR-148b 
mimics promoted wound angiogenesis and accelerated wound closure. In 
contrast, inhibition of miR-148b enhanced EndMT in wounds impairing 
wound closure, which is reverted by SMAD2 silencing. 
Together, the data in this thesis supports the hypothesis that miR-148b 
regulates angiogenesis and endothelial cell plasticity, and provides the 
evidence that miR-148b upregulation enhances both in vitro and in vivo 
angiogenesis, while its knockdown promotes EndMT. This thesis 
demonstrates for the first time that miR-148b could be a key factor controlling 
EndMT and vascularization, thus opening a new avenue for therapeutic 














The human body is composed by a complex network of blood vessels, which 
supply every tissue and every organ with nutrients and oxygen. When there 
is a need for new blood vessels, a process is initiated in the body, called 
angiogenesis. From Ancient Greek the word “angio” means vessel while 
“genesis” means creation. During angiogenesis new blood vessels are formed 
from pre-existing vessels, which is important for different processes in the 
body such as development and wound healing. 
This thesis describes a novel role of a small molecule, called microRNA-148b, 
to induce the process of angiogenesis. MicroRNAs are naturally found in the 
body, where they regulate different genes and processes. This study 
demonstrates that microRNA-148b activates the endothelial cells and makes 
them form capillary networks “in a dish” as well as new blood vessels. When 
microRNA-148b is applied on mice surgical wounds, it can accelerates the 
process of wound healing. 
On the other hand, when microRNA-148b is removed, the endothelial cells 
change into different type, mesenchymal cells – a process also known as 
differentiation. This process is harmful and can occur due to chronic 
inflammation, when the immune system is overstimulated. What is more, in 
mice, the loss of micoRNA-148b leads to poor wound healing due to reduction 
in endothelial function. 
In conclusion, the novel findings in this thesis can be used to create new 
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1.1 Endothelial cells and EC plasticity 
1.1.1 Endothelial cell biology 
One of the first organs systems to develop during embryogenesis is 
vasculature, serving as a fundament for correct functioning and survival of all 
other organs in the body. The composition of a blood vessel includes the inner 
and luminal layer, which are formed by endothelial cells, surrounded by a 
vessel wall made from smooth muscle cells. Notably, endothelial cells are the 
first ones to develop during the formation of the blood vessel, which, 
following a rapid expansion, are remodelled into a circulatory network that 
subsequently forms a vasculature within different organ systems such as 
brain, retina, kidney and liver. What is more, vascular endothelium 
participates in development of blood and the heart, where endothelial cells 
also undergo a differentiation, also known as transition, into hematopoietic 
cells as well as cardiac mesenchyme, respectively (Dejana et al., 2017).  
After the gastrulation process is finished in the extraembryonic yolk sac, 
vasculogenesis is initiated, which gives rise to the primordial endothelial cells. 
When mesodermal progenitor cells receive the signal from visceral endoderm, 
they form the endothelial cells, which then merge into vascular plexi that are 
remodelled into capillary networks during angiogenesis. There are number of 
molecular signals that facilitate endothelial cells formation and differentiation. 
Specifically, fibroblast growth factor 2, such as FGF2 and bFGF, and bone 
morphogenic protein 4 (BMP4) not only promote mesoderm formation, but 
also contribute to endothelial cell differentiation (Marcelo et al., 2013). 
Moreover, BMP4 in turn mediates Indian hedgehog (IHH) signalling, which 
drives the development of endothelial cells (Marcelo et al., 2013). One of the 
most potent regulators of vasculogenesis is vascular endothelial growth factor 
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(VEGF-A), which interacts with its receptors, VEGFR1 (Flt-1) and VEGFR2 
(KDR) that is essential for the development of vascular plexus (Chung and 
Ferrara, 2011). Interestingly, embryonic stem cells, isolated from the double 
negative mutant mouse for VEGFR2-/-, can give rise to endothelial cells, but 
they are not able to expand in vitro, suggesting that VEGF-A regulates survival 
and propagation of endothelial cells, rather than differentiation (Dejana et al., 
2017). Furthermore, endothelial cell development is tightly orchestrated by 
transcription factors. Specifically, the majority of the promoters and enhancers 
of endothelial-specific genes contain binding sites for the transcription 
regulators from ETS family (De Val and Black, 2009, Birdsey et al., 2015). 
Notably, ETS variant 2 (Etv2) modulates the cell fate change from mesodermal 
progenitors to endothelial cells (De Val et al., 2008). 
1.1.2 Angiogenesis 
Angiogenesis is defined as a following step of remodelling of the primary 
vascular plexus into the circulatory network as well as formation if new blood 
vessels from pre-existing ones (Risau, 1997). In a healthy adult body, 
endothelial cells are guarded from the stimuli such as VEGF, NOTCH, 
angiopoietin-1 (ANG-1) and FGFs. However, when quiescent endothelial cells 
are subjected to angiogenic signals listed before as well as chemokines released 
by inflammatory, tumour or hypoxic cells, the pericytes, which normally 
surround the endothelium and suppress its proliferation, start to migrate from 
the vessel wall via proteolytic degradation facilitated by matrix 
metalloproteinases (MMPs) (Fig. 1 a) (Carmeliet and Jain, 2011). In particular, 
hypoxia-inducible factor 1α (HIF-1α) makes endothelial cells sensitive to 
angiogenic cues. In addition to the loss of endothelial cell junctions, which are 
normally composed by VE-cadherin and claudins, and the resulting vessel 
dilation, the endothelial cell layer permeability increases in response to VEGF; 
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this in turn facilitates the increased deposition of the extracellular matrix 
(ECM) proteins, which form the scaffold for the migrating endothelial cells 
following the integrin signalling (Fig. 1 a) (Carmeliet and Jain, 2011). Notably, 
one endothelial cell, known as a tip cell, is selected to lead the tip in response 
to stimuli such as VEGF, neuropilins (NRPs), DLL4 and JAGGED1 (Fig. 1.1 a); 
the tip cell is followed by the remodelled and dividing neighbouring 
endothelial cells, which form the elongating stalk in presence of NOTCH 
signalling, WNT, FGFs and placental growth factor (PIGF), and build the 
lumen of the new vessel facilitated by VEGF, hedgehog, CD34, sialomucins 
and VE-cadherin (Carmeliet and Jain, 2011). The filopodia that resides on the 
tip cells facilitates the response to environmental signals such as ephrins and 
semaphorins; on the other hand, the stalk cells release the signals such as 
EGFL1 into the extracellular matrix scaffold in order to provide the positional 
information of the adjacent endothelial cells to promote further stalk 
elongation (Fig. 1.1 b) (Carmeliet and Jain, 2011). The blood flow is established 
following the assembly of the bridge between two nascent vessels made from 
myeloid cells (Fig. 1.1 c); the endothelial cells are then put back into quiescent 
state followed by coverage with pericytes in response to stimuli such as 
transforming growth factor-β (TGF-β), platelet-derived growth factor B 
(PDGF-B), ephrin-B2, NOTCH and ANG-1 (Carmeliet and Jain, 2011). Finally, 
the basement membrane is reassembled as a result of the action of protease 
inhibitors, such as tissue inhibitors of metalloproteinases (TIMPs) and 
plasminogen activator inhibitor-1 (PAI-1), followed by formation of cell-to-cell 
junctions, which ensure the correct blood flow through newly made vessels 




Figure 1.1| Molecular basis of angiogenesis. The key steps of the vessel branching are 
displayed with the key molecules, which facilitate angiogenesis. a. After the stimulation with 
angiogenic stimuli, the quiescent vessel dilates followed by the formation of the tip cell, which 
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directs the subsequent branch formation. The degradation of basement membrane, loosening 
of endothelial cell junctions and pericytes detachment are needed for tip cell assembly. 
Enhanced permeability of the endothelium contributes to the deposition of ECM proteins and 
formation of the scaffold. b. Tip cells follow the navigation of the angiogenic signals and attach 
to ECM in order to migrate. The lumen is formed by the stalk cells that proliferate and elongate 
resulting into fusion of the sprouts that form the nascent vessel. c. Following the joining of the 
neighbouring branches, the blood flow is established and the endothelial cells become 
quiescent (reproduced with permission from Carmeliet and Jain 2011). 
There is a direct link between inflammation and endothelial cell biology as 
well as angiogenesis. The first evidence of the association between 
inflammation and angiogenesis came from the study in 1995, where it was 
demonstrated that the infiltrating monocytes, associated to capillary sprouting 
after microembolization in the ischemic porcine myocardium, express the 
proangiogenic insulin growth factor-1 (IGF-1) (Kluge et al., 1995). Under 
ischemic conditions, the inflammatory cells start to secrete proangiogenic 
stimuli, such as VEGF and TNF-α, which lead to an increase in vascular 
permeability as well as attract more inflammatory cells (Grivennikov et al., 
2010, Costa et al., 2007, Eltzschig  and Carmeliet 2011, Konisti et al., 2012). 
Moreover, leukocytes and macrophages are able to secrete MMPs, 
plasminogen and cathepsins, which facilitate the remodelling of extracellular 
matrix allowing the formation of neovessels (Rüegg, 2006, Kundu and Surh, 
2012). Another link between inflammation and angiogenesis is a production 
of reactive oxygen species (ROS) by inflammatory cells, which can acutely 
promote angiogenesis (Reuter et al., 2010, Guzik et al., 2003). 
1.1.3 Models for evaluation of angiogenesis 
In the past 20 years a significant progress has been made in generation of in 
vitro methods to analyse angiogenesis. The most widely used approach is the 
model of endothelial cells tubulogenesis, in which ECs form tube structures 
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and cellular networks in 3D matrixes, such as type I collagen and fibrin 
(Simons et al., 2015). In short, endothelial cells are seeded into 3D matrix that 
come together and assemble into tubes with a lumen; the tubes then can be 
analysed using electron and confocal microscopy. Notably, tube formation 
also produces physical tunnel spaces within the 3D matrix which are 
generated by the action of MT1-matrix metalloproteinase that degrades the 
extracellular matrix (Davis et al., 2011). Alternatively, another in vitro method 
is a sprouting model, which involves seeding endothelial cells into a collagen 
or fibrin matrix to facilitate sprouting and lumen-forming capillary-like 
structures formation (Simons et al., 2015). This process can be assisted by 
coating endothelial cells with microcarrier beads, which enables the 
visualization of endothelial cell growth over time (Nehls and Drenckhahn, 
1995). One of the most reproducible in vitro angiogenic assays is a 2D sprouting 
assay using a rich in laminin Matrigel matrix, which allows endothelial cells 
to form capillary-like lumenless structures (Ponce, 2009). 
In terms of in vivo methods, one of the most easy to manipulate, visual and 
physiologically significant postnatal angiogenic assays is a wound healing 
model (Simons et al., 2015). Wound healing is a tightly organised physiological 
reparative response to the skin injury and involves a cascade of complex and 
synergic cellular processes such as hemostasis, inflammation, proliferation 
and remodelling. Angiogenesis plays a crucial role during the proliferative 
stage of wound healing, which supplies the granulation tissue with oxygen 
and nutrients. Notably, the change in vessel density during the wound repair 
is in a form of a bell-shaped curve. Specifically, during intense wound healing 
angiogenic response is very strong peaking at ~5 days post-injury, where 
vessel density is many-fold higher than in uninjured skin; moreover, after the 
healing processed is finished the vascular density returns to control levels 
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(Simons et al., 2015). In a mouse model of punch wound repair (Dunn et al., 
2013), the vascularization is the most elevated in a period between 4 and 8 days 
post-injury, thus before and during this peak the model of wound healing 
represents the angiogenic response (Simons et al., 2015). Moreover, the 
inflammatory stage of the healing is to be under stringent control as excessive 
or prolonged inflammatory response is detrimental for the healing process. 
Failure in regulation of angiogenesis and inflammation during wound healing 
causes poor wound closure and might lead to skin ulceration. 
1.1.4 Endothelial-to-mesenchymal transition 
In a healthy blood vessel, the endothelial cell is maintained endothelial via a 
number of different mechanisms and signalling pathways. Spacial localization 
of the endothelial cell strongly determines the endothelial phenotype. A 
quiescent endothelial cell resides in the tight contact with neighbouring 
endothelial cells via receptors such as VE-Cadherins, CD31 and VEGFR2 as 
well with the basement membrane via the integrins α/β. The integrins, in turn, 
activate FAK/ILK cascade, promotes endothelial cell homeostasis (Fig. 1.2) 
(Krenning et al., 2016).  Moreover, the signalling via ALK1/TGFβR2 in 
response to the binding of the ligands, including TGF-β and BMPs, induces 
the phosphorylation of SMAD1/SMAD5 complex, which maintains the 
endothelial cell function, such as angiogenesis (Fig. 1.2) (Gonzalez-Nunez et 
al., 2013). Importantly, shear stress induced by the blood flow is another strong 
modulator of the endothelial fate. When endothelial cells are subjected to 
laminar shear stress, it is sensed by the mechanoreceptors, which activate 
MEK5-ERK5-MEF2 signalling cascade that, in turn, promotes the expression 
of KLF2 transcription factor leading to endothelial phenotype maintenance 
(van Thienen et al., 2006).  
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On the other hand, endothelial-to-mesenchymal transition (EndMT) is a 
process by which endothelial cells lose their endothelial specific markers and 
acquire mesenchymal-like phenotype (Piera-Velazquez and Jimenez, 2012). 
Specifically, EndMT is characterized by the loss of endothelial cell markers 
such as VE-cadherin (VE-cad), von Willebrand factor (vWF) and platelet-
endothelial cell adhesion molecule 1 (PECAM-1, CD31), and elevated 
expression of α-SMA, vimentin, N-cadherin and extracellular matrix (ECM) 
proteins such as collagen type I and III (Table 1) (Arciniegas et al., 2007). What 
is more, during the process of EndMT, the endothelial cells exhibit 
cytoskeleton rearrangement resulting in a change in cell polarity and leading 
to acquisition of stretched and more fibroblast-like morphology (Arciniegas et 
al., 2007). As a consequence, these phenotypical and morphological alterations 
during EndMT lead to the disruption of endothelial cell monolayer.  
Depending on the final EndMT markers, which are expressed by the 
differentiated cells, it is now believed that the transition program has three 
possible outcomes: mesenchymal cells, fibroblasts and smooth muscle cells 
(Fig. 1.2). Specifically, mesenchymal “stem” cells start to express proteins such 
as FSP1 and Sca1; fibroblasts become enriched in fibronectin, N-cadherin, 
vimentin and collagen (mostly type I and III); smooth muscle cells acquire 
markers of cytoskeleton rearrangement such as α-SMA, SM22α as well as 
smooth muscle-specific calponin (SM-calponin) and Notch3 (Table 1) (Chen 






Markers of EndMT 
Downregulated Upregulated 
CD31, VE-Cadherin, eNOS, von 
Willebrand factor (vWF), Tie-1, Tie-2 
α-SMA, Sca1, Vimentin, Collagen I/III, 
FSP-1, SM22α, N-Cadherin, SM-
calponin, Fibronectin, Notch3, MMP2, 
MMP9, VCAM, ICAM1 
Table 1| Selected markers of EndMT. (Dejana et al., 2017, He et al., 2013) 
It is widely accepted that transforming growth factor beta (TGF-β) is the main 
inducer of EndMT, which binds to its heteromeric receptor (TGFβR), 
consisting of activin-like kinase 5 (ALK5, also known as TGF-β type I receptor, 
TGFBR1) and the TGFβ type II receptor (TGFBR2); ALK5 phosphorylation 
triggers formation Smad 2/3/4 complex and its translocation to the nucleus 
where it induces EndMT gene expression (van Meeteren and ten Dijke, 2012) 
(Fig. 1.2).  
The first claim that endothelial cells enter the process of endothelial-to-
mesenchymal transition was made by Arciniegas et al. (Arciniegas et al., 1992), 
who has demonstrated that bovine aortic endothelial cells (BAEC) are able to 
differentiate into smooth muscle cells (SMCs) in vitro. The study showed that 
stimulation with TGF-β1 facilitated the expression of α-SMA and loss of 
coagulation factor VIII (FVIII) in the endothelial cells (Arciniegas et al., 1992). 
Notably, TGF-β1-induced EndMT is firmly modulated by the transcription 
factors Snail and Slug and occurs partially via TGF-β receptor 1 (TGF-βR1), 
due to the fact that its inhibition by small molecule drug can to decrease but 
not stop the transition program (Diez et al., 2010). Similarly, TGF-β2 is able to 
promote EndMT program in Snail-mediated manner and lead to 
downregulation of endothelial-specific markers and increase in smooth 
muscle cell-specific proteins such as α-SMA, SM22-α and calponin (Kokudo et 
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al., 2008). It is important to point out that TGF-β2 can switch on the EndMT 
program in endothelial cells via activation of Smad signalling pathway; the 
induction of this cascade in turn leads to overexpression of Snail transcription 
factor (Medici et al., 2011). Both TGF-β1- and TGF-β2-induced transition 
programs can be inhibited by the action of FGF signalling, which occurs via 
FGF receptor (FGF-R) and its adaptor FRS2. In particular, the silencing of FRS2 
in human umbilical artery endothelial cells (HUAECs) led to elevation in the 
expression of markers of smooth muscle cells such as α-SMA, SM22-α, SM-
calponin and Notch3; moreover, the levels of both mediators of EndMT, TGF-
β1 and TGF-β2, were upregulated (Chen et al., 2012).  
 
 
Figure 1.2| Stimuli determining EC behaviour and EndMT. The cell-to-cell contact between 
the ECs via interactions of VE-Cadherins, CD31 as well as VEGFR2 maintains the endothelial 
phenotype. The signalling pathway TGFβR2/ALK1, upon the interaction with the ligand such 
as TGF-β, induces the activation of SMAD1/SMAD5 leading to the maintenance of the 
endothelial homeostasis. Endothelial cells’ spacial sensing of the basement membrane via the 
integrins α/β induces FAK/ILK signalling, enhancing the endothelial characteristics. The 
molecular cascade TGFβR-Smad2/Smad3 upon interaction with the ligands, BMP6 and 
TGFβ1/TGFβ2, lead to induction of EndMT program. The inflammatory pathways induced by 
TNF-α and IL-1β actvates the NF-κB signalling, which promotes EndMT. The shear stress 
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induced by laminar blood flow is sensed by mechano-receptors leading to the induction of 
MEK5/ERK5/MEF2 cascade, promoting KLF2 expression, which enhances the endothelial cell 
phenotype and blocks EndMT. 
Specifically, FGF signalling via its receptor, FGFR1, induces the expression of 
let-7 miRNA, which directly targets TGFβR and inhibits its expression, leading 
to the blockage of the EndMT program (Fig. 1.2) (Chen et al., 2012); 
inflammation and shear stress are strong modulators of FGFR1, which can 
reactivate EndMT via silencing of the receptor.  
In addition, to the discussed above inducers of EndMT, there are other known 
modulators of transition program such as miRNAs (Ghosh et al., 2012a), shear 
stress (Moonen et al., 2015) and inflammation (Perez et al., 2017). In particular, 
it has been recently shown that inflammatory cytokines, such as tumour 
necrosis factor alpha (TNF-a) and interleukin-1 beta (IL-1β), can trigger 
EndMT process via binding to their receptors, TNF-R and IL-R1 respectively, 
and inducing NF-κB translocation to the nucleus, where it drives the 
expression of EndMT-specific genes (Fig. 1.2) (Mahler et al., 2013, Chaudhuri 
et al., 2007, Arciniegas et al., 2008). Romero et al. has demonstrated for the first 
time that IL-1β is able to facilitate phenotypic changes in endothelial cells such 
as acquisition of spindle-shaped morphology, cytoskeleton rearrangements 
and loss of endothelial-specific CD31 and von Willebrand factor markers 
(Romero et al., 1997); these findings were then validated by a number of 
studies stating that IL-1β can induce EndMT (Rieder et al., 2011, Maleszewska 
et al., 2013). Similarly, TNF-α has been reported to activate EndMT program 
in the endothelial cells via activation of NF-κB signalling (Mahler et al., 2013). 
Notably, both IL-1β and TNF-α are able to promote skin fibrosis (Romero et 
al., 1997, Chaudhuri et al., 2007). 
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Importantly, the presence of high laminar shear stress attenuates EndMT 
program via expression of KLF2 transcription factor (Fig. 1.2). As a result, 
EndMT can only occur when the endothelial cells within the blood vessel are 
subjected to the low shear stress, mainly via Snail upregulation (Mahmoud et 
al., 2017). 
Notably, EndMT can occur as a partial or a complete transition. Partial or early 
EndMT is characterized by the downregulation or partial loss of endothelial-
cell specific markers and dismantled adherens junctions as well as by the 
acquisition of early mesenchymal markers, such as αSMA, SM22α and Fsp1. 
On the other hand, a complete or late EndMT is characterized by a strong 
downregulation or complete loss of endothelial markers and upregulation of 
late mesenchymal or fibroblast markers, such as SM-calponin, Fibronectin, 
Collagen III, Vimentin, Notch3, SCA1, ZEB2, MMP2 and 9, VCAM and ICAM1 
(Dejana et al., 2017). It could be speculated that a partial EndMT can be 
reverted, when the cells are subjected to pro-endothelial stimuli and laminar 
shear stress, whereas the cells, which entered a complete transition program 
will remain mesenchymal. 
1.1.3 Endothelial-to-mesenchymal transition in cardiovascular disease 
This thesis discusses the literature on EndMT at the point the current study 
was initiated. During the last four decades, EndMT has been reported to play 
an important role in cardiac as well as pulmonary artery development during 
the embryonic stages by promoting endothelial cells to maintain a 
mesenchymal-like state (Krug et al., 1985, Armstrong and Bischoff, 2004, 
Arciniegas et al., 2005). However, it has been recently demonstrated that 
EndMT occurs in adults as well by showing that mature bovine endothelial 
cells can differentiate into smooth muscle cells (Frid et al., 2002). Moreover, 
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currently it is believed that EndMT plays an important role in pathological 
conditions such as cancer progression and organ fibrosis. Specifically, 
Zeisberg et al. showed that not only does EndMT participate in promoting 
tumour growth and progression, but also in generation of fibroblasts in vivo in 
mouse model of cardiac fibrosis (Zeisberg et al., 2007a, Zeisberg et al., 2007b). 
What is more, it has been reported that detrimental consequences of EndMT, 
such as impaired endothelial cell junctions, loss of cell polarity and enhances 
migratory ability (Kalluri and Weinberg, 2009), lead to cardiovascular 
disorders including atherosclerosis (Chen et al., 2015), neointima formation 
(Chen et al., 2012), cavernous cerebral malformations (CCM) (Maddaluno et 
al., 2013) and tissue fibrosis (Piera-Velazquez et al., 2011). 
Recently, EndMT process has been assigned to be involved in atherosclerotic 
lesions as well as in transplant atherosclerosis, which both share the same 
feature, which is a formation of neointima that is primarily composed of a 
combination of immune and inflammatory cells, smooth muscle cells, 
fibroblasts and extracellular matrix (Dejana et al., 2017). Together, they are 
strongly induced by chronic vascular inflammation resulted from mechanical 
forces as well as deposition of lipids during atherosclerosis (Baeyens and 
Schwartz, 2016) and immune mismatches in the case of transplant 
artheriopathy (Tellides and Pober, 2015). Strikingly, it has been reported that 
in a mouse acute transplant rejection model, 80% of neointimal and 60% 
luminal endothelial cells were enriched in EndMT markers; in addition to that, 
almost 80% of coronary artery luminal endothelial cells from the rejected 
hearts of the patients were exhibiting EndMT program (Chen et al., 2012). 
What is more, EndMT was also confirmed in coronary (Evrard et al., 2016) as 
well as carotid artery atherosclerotic plaques (Moonen et al., 2015). 
Interestingly, a solid association has been observed between the severity of 
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coronary artery disease and the level of EndMT being exhibited by luminal 
endothelial cells in the coronary artery (Evrard et al., 2016). 
Another serious cardiovascular disorder is the cardiac fibrosis, which can 
ultimately lead to pathologies such as hypertension and ischemic heart 
disease. On itself, cardiac fibrosis can affect the cardiac output due to distorted 
relaxation of the heart chambers (Dejana et al., 2017). There is still a major 
debate on the exact origin of the cardiac fibroblasts (Kong et al., 2013). The 
study using lineage tracing mice has confirmed that EndMT occurs during 
heart fibrosis (Zeisberg et al., 2007b); however, it has been later reported that 
EndMT is not the major contributor for cardiac fibroblasts (Moore-Morris et 
al., 2014). 
Cavernous cerebral malformations is a serious vascular condition that targets 
venous microvasculature in retina and central nervous system; due to the fact 
that malformations lack the integrity from mural cells, they often bleed and 
lead to a range of neurological disorders from headaches to stroke (Fischer et 
al., 2013). The prevalence of CCM is just 0.5% of world population and can be 
in a hereditary or sporadic form (Dejana et al., 2017). The genetic form of the 
disease is an autosomal dominant disorder characterized by the loss-of-
function of Ccm 1(Krit1), Ccm 2 (Osm) and Ccm 3 (Pdcd10) genes, with the sole 
treatment being a neurosurgery (Draheim et al., 2014). The studies, utilizing a 
mouse model with endothelial-specific aberration of any of three of the genes, 
have reported that inactivation of Ccm1 or Ccm3 leads to loss of cell-to-cell 
junctions and EndMT phenotype in the luminal endothelium in cavernomas; 
in particular, this phenotypic transitional program can be associated with 
CCM disease characteristics, as the EndMT-related disorganisation of 
endothelium contributes to the generation of disordered lumen of cavernomas 
(Maddaluno et al., 2013, Bravi et al., 2015).  
34 
 
1.2 TGF-β pathway 
1.2.1 Characterization of TGF-β pathway 
Transforming growth factor‑β (TGF-β) signalling exerts a number of 
important roles on mammalian cells, ranging from regulation of development 
and differentiation to modulating cellular responses. After the introduction of 
TGF-β signalling, there was some ambiguity about pathway; the downstream 
effects of TGF-β differed between cell types and environments with the 
stronger association with cellular context (Massague, 2012). Eventually, the 
mechanism of the pathway was mostly uncovered with TGF-β receptor system 
and SMAD transducers, which also act as a substrate for the receptors; 
moreover, disease-causing mutations in the cascade were identified that 
highlighted the medical importance of TGF-β pathway (Massague, 2012). It is 
now clear that the pathway plays a vital role in the processes of inflammation, 
immunity, fibrosis, cancer and homeostasis (Massague, 2012). 
The main regulatory method of TGF-β signalling is modulation of gene 
expression, which range from a couple of genes in pluripotent ES cells to 
numerous in differentiated cells; moreover, the effect of the signalling cascade 
can be either positive or negative, depending on the cell type and target genes 
(Mullen et al., 2011). The versatile mode of TGF-β-based regulation of gene 
expression is demonstrated by the fact that the inhibitor of differentiation 1 
(ID1) is downregulated by TGFβ in epithelial cells (Kang et al., 2003); on the 
other hand, TGF-β upregulates ID1 expression in metastatic breast cancer cells 
(Padua et al., 2008). 
There are more than 30 members of TGF-β family in humans, the orthologues 
of which can be traced to metazoans (Huminiecki et al., 2009). The complexity 
of the TGF-β signalling cascade is demonstrated on the Figure 1.3 Upon 
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binding of the TGF-β ligand, the TGF-β receptor complex is assembled from 
the signal propagating type I component and the activator type II component 
(Fig. 1.3), which are both Ser/Thr protein kinases (Massague, 2012). In total, 
there are seven type I and five type II receptors in human organism. Following 
the assembly, TGF-βR2 phosphorylates the type I receptor, which activates the 
signalling cascade (Fig. 1.3) (Wrana et al., 1994). Specifically, the 
phosphorylation results in replacing the occupied by FKBP12, kinase silencer, 
site on TGF-βR1 with SMAD proteins, promoting their phosphorylation (Huse 
et al., 2001). Phosphorylated SMAD transcription factors promote the 
expression of transcriptionally active genes, but are also able to open the 
silenced chromatin (Fig. 1.3) (Massague, 2012). SMAD proteins are constituted 
by MH1 and MH2 domains; MH1 contains DNA-binding moiety while MH2 
mainly interacts with cytoplasmic adaptor proteins, phosphorylated TGF-β 
receptors and various transcription factors (Massague, 2012). Different types 
of SMADs are activated by different phosphorylated receptors: SMAD1, 
SMAD5 and SMAD8 are activated by BMP type I receptors (such as ALK1) 
while SMAD2/SMAD3 are phosphorylated by TGF-β type I receptor (such as 
ALK5), activin and Nodal (Fig. 1.3) (Massague, 2012). Specifically, 
phosphorylation of SMAD2/SMAD3 (receptor-regulated SMAD proteins (R-
SMAD proteins)) produces a knob on its MH2, which interacts with MH2 of 
SMAD4 protein resulting in the assembly of the functional unit that drives 
gene expression assisted by context-dependent transcription factors 
(Massague, 2012). Interestingly, activated SMAD2/SMAD3 can also interact 
with TRIM33, which is a histone-binding protein (He et al., 2006). The complex 
signalling pathway is regulated by different miRNAs, which target the main 






Figure 1.3| Canonical TGF-β signalling cascade. A hetero-tetrameric TGF-β receptor 
complex is assembled consisting of two subunits of type I and two subunits of type II 
components upon interaction with activated TGF-β ligands. The signal propagator subunit I 
then phosphorylates the SMADs. Activated SMADs can then form a transcriptional complex 
with SMAD4 and other transcription factors, which regulates the expression of specific genes. 
The whole signalling network is tightly regulated by miRNAs. 
In addition to protein interaction domains, TRIM33 also possesses a plant 
homeodomain as well as bromodomain, which both are able to interact with 
histones and transduce TGF-β signals via chromatin opening (Xi et al., 2011). 
Furthermore, SMAD proteins also play important role in modulating miRNA 
biogenesis. In particular, in human vascular smooth muscle cells (VSMC), 
phosphorylated SMAD3 is able to bind DDX5 RNA helicase, which is a part of 
miRNA microprocessor Drosha; as a result, this leads to enhanced processing 
of primary transcript of miR-21 (pri-miR-21) into precursor miR-21 (pre-miR-
21), which in turn upregulates cellular miR-21 levels and downregulated its 
target gene PDCD4 thereby inducing the contractile phenotype of VSMCs 
(Davis et al., 2008). 
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miRNA Target Reference 
miR-21 SMAD7 (Liu et al., 2010) 
miR-101 TGFβR1 (Huang et al., 2017) 
miR-326 SMAD3 (Das et al., 2014) 
miR-27b TGFβR1, SMAD2 (Zeng et al., 2017) 
miR-26a SMAD4 (Liang et al., 2014) 
miR-489 SMAD3 (Wu et al., 2016) 
miR-9-5p TGFβR2 (Fierro-Fernandez et al., 
2015) 
miR-199a SMAD1 (Lin et al., 2009a) 
miR-200a TGF-β2 (Lu et al., 2015) 
Table 2| Regulation of TGF-β signalling pathway by miRNAs. 
1.2.2 TGF-β pathway and angiogenesis 
The role of TGF-β in regulating angiogenesis is quite contradictory. In fact, the 
effect of TGF-β on angiogenic response seems to be dose-dependent: 
specifically, TGF-β increases endothelial cell proliferation at low dose, but 
attenuates EC proliferation at high doses (Viloria-Petit et al., 2013). The dual 
effect of TGFβ on angiogenesis can be explained by the interchange between 
ALK1 and ALK5 type I receptors. Specifically, ALK1 activation promotes 
endothelial cell proliferation as well as migration at the initial phase of 
angiogenesis; this effect is achieved through upregulation of Id1 protein, 
which is required for migration and proliferation (Goumans et al., 2002). On 
the other hand, ALK5 exerts anti-proliferative effect on the angiogenesis; in 
vitro studies have shown that in endothelial cells ALK5 activation leads to 
induction of plasminogen activator inhibitor (PAI)-1, which promotes vessel 
maturation by attenuating the degradation of extracellular matrix around the 
growing vessel (Goumans et al., 2002). What is more, while there is much 
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evidence that ALK1 facilitates endothelial cell sprouting, it has been 
demonstrated that ALK5 pathway makes endothelial cells less sensitive to 
VEGF stimulus that is important for the resolution step of angiogenesis 
(Viloria-Petit et al., 2013). Nevertheless, some studies report that ALK1 exerts 
anti-proliferative and anti-migratory effects on endothelial cells (Lamouille et 
al., 2002), which is possibly due to differential regulation in different cell types 
(Holderfield and Hughes, 2008). Thus, it is clear that the balance between 
ALK1 and ALK5 is vital for the regulation of angiogenesis. 
1.2.3 TGFβ pathway in cardiovascular disease 
The cardiovascular system (CVS) is tightly regulated by the proteins in TGF-β 
superfamily: specifically, by TGF-β1, TGF-β2, BMP4, BMP6 and BMP7, which 
are highly expressed in CVS (Bobik, 2006). It is quite evident that TGF-β 
superfamily is vital for cardiovascular development because knock-out mice 
for members such as TGFB1, TGFB2, TGFBR3 and SMAD4 are embryonic 
lethal due to cardiac defects as well as high inflammatory response in the heart 
(Kulkarni and Karlsson, 1993, Sanford et al., 1997, Stenvers et al., 2003, 
Compton et al., 2007).  
In particular, Hereditary Hemorrhagic Telangiectasia (HHT), a disorder 
characterized by vascular dysplasia, telangiectasia as well as arteriovenous 
malformations, is caused by mutation in co-receptor endoglin (ENG) and 
ALK1 (Fernandez et al., 2006). Patients affected by HHT develop skin 
telangiectases, nose bleeds, gastrointestinal bleeding, neurological disorders, 
as a consequence of arteriovenous malformations, as well as heart failure 
(Shovlin and Letarte, 1999). The disease has two forms, HHT1 and HHT2, 
which account for almost 80% of all cases; HHT1 type occurs as a result of ENG 
mutation is associated with pulmonary, hepatic and cerebral arteriovenous 
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malformations while HHT2 is caused by ALK1 mutation and is characterized 
by vascular liver disorders (Gordon and Blobe, 2008, Fernandez et al., 2006). It 
is also speculated that mutation in SMAD4 makes up remaining 20% of the 
cases of HTT (Abdalla and Letarte, 2006). 
Alterations in TGF-β signalling are also responsible for disorders within the 
aorta. Specifically, somatic mutations in the serine/threonine kinase domains 
of TGFBR1 and TGFBR2 genes cause Loeys-Dietz syndrome, which is 
characterized by aortic aneurysms, arterial dissections, widely spaces eyes, 
cleft palate, general arterial tortuosity and structural brain abnormalities 
(Loeys et al., 2005). Similarly, familial thoracic aortic aneurysm syndrome 
(TADD) is caused by the germline mutations in TGFBR2 kinase domain and 
TGFBR1 cytoplasmic domain and leads to massive arterial aneurysms, severe 
aortic dissection and, ultimately, significant blood loss (Pannu et al., 2006, 
Matyas et al., 2006). Finally, arterial tortuosity syndrome (ATS) causes 
elongation of major arteries, general tortuosity and hyperflexibility of joints 
and is a result of GLUT10 loss-of-function mutations, which upregulate the 
TGF-β pathway in arterial wall (Coucke et al., 2006). 
Furthermore, dysregulation in TGF-β cascade is responsible for the primary 
pulmonary arterial hypertension (PAH), which can cause cardiac arrest due to 
remodelling of small pulmonary arteries, increased arterial pressure and right 
ventricular heart failure (Gordon and Blobe, 2008, Eddahibi et al., 2002). 
Pulmonary arterial hypertension exists in two forms: idiopathic PAH (IPAH) 
and familial PAH (FPAH); both variants of disease are associated with 
heterozygous germline mutation in BMPR2 (Machado et al., 2006). 
TGF-β signalling plays important role in biology of atherosclerosis, which is 
characterized by endothelial dysfunction, accumulation of lipids, vascular 
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inflammation, increased oxidation and cellular debris, which lead to formation 
of plaques within the arteries (Gordon and Blobe, 2008). Atherosclerosis acts 
as a major cause of cardiovascular disease, stroke and myocardial infarction. 
Moreover, the expression pattern of the members of TGF-β cascade is very 
prevalent in the cells contributing to the formation of the plaque: smooth 
muscle cells, endothelial cells, macrophages and T-cells (Bobik et al., 1999b). It 
is interesting to note that the role of TGF-β cascade remains controversial in 
the setting of atherosclerosis: there is little evidence supporting pro-
atherosclerotic action of TGF-β pathway (Bobik et al., 1999a, Tang et al., 2013), 
while most findings demonstrate that TGF-β signalling is in fact inhibiting the 
progression of atherosclerosis. In particular, activation of TGF-β pathway is 
sufficient to attenuate the proliferation as well as migration of endothelial cells 
and vascular smooth muscle cells and is able to decrease the immune response 
(Gordon and Blobe, 2008). It has been demonstrated before that upregulation 
of TGF-β signalling by tamoxifen inhibits the formation of atherosclerotic 
plaques (Grainger et al., 1995). On the other hand, inhibition of TGF-β cascade 
using neutralizing anti-TGF-β1, -β2 and -β3 antibodies facilitates the 
development of atherosclerotic lesions and weakens the stability of the 
plaques (Mallat et al., 2001). In fact, TGF-β1 is able to stabilize atherosclerotic 
plaques due to promoting the production and release of collagen (Cipollone et 
al., 2004). 
The last example, which is important to mention are fibrotic diseases as a result 
of poor TGF-β signalling regulation. Fibrosis is complex tissue disorder, which 
is characterized by excessive expression and secretion of extracellular matrix 
(ECM) proteins, such as collagen, fibronectin, vitronectin and laminin, and by 
activation and recruitment of myofibroblasts (Gordon and Blobe, 2008, 
Verrecchia and Mauviel, 2007). In particular, myofibroblasts get differentiated 
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from fibroblasts during the process of wound healing (Krieg et al., 2007). In 
this case if extracellular matrix proteins get accumulated in vital organs such 
as kidney, liver, skin and lungs, it can ultimately cause organ failure. 
Specifically, it has been shown that in a mouse model of scleroderma, which 
is characterized by early inflammation and vascular injury, followed by 
progressive fibrosis, deletion of SMAD3 is able to decrease collagen deposition 
and attenuate skin fibrosis (Lakos et al., 2004). 
1.3 MiRNA 
1.3.1 MiRNA biogenesis 
MicroRNAs (miRNAs) are short non-coding RNAs (ncRNAs) of ~22 
nucleotides that facilitate gene silencing through interaction with 3′ 
untranslated region (UTR) of the target mRNAs. MiRNAs bind 3’ UTR of the 
mRNAs primarily through Watson–Crick pairing between by the miRNA 
“seed region”, which is usually 7-8 nt long facilitating target recognition. 
Moreover, miRNAs are assembled into families based on their target genes 
profile and its specificity depends on the miRNA seed region (Bartel, 2009).  
MiRNAs are the most abundant small RNAs in somatic tissues. In humans, 
the largest part of miRNA are encoded within the introns of coding and non-
coding sequences in the genome; nevertheless, a small portion of miRNAs is 
encoded in exons (Ha and Kim, 2014). In particular, miRNAs that are found in 
the introns of protein-coding genes can be transcribed from the same promoter 
as a host gene; it has been also demonstrated that sometimes miRNA possess 
more than one transcription start site (Ozsolak et al., 2008) and can be also 
transcribed by a promoter different from the gene they reside in (Monteys et 
al., 2010). Commonly, miRNAs are transcribed by RNA polymerase II (Pol II) 
and the process is regulated by RNA Pol II-related transcriptional regulators 
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(Lee et al., 2004); moreover, some viral miRNAs can also be transcribed by 
RNA polymerase III (Pfeffer et al., 2005). The product of the transcription is a 
long primary miRNA (pri-miRNA) almost 1 kb in length and is composed of 
stem-loop structure (Fig. 1.4). Moreover, a number of miRNAs can be 
transcribed as one pri-miRNA, if they reside in close proximity and at the same 
cluster genomically (Gebert and MacRae, 2019). 
 
Figure 1.4| Canonical miRNA biogenesis pathway. Primary miRNA transcript (pri-miRNA) 
is transcribed in the nucleus by RNA polymerase II or III and can originate from miRNA 
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coding gene or from an intron. Microprocessor complex consisting of Drosha and DGCR8 
(Pasha) proteins then cleaves pri-miRNA into a precursor pre-miRNA, which is then exported 
into cytoplasm by Exportin-5-Ran-GTP. A cytoplasmic pre-miRNA is then bound by 
Dicer/TRBP complex and cleaved into a double-stranded miRNA molecule. After that, one of 
the strands is loaded with Argonaute (Ago) to generate a RNA-induced silencing complex 
(RISC), which can silence the expression of the gene via degradation of its mRNA via 
deadenylation or repression of translation. Modified from (Winter et al., 2009). 
After that, pri-miRNA is bound by RNase III enzyme Drosha, which crops the 
stem-loop construct and generates smaller precursor miRNA (pre-miRNA) 
molecule that has a hairpin shape and consists of around 65 nucleotides (Fig. 
1.4) (Lee et al., 2003). Specifically, this step is achieved after formation of 
Microprocessor complex, which consists of Drosha and its partner protein 
DGCR8 (Pasha). The next step after precursor miRNA processing, pre-miRNA 
is exported into cytoplasm to initiate the further maturation step. Transport 
complex is formed by exportin 5 protein, which specifically bind dsRNA, GTP-
binding nuclear cofactor, Ran-GTP, and pre-miRNA (Fig. 1.4); after construct 
is translocated through nuclear pore complex, the GTP is hydrolysed, which 
induces the disassembly of the pre-miRNA-protein complex and release of 
pre-miRNA into cytoplasm (Fig. 1.4) (Bohnsack et al., 2004, Lund et al., 2004). 
Once cytoplasmic, pre-miRNA is bound by Dicer enzyme, which produces a 
smaller double-stranded miRNA molecule (Knight and Bass, 2001) (Fig. 1.4); 
moreover, Dicer interacts with TAR RNA-binding protein (TRBP), which 
regulates the cleavage and guides the proper length of miRNA duplex (Fig. 
1.4) (Fukunaga et al., 2012). The mature miRNA comprises a 5p strand, which 
is generated from the 5′ arm of the pre-miRNA hairpin and a 3p strand, arising 
from the 3’ arm (Gebert and MacRae, 2019). Finally, the processed double-
stranded miRNA is bound by Argonaute protein generating RNA-induced 
silencing complex (RISC) (Fig. 1.4). Interestingly, in humans there is no 
44 
 
stringent sorting system and the majority of miRNA duplexes can interact 
with all four AGO proteins (AGO1-4) (Huntzinger and Izaurralde, 2011). The 
AGO-bound miRNA duplex is then unwinded and the 5p or 3p strand is 
selected and incorporated into mature RISC complex. It is important to point 
out, that Ago-independent miRNA strand is not always cleaved that the new 
findings suggest that both 5p or 3p strands of many miRNAs can be detected 
in different types of tissues; moreover, miRNA that have more than one 
sequences in the genome can have both strands, which are processed 
independently (Meijer et al., 2014). Moreover, AGO proteins are subjected to 
a number of post-translational modification with phosphorylation being the 
best characterized one. In particular, Ser387-specific phosphorylation of 
human Ago2 enhances miRNA activity by facilitating miRISC generation 
(Lopez-Orozco et al., 2015). On the other hand, Tyr393-specific 
phosphorylation of Ago2 attenuates the assembly of the miRISC function 
(Yang et al., 2014). Similarly, Ago2 phosphorylation on Tyr529 also prevents 
loading of miRNA into Ago2, due to the fact that Tyr529 interacts with the 5′ 
phosphate and first nucleotide of miRNAs undergoing the loading (Rudel et 
al., 2011, Schirle and MacRae, 2012). The mature RISC-bound miRNA 
molecule is then involved in post-transcriptional gene silencing. The target 
recognition occurs via binding between miRNA seed sequence and 3’ UTR of 
target mRNA. In some instances, miRNA seed sequence can also bind to the 
5’ UTR as well the open reading frame (OFR) of the mRNA (Bartel, 2018). 
Specifically, miRNA can silence gene expression via degradation of its target 
mRNA or by repression of translation (Fig. 1.4). It has been demonstrated that 
mRNA degradation accounts for 66-90% of miRNA-modulated gene silencing 
(Jonas and Izaurralde, 2015). During this process, the target mRNA is first 
deadenylated by PAN2-PAN3 and CCR4-NOT deadenylase complexes 
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(Wahle and Winkler, 2013), followed by decapping by DCP2; the pathway is 
finished by mRNA degradation by the major cytoplasmic nuclease XRN1 
(Fabian and Sonenberg, 2012). Translational repression, on the other hand, 
accounts for 6-26% of miRNA-induced gene silencing (Eichhorn et al., 2014). 
The mechanism behind this process has been unclear for many years, however 
the ribosome profiling has shown that translational repression is achieved due 
to inhibition of cap-dependent translation at initiation via RNA helicases such 
as eIF4A and DDX6 (Jonas and Izaurralde, 2015).  
Strikingly, each of the 90 conserved miRNA families have >300 binding sites 
to the seed regions consisted of 7-8 nts and >500 binding sites to the seed 
regions of 6 nt in length (Friedman et al., 2009). Moreover, one miRNA can 
target some 3’ UTRs more than once. Nevertheless, the average number of 
conserved target mRNAs per miRNA family is more than 400, and more than 
half of 3’ UTRs of the human mRNAs are conserved targets of miRNAs 
(Friedman et al., 2009). What is more, taking into account the miRNA binding 
sites in ORFs of the mRNA, the number of conserved targets rises to 60% of all 
human mRNAs. Interestingly, when a certain miRNA family is inhibited 
experimentally, it is observed that many mRNA targets with conserved 
binding sites for that miRNA family become downregulated (Bartel, 2018). It 
is therefore clear that every process happening in the cell is influenced by 
miRNA regulation. Furthermore, even though the single contribution of a 
noncanonical low-affinity interaction miRNA:mRNA is weak, in sum they do 
contribute to target downregulation. Due to this redundancy, the abundance 
of target mRNAs target normally exceeds the number of miRNAs (Denzler et 
al., 2016). Therefore, due to this target abundance, which are competing for 
miRNA binding, a lot of 3’ UTRs remain unsaturated resulting in a further 
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downregulation of already repressed targets in response to upregulation of 
certain miRNAs, which are ultimately sponged up (Denzler et al., 2016). 
1.3.2 Role of miRNAs in angiogenesis 
The first evidence of a possible miRNA involvement in angiogenesis was back 
in 2006, where it has been demonstrated that specific miRNAs are expressed 
in endothelial cells (Poliseno et al., 2006). In particular, the study has shown 
that 15 of highly expressed miRNAs in HUVECs have the receptors of 
angiogenic factors as potential target genes; both miR-221 and miR-222 target 
c-Kit expression, which is responsible for endothelial cell migration, tube 
formation and survival (Poliseno et al., 2006). Later on, the expression of 200 
miRNA has been elucidated in endothelial cells; after analysing different 
expression studies, 28 miRNAs have been confirmed to be common in the 
majority of the studies, which include examples such as let-7 family, miR-
17~92, miR-126, miR-210, miR-221/222 and others (Heusschen et al., 2010).  
Specifically, miR-126 is quite highly expressed in human endothelial cells as 
well as in tissues with dense vasculature such as lungs and heart (Wang et al., 
2008); in vitro studies have shown that it facilitates proliferation, stability and 
migration of endothelial cells (Fish et al., 2008) while inhibition of miR-126 
attenuates angiogenic response both in vitro and in vivo (Wang et al., 2008, 
Kuhnert et al., 2008). MiR-126’s proangiogenic effect can be attributed to its 
target genes, Spred-1 and PIK3R2, which are both negative regulators of VEGF 
and FGF signalling pathways (Fish et al., 2008, Wang et al., 2008). On the other 
hand, it has been reported that miR-17~92 cluster exhibits anti-angiogenic 
effects on endothelial cells both in cellular and in vivo models, which is 




Interestingly, it has been found that miR-210 is being upregulated during 
hypoxic conditions (Fasanaro et al., 2008). Moreover, during normal oxygen 
levels, miR-210 facilitates migration and cellular network formation of 
endothelial cells in response to VEGF, while inhibition of this miRNA leads to 
anti-angiogenic effects under hypoxic environment (Fasanaro et al., 2008). 
Specifically, HIF1α acts as a messenger between hypoxia and miR-210 
expression induction, which downregulates anti-angiogenic Ephrin-A3 
(Fasanaro et al., 2008). As expected, Gene Ontology analysis has elucidated 
HIF1α pathway as the most enriched miR-210-regulated pathway (Fasanaro 
et al., 2009). Therefore, it can be concluded that an angiogenic program, 
switched on by VEGF stimulus, that occurs in response to ischemia is 
modulated by miR-210. 
On the other hand, Caporali et al. has found that miR-503 is strongly 
downregulated in endothelial cells in response to high glucose in combination 
with low growth factors in the medium, increasing the expression of miR-503 
target genes cdc25A and CCNE1 (Caporali et al., 2011). Moreover, the study 
has demonstrated that miR-503 is a strong inhibitor of angiogenesis, which is 
upregulated during diabetes mellitus. Specifically, in vivo inhibition of miR-
503 is able to improve the diabetes-induced impairment of post-ischemic 
angiogenesis and restore the blood perfusion in ischemic adductor of diabetic 
mice (Caporali et al., 2011). 
Finally, it has been also demonstrated that inflammatory cytokines are able to 
modulate miRNA-dependent angiogenic response. Specifically, in a model of 
intraplaque neovascularization the inflammatory cells, which reside in 
neointima, release pro-angiogenic cytokines and growth factors such as IL-3 
and bFGF that are able to modulate differential expression of specific miRNAs 
(Dentelli et al., 2010). In particular, miR-222 is strongly downregulated upon 
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exposing the endothelial cells to acute inflammatory stimuli; miRNA gain-of-
function results into impairment in proliferation and migration of endothelial 
cells subjected to IL-3 and bFGF (Dentelli et al., 2010). What is more, it has been 
demonstrated that miR-222 is able to negatively modulate neoangiogenesis in 
mice and intraplaque vessel formation in humans via targeting signal 
transducer and activator of transcription 5A (STAT5A) expression (Dentelli et 
al., 2010). 
1.3.3 MiRNA and EndMT 
In these subchapters only the literature at the point of the start of the study is 
being discussed. 
There are only a few examples of the role of miRNA to modulate EndMT. The 
first prominent example of miRNA-dependent regulation of EndMT came 
from the study in 2012 (Kumarswamy et al., 2012). Firstly, it has been reported 
that miR-21, which is highly abundant in cardiac fibroblasts, is being 
upregulated in endothelial cells following TGF-β stimulation leading to 
induction of EndMT program in HUVECs (Kumarswamy et al., 2012). 
Interestingly, PTEN gene is a direct target of miR-21 and also is an inhibitor of 
Akt, which acts as an inducer of EndMT program; therefore, the TGF-β-
modulated miR-21 upregulation promotes EndMT phenotype in HUVEC via 
silencing the expression of PTEN, which in turn upregulates Akt and decreases 
the expression of PECAM1 (CD31) and endothelial nitric oxide synthase 
(eNOS) (Kumarswamy et al., 2012). Moreover, in a mouse model of transaortic 
constriction (TAC) surgery, the ventricular pressure overload induces cardiac 
fibrosis due to overexpression of miR-21 and partial EndMT induction 
(Kumarswamy et al., 2012). 
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Next example on miRNA involvement in EndMT comes from a study carried 
out at the same year. In particular, the group has demonstrated that basal FGF 
signalling is able to block TGF-β-induced EndMT via inducing the expression 
of let-7 miRNA, which targets TGF-βR1 (Chen et al., 2012). Specifically, it has 
been elucidated that the knockdown of fibroblast growth factor receptor 
substrate 2 (FRS2) attenuates the expression of let-7 family leading to EndMT 
phenotype (Chen et al., 2012). Moreover, in vivo downregulation of let-7 
increases vimentin expression while decreasing CD31 levels in mice liver 
sections, thus promoting the transition program (Chen et al., 2012). Another 
novelty of this study was their discovery that inflammatory cytokine IFN-γ is 
able to downregulate let-7 and induce EndMT in the endothelial cells in vitro 
and together with TNF-α and IL-1β inhibit the expression of FGF receptors 
(Chen et al., 2012). Finally, the group was able to demonstrate that EndMT 
occurs in the models of mouse atherosclerosis as well as human graft 
arteriosclerosis, where downregulation of let-7 increased the expression of 
EndMT markers in neointima such as α-SMA, collagen 1 and Notch3, which 
were decreased upon let-7 overexpression (Chen et al., 2012). 
1.3.4 Dysregulation of miRNAs in cardiovascular disease 
The significance of miRNAs in cardiovascular biology has been elucidated by 
deletion of Dicer gene in specific tissues: in particular, Dicer knockout was 
lethal after its deletion in vascular and myocardial systems (Albinsson et al., 
2010, Chen et al., 2008).  
The multi-regulatory properties of miRNA make them perfect modulators of 
heart formation, which requires very complex and precise orchestration of 
different cell types. Interestingly, in the heart only the highest expressed 
miRNAs have been assigned a functional role, probably due to functional 
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redundancy (Small and Olson, 2011). The most enriched miRNA in 
cardiomyocytes is miR-1, which was the first one reported to regulate heart 
development (Zhao et al., 2007). MiR-1 and miR-133 are both from the same 
miRNA family and are transcribed in the embryonic heart under the 
regulation of serum response factor (SRF) and myocyte enhancer factor-2 
MEF2 transcription factors (Liu et al., 2007, Zhao et al., 2005). These miRNAs 
facilitate differentiation of mesoderm and inhibit development of endodermal 
and ectodermal cell types (Ivey et al., 2008). Notably, miR-1 and miR-133 
exhibit opposite roles in the adult heart, where miR-1 induces while miR-133 
attenuates differentiation of cardiomyocytes (Ivey et al., 2008). Moreover, 
there seems to be a compensatory mechanism between miR-1 and miR-133 as 
only 50% of mice, lacking either of these miRNA in cardiomyocytes, are lethal 
(Small and Olson, 2011). 
The role of specific miRNAs in certain cardiovascular pathologies has been 
elucidated using knockout mice. Specifically, miR-1, miR-133 and miR-208a 
are involved in arrhythmias (Yang et al., 2007, Callis et al., 2009b), miR-21 and 
miR-29 play role in fibrosis (Thum et al., 2008, van Rooij et al., 2008), and miR-
133 and miR-208 in pressure-induced remodelling (van Rooij et al., 2007, Care 
et al., 2007). One of the most described family of miRNAs, which modulates 
the expression of stress-induced genes, consists of miR-208a, miR-208b and 
miR-499 and is encoded by myosin heavy chain (MHC) genes; this miRNA 
family is called MyomiRs (van Rooij et al., 2009). Specifically, MyomiRs 
modulate a number of transcriptional repressors and signalling proteins, 
which tune the expression of MHC and responsiveness of cardiomyocytes to 
stress (van Rooij et al., 2009). Moreover, Mir208a loss-of-function prevents the 
re-activation of fetal β-MHC induced by haemodynamic cardiac stress, thus 
attenuating cardiac hypertrophy (Callis et al., 2009a). Similarly, antagomir 
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silencing of miR-23a expression, which is upregulated by cardiac-stress 
inducing NFATc3, is able to decrease heart hypertrophy (Lin et al., 2009b). 
Interestingly, myocardial infarction inhibits the expression of miR-29 family, 
which normally targets certain collagens and ECM proteins thus attenuating 
fibrosis (van Rooij et al., 2008). In addition to this, in a model of hypoxia 
preconditioning, miR-199 family is repressed in cardiomyocytes in response 
to hypoxia, thereby re-activating the expression of its target genes Sirtuin 1 
and HIF-1α (Rane et al., 2009). In another example inhibition of miR-21, which 
a positive modulator of fibrosis and cardiac hypertrophy, is able to decrease 
heart remodelling upon thoracic aortic constriction (Thum et al., 2008). This 
protective effect is achieved due to miR-21-induced repression of sprouty 
homologue 1 (Spry1), which enhances ERK–MAP kinase activity modulating 
fibroblast survival and controlling cardiac hypertrophy (Thum et al., 2008). 
MiR-21 has been also reported to negatively regulate migratory capacity and 
promote the dysfunction of angiogenic progenitor cells in patients with 
coronary artery disease (Fleissner et al., 2010). What is more, ischemia-
facilitated angiogenesis is induced by silencing of miR-92a (Bonauer et al., 
2009) and attenuated by inhibition of miR-126 (van Solingen et al., 2009). MiR-
126 is also involved in exerting protective effects from atherosclerosis via 
upregulation of the CXC chemokine CXCL12 upon silencing its repressor 
RGS16 (Zernecke et al., 2009). Finally, it has been demonstrated that miR-145 
is downregulated upon neointimal lesion formation and restoration of its 
expression is able to inhibit neointimal growth (Cheng et al., 2009). 
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1.4 Preliminary studies 
1.4.1 MiRNA high throughput phenotypic screening 
Due to the evident importance of miRNA in regulating angiogenesis, miRNA 
high throughput phenotypic screening has been carried out in BHF Centre for 
Cardiovascular Target Discovery in University of Oxford (unpublished). The 
purpose of the screen was to identify miRNA, which enhance or inhibit 
proliferation of HUVECs. Specifically, HUVECs were transfected with a 
library of 1500 miRNA mimics and the effect of each miRNA mimic on cellular 
proliferation was analysed using cellHTS2 package (Open source). Figure 1.5a 
shows a scatter plot distribution representing the effect of each miRNA mimic 
on HUVEC proliferation by B-score, which is a number of standard deviations 





Figure 1.5| Phenotypic-screen of human miRNA mimics library for regulators of 
endothelial cell growth. a. Right panel: Scatter plot distribution showing the B-score of 
endothelial cell count. The cell count reading values were normalized according to B-score 
method using CellHTS2 package (Open source). The selection enhancer hit cutoff was set at 
+1.69; miR-302c was used as a positive control (green); miR-503 was used as a negative 
control (blue); left panel: representative fluorescent images showing DAPI stained HUVECs 
treated with Non-targeting miRNA mimic control (NTC), negative control (miR-503) and an 
example of a positive enhancer hit (miR-302c). b. Screening summary shows the enhancer hit 
selection workflow. c. Secondary cell-based assays to validate the effect of selected enhancer 
hits on the endothelial cell proliferation; left panel: cells count after transfection with selected 
miRNA mimics; right panel: results from EdU incorporation assay performed with HUVECs 
transfected with selected set of miRNA mimics. Unpublished data. 
During this study, the miRNAs which were above the hit cut-off line (+1.69) 
established between positive control miR-302c and negative control miR-503, 
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were considered to be enhancers of HUVEC proliferation (Fig. 1.5 a). Next, 
123 miRNA enhancers were selected and based on their evolutionary 
conservation the 79 miRNA were prioritized; finally, the selection was 
narrowed down to 24 miRNAs based on high expression level in endothelial 
cells (Fig. 1.5 b). During this investigation, secondary functional cellular 
assays have validated the strongest enhancers, miR-148b, miR-26b, miR-148a, 
miR-17 and miR-20a, as potent inducers of HUVEC proliferation (Fig. 1.5 c). 
Given the fact that miR-148b is one of the strongest enhancers of proliferation 
out of this list above and that it hasn’t been reported to play a role in 
angiogenesis or endothelial cell plasticity, it has been selected as a strongest 
candidate for subsequent characterization. 
1.4.2 MiR-148b characterization 
MiR-148b, together with miR-148a and miR-152, comprises the miR-148/152 
family. MiR-148b is genomically located at chromosome 12q13 with a genomic 
size of 22 bp (UCSC Genome Browser). Importantly, miR-148b is located 
genomically within the first and the longest intron of COPZ1 host gene (UCSC 
Genome Browser). Interestingly, COPZ1 gene is encoding a coatomer subunit 
zeta-1 protein that constitutes a coatomer protein complex I (COPI) in the 
cytoplasm, which is involved in the assembly of coated vesicles on Golgi 
membranes, retrograde transport of luminal and membrane cargo proteins in 
the ER-Golgi secretory pathway, maturation of the endosome, autophagy 
(Beck et al., 2009, Razi et al., 2009) as well as lipid homeostasis (Beller et al., 
2008). Moreover, it was later demonstrated that the knockdown of COPZ1 
leads to apoptosis, accumulation of unfolded proteins, attenuated autophagy 
and ER stress and, ultimately, to thyroid tumor cell death (Anania et al., 2017). 
Importantly, miR-148b-3p targets 802 mRNAs with 889 conserved and 268 
poorly conserved sites (TargetScan 7.2). 
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1.4.2 MiR-148b in the literature 
Table 3 summarises current known miR-148b target genes as well as their 
involvement in different physiological conditions and pathologies. 
The first time miR-148b has been reported in literature was in 2008, where the 
study has found miR-148b expression was significantly upregulated among 
other miRNAs in osteoblast-like cells in response to culturing with plastic 
polymer, porous polyethylene (Palmieri et al., 2008).  
Later, it has been described that miR-148b plays a role in modulating innate 
immunity (Kotake et al., 2010). Specifically, the study demonstrated that Toll-
like receptors (TLR) agonists are able to induce the expression of miR-148a, 
miR-148b and miR-152, which constitute miR-148 family, in dendritic cells 
(Kotake et al., 2010). Moreover, the overexpression of miR-148b decreases the 
production of inflammatory cytokines, IL-6, TNF-a, IL-12, and IFN-b, in LPS-
stimulated dendritic cells, suggesting that miR-148/152 might act as a 
suppressor of TLR-induced innate immune response (Kotake et al., 2010). 
Finally, it has been shown that miR-148/152 targets the expression of 
calcium/calmodulin-dependent protein kinase II (CaMKII) and, thereby, 
attenuating the maturation and proliferation of dendritic cells (Kotake et al., 
2010). 
The most reported role of miR-148b is the involvement in modulation of tumor 
development. The first study to demonstrate this has been carried out in 2011, 
which has reported that miR-148b is significantly downregulated in 106 gastric 
cancer tissues and has a strong correlation with tumor size (Song et al., 2011). 
Moreover, it has been elucidated that miR-148b is able to suppress gastric 
cancer cell proliferation via targeting cholecystokinin-B receptor (CCKBR) 
(Song et al., 2011). Later, the same group reported that miR-148b is also 
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suppressed in colorectal cancer tissues, where it could inhibit tumorigenicity 
via blocking the expression of cholecystokinin-2 receptor gene (CCK2R) (Song 
et al., 2012). On the other hand, Chang et al. reported that miR-148b is strongly 
overexpressed in ovarian cancer tissues (Chang et al., 2012). Interestingly, 
miR-148b is able to elevate the radiosensitivity of non-Hodgkin's lymphoma 
cells possibly via facilitating radiation-induced apoptosis (Wu et al., 2012). 
What is more, in pancreatic cancer tissues miR-148b is downregulated, while 
its overexpression is able to supress pancreatic cancer cell proliferation and 
invasion through targeting AMP-activated protein kinase α1 (AMPKα1) (Zhao 
et al., 2013). 
Notably, miR-148b has also been reported to play a role in regeneration and 
tissue repair. Specifically, Qureshi et al. demonstrated that photoactivated 
miR-148b mimic oligonucleotide delivery using silver nanoparticle complexes 
leads to differentiation of human autologous adipose derived mesenchymal 
stromal/stem cells (hASCs) into an osteogenic linage via enhancement of 
alkaline phosphatase (ALP) activity, which results in rapid calcification of 
hASCs (Qureshi et al., 2013). The fate change of hASCs into osteogenic cell 
type was also confirmed by upregulation of osteogenic markers RunX2 and 
osteocalcin (OCN) upon delivery of conjugated miR-148b mimic 
oligonucleotides (Qureshi et al., 2013). These findings were confirmed by 
another study, which showed that miR-148b overexpression using baculovirus 











HLA-G Asthma (Tan et al., 2007) 
hsa-miR-148b-
3p 
CCKBR Gastric cancer (Song et al., 2011) 
hsa-miR-148b-
3p 




















CaMKIIα Innate immunity (Kotake et al., 
2010) 
Table 3. MiR-148b and its target genes in disease and physiology. 
1.5 Hypothesis 
Given the preliminary data demonstrating that miR-148b is able to strongly 
enhance endothelial cell proliferation and its potential involvement in 
differentiation from previous findings, the main goal of this thesis is to test the 
hypothesis that: 
“MiR-148b is a modulator of angiogenesis and endothelial cell plasticity” 
1.6 Aims 
1.  Elucidate miR-148b target genes 
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2. Determine whether miR-148b overexpression enhances angiogenesis in vitro 
and in vivo 
3. Determine whether inhibition of miR-148b attenuates angiogenesis and 
modulates endothelial cell function in vitro and in vivo 



































2.1 Techniques for in vitro studies 
2.1.1 MiR-148b target analysis 
Computational prediction of miR-148b target genes was done using published 
algorithm TargetScan (www.targetscan.org). miRpath v.3 
(http://diana.imis.athena innovation.gr/DianaTools/index.php?r=mirpath) 
has been used to perform gene set enriched analysis of miR-148b target genes. 
The prediction was based on Targetscan parameters such as Context score and 
Conservation score. 
2.1.2 Cells and Cell culture 
Human umbilical vein ECs (HUVECs; Lonza) were grown in EGM-2 (EBM-2 
added with growth factors and other supplements) with 2% Foetal Bovine 
Serum.  Confluent HUVECs were treated with 10 ng/ml TNF-α, IL-1β, TGFβ2 
(PeproTech); medium and cytokines were changed every two days. HEK293T 
cells (ATCC®, CRL-11268) were cultured in D-MEM with 10% FBS (Life 
Technologies). 
2.1.3 Cell transfection 
HUVECs and HEK293T were plated in a 6-well plate in a density of 100,000-
120,000 cells per well and transfected using lipofectamine RNAiMAX (Thermo 
Scientific™, 13778075) (for RNA oligonucleotides) and/or lipofectamine 3000 
(Thermo Scientific™, L3000008) (for plasmid DNA) in the Opti-MEM® I 
Reduced Serum Medium (Thermo Scientific™, 31985062). MiRIDIAN miR-
148b Mimic (Dharmacon, MI0000811) 25 nM, miRIDIAN microRNA Mimic 
Negative Control (Dharmacon, CN-001000-01-05) 25nM, miRCURY LNA™ 
anti-miR-148b (Exiqon) 75 nM, miRCURY LNA™ microRNA Antisense 
Control (Exiqon) 75 nM and SMAD2 siRNA (Thermo Scientific™) were used 
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to transfect HUVECs; pMIR-REPORT miRNA Expression Reporter Vector 
control (Thermo Scientific™, AM5795) and with cloned 3’UTR of TGFB2 and 
SMAD2 genes were used to transfect the cells. The medium was changed after 
5 hours post-transfection to EGM-2 for HUVECs and D-MEM for HEK293T 
cells. Then, the medium was changed every 2 days. After 6 days of transfection 
the cells were detached with Trypsin-EDTA (0.25%) (Thermo Scientific™, 
25200056) for subsequent experiments.  
2.1.4 Cellular proliferation assay 
Cell proliferation was analysed using Cell Proliferation ELISA, BrdU 
(colorimetric) assay (Roche, 11647229001). Next, 10 μM BrdU was added to 
transfected HUVECs and incubated for 24 hours in 96-well plate. Then, the 
cells were fixed and the DNA was denatured by adding FixDenat solution and 
anti-BrdU-POD was applied to the cells. After 3 washes with dPBS 100 μl of 
Substrate solution was added and the cells were incubated at room 
temperature for 5-30 min. After the addition of 25 μl stop solution the 
absorbance was measured at 450 nm with reference wavelength of 690 nm 
using the Infinite® M1000 PRO plate reader (Tecan). A standard curve method 
was used to quantify the results. 
2.1.5 Migration and membrane capacitance assays 
The assays were carried out using ECIS® (Electric Cell-substrate Impedance 
Sensing) (Applied BioPhysics) method. For migration assay HUVECs were 
cultured on the 8W2LE array. At time point 0 a wound was carried out using 
electric charge followed by migration of cells, which was detected by the 
change in impedance over the period of 24 hours. The values were expressed 
as migration speed in μm/h. For membrane capacitance assay the cells were 
plated on 8W10E+ array at time point 0 and the cell membrane capacitance 
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(Cm) was measured over the period of 24 hour, which was expressed in μF/cm2. 
The data was quantified using ECIS Zθ (Theta) software. 
2.1.6 Matrigel assay 
In vitro angiogenesis was measured by Matrigel assay. For this, 10,000 cells 
were plated onto the Matrigel Matrix (Corning) in 96-well plate, which was 
solidified in 37°C for 30 min. The cells were incubated for 5-6 hours at 37°C 
and then fixed with 4% PFA in dPBS. The images of the cells were taken using 
EVOS inverted digital microscope. The images were then processed using 
ImageJ software with Angiogenesis Analyser plug-in. The parameters used for 
analysis were total length of the cellular networks and number of nodes. 
2.1.7 RNA extraction 
HUVECs were centrifuged at 1000 RPM for 5 minutes at 22°C. The medium 
above the cell pellet was removed and 700 μl of QIAzol® Lysis Reagent 
(QIAGEN, Cat No./ID: 79306) was added to each pellet and the content was 
transferred to RNase-free Microfuge Tubes; at this step the lysed cell pellet in 
QIAzol can be stored at -80°C. Then, 140 μl of chloroform was added to each 
tube, vortexed and incubated at room temperature for 5 minutes. After that, 
each microfuge tube was centrifuged for 15 min at 12,000 x g at 4°C. After the 
centrifugation the tubes were placed on ice and the upper aqueous phase was 
transferred to the new RNase-free Microfuge tubes. Then, 1.5 volumes of 100% 
ethanol was added to the tubes and mixed thoroughly by inverting the tubes 
around 10 times. Next, 700 μl of each sample was pipetted into an RNeasy® 
Mini column (QIAGEN, cat. No. 217004) in a 2 ml collection tube and all 
samples were centrifuged at 8000 x g for 15 s at room temperature. Following 
the discarding of the flow-through the previous step was repeated with the 
remainder of the samples. Next, 700 μl of the RWT buffer (QIAGEN, Cat 
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No./ID: 1067933) was added to each RNease Mini column, which were then 
centrifuged for 15 s at 8000 x g. Following the discarding of the flow-through 
500 μl of the RPE buffer (QIAGEN, Cat No./ID: 1018013) was added to each 
RNease Mini column, which were then centrifuged for 15 s at 8000 x g. The 
previous step was repeated two more times (the centrifugation time increases 
to 2 min during the second repeat). Following the discarding of the flow-
through all RNease Mini columns were centrifuged for 1 min at 21,000 x g at 
room temperature to dry the membrane. Then all RNease Mini columns were 
placed under the air-flow hood with lids open for 20 minutes to dry out the 
remaining traces of ethanol. After that 30 μl of RNase-free water was pipetted 
into each RNease Mini column, which were then placed in the new RNase-free 
Microfuge Tubes, incubated for 1 min at room temperature and centrifuged 
for 2 min at 8000 x g. The eluted RNA was then stored at -80°C. 
2.1.8 Reverse transcription polymerase chain reaction (RT-PCR) and Real-
Time PCR (qPCR) with TaqMan and LightCycler 480 Roche 
Firstly, the extracted RNA was quantified using NanoDrop 1000 
Spectrophotometer (Thermo Fisher Scientific) and the concentration of RNA 
was expressed as ng/μl. RT-PCR was carried out using High-Capacity cDNA 
Reverse Transcription Kit (Applied Biosystems™, Catalog number: 4368814). 
Specifically, for each sample a master mix was prepared using the following 
amount of reagents: nuclease free water 2.08 μl, dNTP mix 0.075 μl, 10x RT 
Buffer 0.75 μl, RNase inhibitor 0.095 μl and multiscribe RT enzyme 0.5 μl. Then 
the RT-PCR reactions were prepared in PCR tubes using these amounts of 
reagents: 3.5 μl of the RT master mix, 2.5 μl of diluted RNA (5 ng) and 1.5 μl 
of TaqMan RT primers (hsa-miR-148b, Cat. # 4427975; U6 snRNA, Cat. # 
4427975) to make up 7.5 μl total reaction. The PCR tubes with the reaction 
mixes were then placed into the PCR thermocycler and the following program 
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was inputted: Hold 30 min at 16°C, hold 30 min at 42°C, hold 5 min at 85°C 
and then hold at 4°C. 
Further, the cDNA from previous reaction was used for qPCR using 
LightCycler® 480 Probes Master kit (4707494 - Roche Applied Science). First 
of all, a qPCR master mix was prepared for each sample using the following 
quantities: LightCycler probe 5.00 μl, nuclease free water 3.83 μl and TaqMan 
primers 0.5 μl (hsa-miR-148b, Cat. # 4427975; U6 snRNA, Cat. # 4427975). After 
that, 9.33 μl of master mix was added to each well of 384-well white PCR plate, 
to which was then added 0.67 μl of miRNA-cDNA to make up to 10 μl of total 
reaction volume; each sample was done in duplicate. The PCR plate was then 
covered with transparent film, centrifuged for 2 min at 1500 RPM. The plate 
was then placed into LightCycler® 480 Instrument and the following program 
was selected: Mono Color Hydrolysis Probe – Pre-Incubation at 95°C, 
Amplification for 45 cycles (95°C for 10 sec, 60°C for 30 sec and 72°C for 1 sec) 
and Cooling at 40°C for 10 sec. After the qPCR run was finished, the results 
were analysed by selecting “Abs Quant/2nd Derivative Max” type of analysis 
and “amplification” program. Then, the calculated CT values were copied and 
used for further analysis of relative gene expression. 
2.1.9 Reverse transcription polymerase chain reaction (RT-PCR) using 
genomic DNA wipeout method 
For this technique QuantiTect Reverse Transcription Kit (QIAGEN, Cat. # 
205311) was used. First of all, usually 300-500 ng of extracted RNA was diluted 
in RNase-free water to make up a total of 12 μl in the PCR tubes placed on ice. 
Then, 2 μl of gDNA Wipeout Buffer, 7x was added to each sample. The 
reverse-transcription master mix was prepared using following amounts of 
reagents per sample: Quantiscript Reverse Transcriptase 1 μl, Quantiscript RT 
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Buffer, 5x 4 μl, RT Primer Mix 1 μl. After that, each PCR tube was placed in 
the PCR thermocycler and the following RT-PCR program was set up: 
incubation for 2 min at 42°C, hold for 4 min at 4°C (6 μl of the master mix was 
added to each sample and mixed by pipetting during this step), incubation for 
30 min at 42°C, incubation for 3 min at 95°C and hold at 4°C. Finally, cDNA 
was used for qPCR or can be stored at -20°C. 
2.1.10 Real-Time PCR (qPCR) with AB SYBR Green for gene expression 
Power SYBR® Green PCR Master Mix (Applied Biosystems, Cat. # 4367659) 
was used for the following qPCR protocol. A master mix was for each sample 
was prepared using the following quantities: 5 μl of Power SYBR® Green PCR 
Master Mix, 3 μl of RNase-free water and 1 μl of specific primer mix (10 μM). 
Then, 9 μl of the prepared master mix was added into each well of 384-well 
white PCR plate, to which 1 μl of the cDNA was added. The plate was then 
placed into LightCycler® 480 Instrument and the following program was 
selected: pre-incubation for 10 min at 95°C; 45 cycles of amplification for 15 sec 
at 95°C then for 30 sec at specific annealing temperature for each primer pair 
and 30 sec at 72°C; cooling for 30 sec at 40°C. After the qPCR run was finished, 
the results were analysed by selecting “Abs Quant/2nd Derivative Max” type 
of analysis and “amplification” program. Then, the calculated CT values were 
copied and used for further analysis of relative gene expression. Pre-designed 
from Sigma (KiCqStartTM Primers) were used for TGFB2, SMAD2, NOX2, 
CD31, VE-Cadherin, COL1A1, COL1A2, COL3A1, αSMA and 18S rRNA. 
2.1.11 Analysis of the qPCR data 
The double delta Ct analysis method was used to analyse all qPCR data in this 
study. The average of the Ct values for the housekeeping gene and for the gene 
of interest was taken, which generates 4 values: average experimental gene of 
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interest Ct value, average experimental housekeeping gene Ct value, average 
control gene of interest Ct value and average control housekeeping gene Ct 
value. Next, the differences between the Ct values of gene of interest and 
housekeeping gene were calculated for both experimental and control 
conditions, respectively, which generates delta Ct (ΔCt) values. After that, the 
differences between experimental and control ΔCts was calculated to generate 
the double delta Ct values (ΔΔCt). Finally, the following formula (2^-ΔΔCt) 
was used to calculate the expression fold change due to the fact that the Ct 
values were in logarithm base 2. The housekeeping gene used to calculate the 
expression of miR-148b was U6 snRNA; the housekeeping gene to calculate 
the expression of all target genes and EndoMT marker genes was 18S 
ribosomal RNA. 
2.1.12 Protein extraction from cell pellet 
Firstly, the cells were centrifuged at 1000 RPM for 5 minutes at 22°C. The 
medium on top of the pellet was removed and the cell pellet was then 
resuspended in 100 μl of 1x RIPA buffer (10x RIPA lysis buffer (Millipore, 20-
188), 20x cOmplete ULTRA protease inhibitor cocktail, 100 mM PMSF, 100 mM 
Na3VO4 and 10x 1M NaF) and placed on ice for 15 min for lysis; each tube was 
vortexed periodically to facilitate the lysis. Next the tubes with lysed pellet in 
1x RIPA were placed in 4°C centrifuge and centrifuged for 20 min at 17,000 x 
g. After centrifugation the supernatant with the lysed protein was pipetted 
into new tubes and placed on ice or frozen at 20°C. 
2.1.13 Protein quantification by BCA assay 
For this assay BCATM Protein Assay kit (Pierce, 23225) was used. The principle 
of this assay is the ability of proteins to reduce Cu+2 to Cu+1 in an alkaline 
solution, which generates a purple colour formation by bicinchoninic acid. 
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Amino acids, such as cysteine or cystine, tyrosine, and tryptophan are able to 
reduce copper. Firstly, 2 μl of each protein extract was pipetted into each well 
of transparent 96-well plate in duplicate. Secondly, 0.25, 0.5, 1, 2 and 3 μl of 
Pierce™ Bovine Serum Albumin (BSA) Standard 2 mg/μl was pipetted into 
corresponding wells in duplicate. Then 200 μl of BCATM Protein Assay Reagent 
mix (Reagent A + 50x of Reagent B) was added in each well and the plate was 
placed in 37°C incubator for at least 1 h. After the incubation the plate was 
placed into OptiMaxTM microplate reader and the absorbance of each well was 
read at 560 nm. First of all, the averages of the BSA absorbance values of each 
duplicate were summed together and divided by the total amount of mg of 
BSA standard that was assayed, which was 13.5 mg, to give a value equal to 
absorbance of standard per mg of protein. After that the average of the 
duplicates of the sample proteins was divided by this ratio (OD of 
standard/mg) and then divided by 2 (because the concentration of the BSA 
standard was 2 mg/μl. The resulting value was expressed in mg/μl of the 
sample protein. 
2.1.14 Sample preparation for Western Blot 
Usually, 20 μg of protein was used for the Western Blot and the volume of the 
protein extract corresponding to this amount was mixed with 5x loading 
buffer (Bromophenol blue (0.25%), Bromophenol blue (0.25%), Glycerol (50%), 
SDS (sodium dodecyl sulfate; 10%)) and the total volume was calibrated with 
1x RIPA buffer in order to make the uniform volume for all protein samples. 
Next, each tube was vortexed and placed in the 99°C heating block for 5 min. 




2.1.15 Western Blot 
First of all, the SDS-Polyacrylamide gel electrophoresis (PAGE) gel was 
prepared. Firstly, 10% loading gel was prepared following this recipe: 6.25 ml 
of dH2O, 5 ml of Protogel 30% (w/v) Acrylamide:0.8% (w/v) Bis-Acrylamide 
(National Diagnostics, EC-890), 3.75 ml of Tris/SDS pH=8.8, 50 μl of 10% 
Ammonium persulfate (APS) and 10 μl of TEMED; the mix was poured into 
Mini PROTEAN® System glass plate and left polymerising for 20 min. During 
the polymerisation of the loading gel, the stacking gel was prepared following 
this recipe: 6.1 ml of dH2O, 1.3 ml of Protogel 30% (w/v) Acrylamide:0.8% 
(w/v) Bis-Acrylamide (National Diagnostics, EC-890), 2.5 ml of Tris/SDS 
pH=6.8, 50 μl of 10% Ammonium persulfate (APS) and 10 μl of TEMED and 
poured on top of the loading gel followed by placing the comb. After 20 min 
the glass plate with the SDS-PAGE gel was placed into the chamber, filled with 
1x Tris-Glycine-SDS Buffer (250 mM Tris, 1.92 M glycine and 1% SDS). Then 
the comb was removed and the prepared protein sample and the PageRuler™ 
Prestained Protein Ladder (Thermo Scientific™, 26616) were added into each 
well. Finally, the voltage equal to 60V was applied on the chamber. When the 
sample enters the loading gel, the voltage was increased to 100V. 
2.1.16 Protein transfer on the nitrocellulose membrane 
After the running of the gel was stopped, the glass plate with the SDS-PAGE 
gel was opened and, following the separation of the stacking gel, the loading 
gel was soaked in Tris-Glycine Buffer with 5% methanol. In parallel, sandwich 
consisting of Whatman paper – gel – nitrocellulose membrane – whatman 
paper was prepared and assembled into transfer apparatus and filled with 
Tris-Glycine Buffer with 5% methanol buffer. After this, 100 mA of electrical 
current was applied and the transfer was carried out overnight. 
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2.1.17 Ponceau staining, membrane blocking and incubation with primary 
antibody 
After the transfer was finished, the membrane was stained with Ponceau S 
solution to detect the protein loading on the nitrocellulose membrane. Then, 
0.03% trichloroacetic acid was applied onto the membrane to remove 
unspecific Ponceau S staining. After the picture was taken for future records, 
the membrane was washed in Tris-buffered saline, 0.1% Tween 20 (TBST) for 
5 min and then blocked with 5% non-fat milk in TBST for 1 hour. Following 
the blocking, the membrane was incubated overnight with a corresponding 
primary antibody diluted in 3% Bovine Serum Albumin (Sigma, A9647) in 
TBST. The list of primary antibodies used: 
Antibody Brand Lot. Num. Dilution 
TGFβ2 Abcam Ltd ab36495 1:1000 
SMAD2 SantaCruz  #3102 1:1000 
CD31 Abcam Ltd ab28364 1:1000, 1:50 
VE-Cadherin Abcam Ltd ab33168 1:1000 
COL1A1 Abcam Ltd ab138492 1:200 
FSP-1 Abcam Ltd ab41532 1:50 
α-SMA Sigma A2547 1:100 
β-actin Abcam Ltd ab16039 1:4000 
GAPDH GeneTex GT239 1:1000 
HDAC3 GeneTex GTX113303 1:500 
Table 4. List of antibodies used. 
When using COL1A1 antibody no blocking step was carried prior to 
incubation with the primary antibody 
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2.1.18 Incubation with a secondary antibody, ECL-based Western blots 
detection 
Then, the membrane was washed 3 times with TBST and the corresponding 
secondary antibody was applied in 5% non-fat milk in TBST and incubated for 
1 hour. The list of secondary antibodies used: rabbit anti-mouse (Abcam Ltd., 
ab97046, 1:5000) and goat anti-rabbit (Abcam Ltd., ab6721, 1:10000). Following 
the incubation with the secondary antibody, the membrane was washed 3 
times in TBST. Then, the membrane was incubated in EMD Millipore 
Immobilon™ Western Chemiluminescent HRP Substrate (ECL) (EMD 
Millipore, WBKLS0500) for 5 min and applied onto exposure cassette. The 
following steps were carried out in the dark room: CL-XPosure Film (Thermo 
Scientific, 34089) was applied on top of the membrane in the cassette, which 
was then being exposed for a specific time, starting from 1 minute. Following 
the exposure, the film was loaded onto Konica medical film processor (Konica, 
SRX-101A). Finally, the molecular weights of the protein were assigned and 
the film was scanned to analyse the results on the PC. 
2.1.19 Immunofluorescence 
Cells were plated on the glass coverslips in a 24-well plate in a density of 50,000 
cells per well. Cells were fixed using 4% paraformaldehyde in PBS at room 
temperature for 15 min. Then, the cells were washed with PBS 3 times for 5 
mins. After that, cells were blocked for 1 hour in 3% BSA/PBS with either 0.5% 
Triton X-100 or 0.1% Saponin (for membrane protein immunofluorescence). 
Following the blocking, the primary antibody was applied on the cells in 1% 
BSA/PBS with 0.5% Triton X-100 or 0.1% Saponin at 4°C in the dark overnight. 
The following primary antibodies were used: CD31 (Abcam Ltd., 1:50), VE-
Cadherin (Abcam Ltd. ab33168, 1:100), COL1A1 (Abcam Ltd., ab138492, 
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1:100). Following the incubation with primary antibody, the cells were washed 
in PBS or 1% BSA/PBS with 0.1% Saponin (for membrane protein 
immunofluorescence) and the secondary antibody in 1% BSA/PBS with 0.5% 
Triton X-100 or 0.1% Saponin was applied onto the cells for 1 hour at the dark. 
This list of secondary antibodies was used: Alexa-Fluor-488-conjugated 
antibody to rabbit IgG (Life Technologies, Carlsbad, CA, # A11070) and Alexa-
Fluor-594-conjugated antibody to rabbit IgG (Life Technologies, Carlsbad, CA, 
#A11072). Then, the washing step was repeated and the cells were incubated 
with DAPI (1:2000) in PBS for 5 min. After that, the washing step was repeated 
again and the glass coverslips were mounted with Fluoromount™ (Sigma, 
F4680) on the glass slides (Surgipath, 08001E). The slides were then mounted 
in the dark overnight and were ready to be visualized under the microscope. 
2.1.20 Amplification of 3’UTR of TGFB2 and SMAD2 genes 
The primers for 3’UTR of TGFB2 and SMAD2 were designed using 
Primer3Plus online software (http://www.bioinformatics.nl/cgi-
bin/primer3plus/primer3plus.cgi). The sequences of the primers are the 
following: TGFβ2 3’UTR: Forward 5’-
ATAAAGCTTATTTGCCACATCATTGCAGA-3’, Reverse 5’-
ATAACTAGTGGGAATAAAAAGACGGCACA-3’; SMAD2 3’UTR: Forward 
5’-ATAAAGCTTTGATCCAGCTAAGGTAACTGATGTT-3’, Reverse 5’-
ATAACTAGTTGGTAAACAACTCAAATGGCTTTC-3’. SuperScript III First-
Strand Synthesis kit (Thermo Scientific™, 18080400) was used to amplify 
3’UTR of TGFB2 and SMAD2 from total RNA isolated from HUVECs cultured 
in EGM-2. The mutant truncated version of TGFB2 and SMAD2 3’UTR has 
been amplified from generated pMIR-TGFB2 3’UTR and pMIR-SMAD2 3’UTR 
using following primers: TGFβ2 3’UTR mut: Forward 5’-
ATAAAGCTTATTTGCCACATCATTGCAGA-3’, Reverse 5’- 
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ATAACTAGTCCTATCTGAGAGGAAAATGTCTGC-3’; SMAD2 3’UTR mut: 
Forward 5’- ATAAAGCTTTGATCCAGCTAAGGTAACTGATGTT-3’, 
Reverse 5’- ATAACTAGTGGACTTCCAGAGGGAAACAA-3’. 
2.1.21 DNA restriction digestion 
The plasmid DNA (pMIR-report) and 3’UTR of TGFB2, TGFB2 mut, SMAD2 
and SMAD2 mut were digested with HindIII (NEB, R0104S) and SpeI (NEB, 
R0133S) enzymes. The procedure: 1 μg of DNA, 5 μ of 10X NEBuffer 2.1, 1 μl 
of each enzyme to 50 μl with nuclease-free water. The reaction was carried out 
at 37°C for 2 hours. 
2.1.22 DNA separation using agarose gel electrophoresis 
Firstly, 1% agarose gel was made by melting 2 g of agarose (Bioline, BIO-41025) 
in 200 ml of 1x Tris-acetate-EDTA (TAE) buffer (242 g Tris free base, 18.61 g 
Disodiumn EDTA, 57.1 ml Glacial Acetic Acid, DDI H2O to 1 liter). After that, 
10 μl of GelRed™ (Biotium, #41003) was added to the cooled gel, which was 
then poured into the gel electrophoresis caster and left to solidify. DNA 
samples were mixed with 10x Orange-G loading buffer (20 g sucrose, 100 mg 
Orange-G in 100 ml of dH2O) and loaded inside the well of the agarose gel 
together with 7 μl of 1 kb DNA ladder (NEB, N3232L). Then, 80-100 V was 
applied and the samples were run until the Orange-G bands reach the bottom 
edge of the gel. Specific DNA bands, corresponding to HindIII/SpeI cut pMIR-
report and HindIII/SpeI cut 3’UTR of TGFB2 and SMAD2, were excised with 
a scalpel under UV for subsequent DNA gel extraction. 
2.1.23 DNA gel extraction 
HindIII/SpeI cut pMIR-report and HindIII/SpeI cut 3’UTR of TGFB2 and 
SMAD2 were extracted using this method. For this, The QIAquick Gel 
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Extraction Kit (Qiagen, 28704) was used. Firstly, 3 volumes of Buffer QG were 
added to 1 volume of gel, following by incubation at 50°C for 10 min. After the 
gel was completely melted, 1 gel volume of isopropanol was added and mixed. 
Then the sample was applied in a QIAquick spin column and centrifuged for 
1 min full speed. After that, 500 μl of Buffer QG was applied in the column 
and centrifuged for 1 min full speed. Finally, 750 μl of Buffer PE was added to 
the column, centrifuged for 1 min full speed. After final centrifugation step, 
the column was left for air-dry and then 30 μl of nuclease-free water was 
added and centrifuged for 1 min full speed. The DNA was then stored at -
20°C. 
2.1.24 DNA ligation 
Ligation was carried out using 3:1 ratio of insert (HindIII/SpeI cut 3’UTR of 
TGFB2, TGFB2 mut, SMAD2 and SMAD2 mut) to the vector (HindIII/SpeI cut 
pMIR-report), 2 μl of T4 DNA Ligase Buffer (10X), 1 μl of T4 DNA ligase (NEB, 
M0202) in a final volume of 20 μl with nuclease-free water. The reaction was 
carried out at room temperature for 1-2 hours.  
2.1.25 Bacterial transformation 
Competent high efficiency NEB 5-alpha E.coli (NEB, C2987H) were thawed on 
ice for 15 min. After that, 1-7 μl containing around 100 ng of plasmid DNA 
(pMIR-TGFB2 3’UTR, pMIR-TGFB2 3’UTR mut, pMIR-SMAD2 3’UTR and 
pMIR-SMAD2 3’UTR mut) were added to the cell mixture. The tube was 
carefully flicked 5 times and placed on ice for 30 min. Then, the sample was 
heat shocked for 30 sec at 42°C and placed on ice immediately for 5 min. Next, 
950 μl of SOC (NEB, B9020S) medium was added to cell-DNA mixture and 
tube was placed at 37°C for 1 hour and shaken at 250 rpm. Following the 
warming of selection plates containing LB agar with antibiotic (Ampicilin) to 
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37°C, 100 μl of bacteria was spread onto the plate and incubated overnight at 
37°C. 
2.1.26 Plasmid DNA Purification using the QIAprep Spin Miniprep Kit 
Overnight bacterial culture (pMIR-TGFB2 3’UTR, pMIR-TGFB2 3’UTR mut, 
pMIR-SMAD2 3’UTR and pMIR-SMAD2 3’UTR mut) in a volume of 5-7 ml 
was centrifuged for 5 min at 4500 x g. The bacterial pellet was then 
resuspended in 250 μl buffer P1 and transferred to a microcentrifuge tube. 
After that 250 μl of lysis buffer P2 was added, mixed by inverting 10 times. 
After 5 min of lysis, N3 buffer was added to each tube and mixed by inverting 
10 times. Next, the sample was centrifuged for 10 min at 13,000 rpm in a table-
top microcentrifuge. The supernatant was then applied to Qiaprep 2.0 spin 
column by pipetting and centrifuged for 1 min. After that, the flow-through 
was discarded and 0.5 ml of PB buffer was applied to the column and 
centrifuged for 1 min. The column was then washed with 0.75 ml of buffer PE 
and centrifuged for 1 min. The flow-through was then discarded and the 
column I centrifuged at maximum speed for 1 min to remove the residual 
buffer. The column was then left on the bench to allow the residual ethanol to 
dry out. Finally, 30 μl of nuclease-free water was applied to the column and 
centrifuged for 1 min. The samples were then stored at -20°C. 
2.1.27 Quantification of the DNA/RNA concentration 
Quantification was done using NanoDrop 1000 Spectrophotometer and ND-
1000 software (Thermo Fisher Scientific). Firstly, 1 μl sample was pipetted onto 
the end of a fiber optic cable, following by blanking with 1 μl of nuclease-free 
water. DNA/RNA reads at 260 nm OD. The values for 260/280 nm and 260/230 
nm was around 2. 
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2.1.28 Luciferase assay 
HEK293T cells were transfected with 2ng of pMIR-control, pMIR-TGFB2 
3’UTR, pMIR-TGFB2 3’UTR mut, pMIR-SMAD2 3’UTR, pMIR-SMAD2 3’UTR 
mut, 100 ng of CMV-b-galactosidase plasmid (Clontech Laboratories), and 25 
nM of either MiRIDIAN miR-148b Mimic (Dharmacon, MI0000811) or 
miRIDIAN microRNA Mimic Negative Control (Dharmacon, CN-001000-01-
05). After 3 days of transfection, the cells were lysed with 1X Passive Lysis 
Buffer (Promega) for 15 min at room temperature. The protein was quantified 
using BCA assay and 2 μg of each sample was loaded on the 96-well solid 
white plate (Corning). Then, 100 μl of luciferase assay substrate (Promega, 
E151A) was added to each sample simultaneously using multichannel pipette. 
Immediately after, the absorbance was read at 560 nm (for Firefly luciferase) 
using Infinite® M1000 PRO plate reader (Tecan). Separately, 50 μl of β-
Galactosidase Enzyme Assay buffer (Promega, E2000) was added to 2 μg of 
protein extract and incubated at 37°C; the reaction was stopped 15-20 min later 
with 150µl of 1M Sodium Carbonate and the absorbance was read at 420 nm 
using Infinite® M1000 PRO plate reader (Tecan). The values of luciferase assay 
were normalised to the values of β-Galactosidase assay and expressed as 
luciferase/β-Galactosidase ratio. 
2.1.29 ELISA assay 
Human TGF-beta 2 Quantikine ELISA Kit (R&D, DB250) was used for this 
assay. Prior to the sample preparation the working standards were prepared 
at the concentrations of 1000 pg/mL, 500 pg/mL, 250 pg/mL, 125 pg/mL, 62.5 
pg/mL, 31.3 pg/mL. After that, 100 μl of Assay Diluent RD1-17 is added to each 
well on the assay plate. Next, 100 μl of standard, control, or activated sample 
is added to each well, covered with adhesive strip, incubated for 2 hours at 
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room temperature. After the incubation, each well is aspirated and washed 
three times with 300 μl wash buffer (diluted in PBS). Next, 200 μL of Human 
TGF-β2 Conjugate is added to each well, covered with a new adhesive strip 
and left for incubation for 2 hours at room temperature. The washing step is 
repeated and 200 μL of Substrate Solution (Color Reagents A and B should be 
mixed together in equal volumes within 15 minutes of use) is added to each 
well, incubated for 20 minutes at room temperature, while protected from 
light. After addition of 50 μL Stop Solution to each well, the plate is put into 
the Infinite® M1000 PRO plate reader (Tecan) and the absorbance is read at 
450 nm with wavelength correction set to 540 nm or 570 nm. The results are 
calculated using standard curve method and expressed as a concentration in 
ng/mL. 
2.1.30 Statistical analysis 
Comparisons between different conditions were assessed using 2-tailed 
Student’s t test. Differences among groups were elicited using ANOVA 
followed by Bonferroni post-hoc analyses as appropriate. Continuous data are 
expressed as mean ± SD of three independent experiments, each performed in 
triplicate or quintuplicate. P value <0.05 was considered statistically 
significant. Analyses were performed using GraphPad Prism v5.0. 
2.2 Techniques for in vivo studies 
The in vivo work has been performed by Dr Andrea Caporali and assisted by 
Dr Marco Meloni, Lorraine Rose and myself. 
2.2.1 Animal work 
The experiments involving mice were performed in accordance with the 
Guide for the Care and Use of Laboratory Animals prepared by the Institute 
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of Laboratory Animal Resources and with the prior approval of the UK Home 
Office and the University of Edinburgh ethic committee. CD-1 female mice (7–
10 weeks old) were randomly assigned a treatment group and anaesthetized 
with isofluorane. Two full-thickness excisional wounds were made to the 
shaved dorsal skin. Full-thickness excisional wounds were made by picking 
up a fold of skin and using a sterile, disposable 5-mm biopsy punch (Kai 
Industries), resulting in generation of one wound on each side of the midline. 
MiRIDIAN miR-148b Mimic (Dharmacon, MI0000811), miRIDIAN microRNA 
Mimic Negative Control (Dharmacon, CN-001000-01-05), miRCURY LNA™ 
anti-miR-148b (Exiqon) 75 nM, miRCURY LNA™ microRNA Antisense 
Control (Exiqon)  (1 ug/wound) were delivered topically by pipette into the 
wound cavity immediately after wounding and every two days (20μl in a 
vehicle of 30% Pluronic F-127 gel [is liquid at 4°C but solidifies at body 
temperature]; Sigma Aldrich). Wounds were photographed with an Olympus 
camera on days 0, 2, 4, 6, and 7 after wounding. To this aim, two perpendicular 
diameters of  the  wound  were  measured  by  using  a  Vernier caliper  and  
wound  area  was  calculated  using  a  standard  formula  for  the  area  of  an  
ellipse  (semi-major  diameter  X  semi-minor  diameter  X Pi).  
2.2.2 Histology 
Wounds were harvested on days 5 or 7 post-wounding, fixed in 10% buffered 
formalin (16h at 4°C, Sigma) for embedding in paraffin.  Wounds were 
sectioned through the wound beyond the midpoint and wound centres 
identified by staining with Haematoxylin and Eosin (Sigma). Sections were 
deparaffinised, rehydrated and stained with rat anti-mouse polyclonal CD31 
(Abcam), rabbit anti-mouse FSP-1 (fibroblast specific protein-1, Abcam), and 
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Angiogenesis is the subsequent remodelling of the primary vascular plexus 
formed during vasculogenesis, and the assembly of new vessels from pre-
existing ones (Risau, 1997). A number of recent studies have provided great 
insight into the molecular mechanisms underlying this process, and led to an 
established mechanistic framework of vessel branching (Carmeliet and Jain, 
2011, Potente et al., 2011). Together with the key drivers such as hypoxia, 
inflammation and haemodynamic forces, angiogenesis is tightly orchestrated 
by molecular stimuli such as VEGF, NOTCH, ANG-1, FGFs, TGF-β and PDGF-
B (Carmeliet and Jain, 2011). In addition to the molecular signals angiogenesis 
can be also positively or negatively modulated by miRNAs (Landskroner-
Eiger et al., 2013).  
MiRNAs are small (~22 nucleotides) conserved RNA molecules that function 
as post-transcriptional regulators of gene expression and modulate all known 
biological processes, from cell proliferation, growth and differentiation to 
homeostasis, development and metabolism (Ameres and Zamore, 2013). 
Using computational prediction algorithms and genome-wide elucidation of 
miRNA targets, it has been estimated that each miRNA molecule can bind to 
hundreds target mRNAs, modulating various networks and cascades of 
different proteins. As a result, an impaired regulation of miRNA biogenesis 
and function can lead to severe disorders and pathologies (Hesse and Arenz, 
2014). 
Endothelial cells exert a high expression of miRNAs (Poliseno et al., 2006) and 
recent findings imply that they can modulate vascular development as well as 
angiogenesis (Landskroner-Eiger et al., 2013). Depending on their target 
genes, miRNAs expressed in endothelial cells can be either positive or negative 
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regulators of angiogenesis. Specifically, miR-126 and miR-210 are enhancers 
of angiogenic response, targeting Spred-1 and PIK3R2, and Ephrin-A3, 
respectively, which abrogate cellular responsiveness to angiogenic stimuli like 
VEGF (Fish et al., 2008, Wang et al., 2008, Fasanaro et al., 2008). On the other 
hand, miR-17~92 cluster exerts anti-angiogenic effects on the endothelial cells 
via blocking the expression of pro-angiogenic S1PR1, p21 and Jak1 protein 
kinase (Doebele et al., 2010). Similarly, diabetes-induced miR-503 is able 
inhibit the angiogenic response in endothelial cells (Caporali et al., 2011). 
Recent study carried out in BHF Centre for Cardiovascular Target Discovery 
in University of Oxford (unpublished) describes a high-throughput miRNA 
phenotypic screen, in which 1500 miRNA mimics have been assayed on their 
capacity to modulate proliferation of HUVECs. Specifically, using miR-302c as 
a positive control and miR-503 as a negative control, a subset of proliferation 
enhancer miRNAs and inhibitor miRNAs have been identified. Out of the 
strongest enhancers 24 miRNAs were conserved and highly expressed in the 
endothelial cells, including miR-148b, miR-26b, miR-148a, miR-17 and miR-
20a. Notably, post-screening analysis has demonstrated that between this list 
miR-148b is the strongest enhancer of HUVEC proliferation. In addition to 
this, miR-148b has not been reported before to regulate endothelial cell biology 
or angiogenesis. In particular, limited number of studies describe the 
involvement of miR-148b in different types of cancer (Song et al., 2011, Song 
et al., 2012, Chang et al., 2012, Wu et al., 2012, Zhao et al., 2013) as well as 






In light of the novel findings on the capacity of miR-148b to strongly enhance 
HUVEC proliferation, the main goal of this chapter was to the hypothesis that: 
“Overexpression of miR-148b facilitates in vitro and in vivo angiogenesis” 
3.1.2 Aims 
The aims of this chapter were: 
1.    Identify miR-148b target genes 
2. Determine whether miR-148b overexpression enhances HUVEC 
proliferation, migration and cellular network formation in vitro 
3. Determine whether overexpression of miR-148b is able to induce 












3.2.1 Cells and Cell Culture 
Human umbilical vein ECs (HUVECs; Lonza) were grown in EGM-2 
(comprising EBM-2 with growth factors and other supplements) with 2% 
Foetal Bovine Serum. HEK293T cells (ATCC®, CRL-11268) were cultured in 
D-MEM with 10% FBS (Life Technologies). 
3.2.2 miR-148b Target Analysis 
Computational prediction of miR-148b target genes was done using published 
algorithm TargetScan (www.targetscan.org). miRpath v.3 
(http://diana.imis.athena-innovation.gr/DianaTools/index.php?r=mirpath) 
was used to perform gene set enriched analysis of miR-148b target genes. The 
prediction is based on Targetscan parameters such as Context score and 
Conservation score. 
3.2.3 RNA Extraction and Quantitative Real-Time Analysis 
Total RNA was extracted using miReasy kit (Qiagen). Real-time quantification 
to measure miRNAs was performed with the TaqMan miRNA reverse 
transcription kit and miRNA assay (Life Technology) using Lightcycler 480 
(Roche). MiRNAs expression was normalized to the U6 small nucleolar RNA 
(snRU6). For mRNA analysis, cDNA was amplified by quantitative real-time 
PCR (qPCR) and normalized to 18S ribosomal RNA. Each reaction was 
performed in triplicate. Quantification was performed by the 2–ddCt method. 
qPCR was used to measure the expression of miR-148b (miR-148b-3p Thermo 
Fisher Scientific, Cat. #4426961), snRU6 (Thermo Fisher Scientific, Cat. 
#4331182), TGFB2, SMAD2 and 18S rRNA. Primers are pre-designed from 
Sigma (KiCqStartTM Primers). 
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3.2.4 Cells transfection, transduction and functional assays 
Lipofectamine RNAiMAX (Thermo Fisher Scientific) was used to transfect 
HUVECs with miR-148b mimic, mimic control (25nM final concentration), 
according to the manufacturer's instructions. The following functional assays 
were performed: BrdU incorporation assay using Cell Proliferation 
colorimetric assay (Roche); migration assay and endothelial barrier function 
were performed using ECIS machine as described below. Matrigel assay with 
HUVECs was performed using BD Matrigel Basement Membrane Matrix (BD 
Biosciences). 
3.2.5 ECIS Assays 
Confluent HUVECs were transfected with miR-148b mimic and mimic control 
and plated on the ECIS chip array (8W1E). The migration speed was calculated 
in μm/h, distance from cells to chip surface in α (Ω0.5cm). 
3.2.6 Western-Blot analyses  
Proteins were extracted from cultured cells or muscles by using ice-cold buffer 
A (50mM Hepes, 150mM NaCl, 1mM EDTA, 1mM EGTA, 25mM NaF, 5mM 
NaPPi, 1%Triton, 1% NP40, 1 mM Na3VO4, 0,25% sodium deoxycholate, 
0.5mM Na-orthovanadate, 1 mM benzamidine, 0.1mM phenylmethylsulfonyl 
fluoride). Protein concentration was determined using the Bio-Rad Protein 
Assay Reagent (Bio-Rad Laboratories, UK). Detection of proteins by Western 
blot analyses was done following separation of whole cell extracts (20µg) on 
SDS-polyacrylamide gels. Proteins were transferred to nitrocellulose 
membranes and probed with the following antibodies: TGFβ2 (Abcam Ltd. 
ab36495, 1:1000), SMAD2 (SantaCruz Biotechnology, Santa Cruz, CA, USA; 
#3102, 1:1000) and β-actin (Abcam Ltd., ab16039, 1:4000). For detection, we 
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used secondary antibodies conjugated to horseradish peroxidase which were 
rabbit anti-mouse (Abcam Ltd., ab97046, 1:5000) and goat anti-rabbit (Abcam 
Ltd., ab6721, 1:10000). Detection was developed by chemiluminescence 
reaction (ECL) (Immunoblot, Millipore, 23225). 
3.2.7 Luciferase assay 
TGFB2 3'-UTR and SMAD2 3'-UTR vectors were cloned in pMIR-Reporter 
(Life Technology). Primers are used for the cloning are: TGFβ2 3’UTR: 
Forward 5’-ATAAAGCTTATTTGCCACATCATTGCAGA-3’, Reverse 5’-
ATAACTAGTGGGAATAAAAAGACGGCACA-3’; SMAD2 3’UTR: Forward 
5’-ATAAAGCTTTGATCCAGCTAAGGTAACTGATGTT-3’, Reverse 5’-
ATAACTAGTTGGTAAACAACTCAAATGGCTTTC-3’ TGFβ2 3’UTR mut: 
Forward 5’-ATAAAGCTTATTTGCCACATCATTGCAGA-3’, Reverse 5’- 
ATAACTAGTCCTATCTGAGAGGAAAATGTCTGC-3’; SMAD2 3’UTR mut: 
Forward 5’- ATAAAGCTTTGATCCAGCTAAGGTAACTGATGTT-3’, 
Reverse 5’- ATAACTAGTGGACTTCCAGAGGGAAACAA-3’. Luciferase 
constructs were transfected into HEK293T cells together with miR-148b 
mimics or p-SV-beta –Gal control vector. Cells were cultured for 48h and 
assayed with the Luciferase and β-Galactosidase Reporter Assay Systems 
(Promega). Luciferase values were normalized to protein concentration and β-
galactosidase activity. 
3.2.8 Animal experiments 
All experiments involving mice were performed in accordance with the 
guidance and the operation of Animals (Scientific Procedures) Act 1986 and 
prior approval of the UK Home Office and the University of Edinburgh ethic 
committee. CD-1 female mice (7–10 weeks old) were randomly assigned a 
treatment group and anaesthetized with isofluorane. Two full-thickness 
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excisional wounds were made to the shaved dorsal skin. Full-thickness 
excisional wounds were made by picking up a fold of skin and using a sterile, 
disposable 5-mm biopsy punch (Kai Industries), resulting in generation of one 
wound on each side of the midline. Control oligonucleotides (scramble 
sequence) and miR-148b mimic (1 ug/wound) were delivered topically by 
pipette into the wound cavity immediately after wounding and every two 
days (20μl in a vehicle of 30% Pluronic F-127 gel [is liquid at 4°C but solidifies 
at body temperature]; Sigma Aldrich). Wounds were photographed using an 
Olympus camera on days 0, 2, 4, 6, and 7 after wounding. To this aim, two 
perpendicular diameters of  the  wound  were  measured  by  using  a  Vernier 
caliper  and  wound  area  was  calculated  using  a  standard  formula  for  the  
area  of  an  ellipse  (semi-major  diameter  X  semi-minor  diameter  X Pi). 
3.2.9 Histology 
At days 5 or 7 post-wounding, wounds were harvested and fixed in 10% 
buffered formalin (16h at 4oC, Sigma) for embedding in paraffin.  Sectioning 
was done through the wound beyond the midpoint and wound centres as 
identified by staining with Haematoxylin and Eosin (Sigma). Sections were 
deparaffinised, rehydrated and stained with rat anti-mouse polyclonal CD31 
(Abcam, ab28364, 1:50) and Cy3-conjugated α-vascular smooth actin (Sigma) 
all antibodies overnight at 4oC. 
3.2.10 Statistical analysis 
Comparisons between different conditions were assessed using 2-tailed 
Student’s t test. Differences among groups were elicited using ANOVA 
statistical test followed by Bonferroni post-hoc analyses as appropriate. 
Continuous data are expressed as mean ± SD of three independent 
experiments, each performed in triplicate or quintuplicate. P value <0.05 was 
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3.3.1 Identification of miR-148b putative targets 
Using gene set enriched analysis miRpath (Vlachos et al., 2015), one of the 
pathways regulated by miR-148b was the TGF-β pathway (Fig. 3.1 a). 
Moreover, the Targetscan algorithm predicted TGFB2 and SMAD2 to be direct 
targets of miR-148b. Specifically, both genes contain one a single conserved 
binding sequence for miR-148b in their 3′ untranslated region (UTR) (Fig. 3.1 
b). Moreover, according to miRpath algorithm, TGFB2 hasn’t been yet 
supported experimentally to be a direct target of miR-148b. Thus, TGFB2 and 
SMAD2 were selected for subsequent in vitro validation. 
 
Figure 3.1| MiR-148b in silico targets analysis. a. Analysis of miR-148b target genes using 
miRpath software. Table shows Context Score and whether the targets have been 
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experimentally validated. b. In silico analysis of TGFB2 and SMAD2 3’UTR with Targetscan 
identifies putative miR-148b-binding sites (blue). 
3.3.2 Experimental validation of TGFB2 and SMAD2 as direct miR-148b targets 
To see if miR-148b overexpression modulates other predicted miR-148b target 
genes a qPCR was run to test the expression of selected candidates, including 
SMAD5, GADD45B, BCL2L11, p27, SNAI1, MEOX2, TNRC6A, AGO1, S1PR1 
and COPZ1, which is also a miR-148b host gene. As a result, it is evident that 
miR-148b modulates the expression of all of these predicted targets (Fig. 3.2 f). 
Nevertherless, due to the fact that TGFB2 and SMAD2 act at the same 
signalling pathway, these candidates were chosen for further analysis. To 
investigate whether miR-148b directly binds the 3’UTR of TGFB2 and SMAD2, 
luciferase reporter assay was performed, in which luciferase reporter gene was 
fused to the wild-type 3′UTR of TGFB2 or SMAD2, respectively. 
Overexpression of miR-148b decreased luciferase activity for each of the 
putative target genes (Fig. 3.2 a). Moreover, the elevated levels of miR-148b 
did not affect the luciferase activity of the targets, in which the 3’UTR has been 
truncated, deleting the seed sequence (Fig. 3.2 a). This date validates TGFB2 
and SMAD2 as direct target genes of miR-148b. In order to see whether miR-
148b is able to modulate the expression of TGFB2 and SMAD2 in endothelial 
cells, HUVECs were transfected with miR-148b mimic and control. 
Overexpression of miR-148b (Fig. 3.2 b) reduced both target gene mRNA (Fig. 
3.2 c) and protein levels (Fig. 3.2 d, e), confirming miR-148b regulation of 
TGFB2 and SMAD2 in vitro. Together, these findings demonstrate that TGFB2 
and SMAD2 are direct targets of miR-148b, which can downregulate their 
expression in the endothelial cells. 
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Figure 3.2| In vitro validation of TGFB2 and SMAD2 as direct miR-148b targets. a. Luciferase 
activity expressed as luciferase/β-Gal ratio at 48h post-co-transfection of HEK293T cells with 
both miR-148b and the following plasmids: 3’-UTR-TGFB2. 3’-UTR-SMAD2 and pMIR as 
empty plasmid (n=5); b. qPCR showing miR-148b expression levels after miR mimic 
transfection; average Ct values: miR-148b (control: 30; miR-148b mimic: 22). c. qPCR showing 
relative gene expression of TGFB2 and SMAD2, after miR-148b overexpression (n=3); average 
Ct values: TGFB2 (control: 23; miR-148b mimic: 30), SMAD2 (control: 22; miR-148b mimic: 24); 
d. Western blot analysis of TGFB2 and SMAD2 in samples transfected with miR-148b mimic 
vs control; β-actin is used as a loading control at dilution 1:4000 (n=3); antibody dilutions for 
anti-TGFB2 and anti-SMAD2 are 1:1000; e. Quantification of TGFB2 and SMAD2 western 
blots; f. qPCR showing relative gene expression of putative miR-148b target genes after miR-
148b overexpression (n=2); average Ct values: SMAD5 (control: 22; miR-148b mimic: 27), 
GADD45B (control: 22, miR-148b mimic: 28), BCL2L11 (control: 25; miR-148b mimic: 30), p27 
(control: 23; miR-148b mimic: 26), SNAI1 (control: 26; miR-148b mimic: 32), MEOX2 (control: 
24; miR-148b mimic: 25), COPZ1 (control: 25; miR-148b mimic: 27), TNRC6A (control: 25; miR-
148b mimic: 26), AGO1 (control: 30; miR-148b mimic: 31), SP1PR1 (control: 24; miR-148b 
mimic: 25); HUVECs were transfected with miR-148b mimic or control oligonucleotides for 
48hrs; For miRNA qPCR U6 was used as a house-keeping control; For target gene qPCR 18s 
was used as a house-keeping control; Values are means±SEM *P<0.05; **P<0.01 vs control and 
pMIR vector in experiment b. Unpaired two-tailed Student’s t-test was applied. 
3.3.4 MiR-148b induces HUVEC proliferation, migration and in vitro 
angiogenesis 
To better understand the effect of miR-148b on cellular phenotype, functional 
cellular assays have been performed with the HUVECs transfected with miR-
148b mimic and control. Specifically, miR-148b overexpression significantly 
increased the proliferation of HUVEC, as demonstrated by BrdU 
incorporation assay (Fig. 3.3 a). Next, in order to elucidate miR-148b effect on 
in vitro angiogenesis, two pro-angiogenic properties of HUVEC were 
analysed: migration and cellular network formation. The migration capacity 
of HUVECs transfected with a miR-148b mimic was significantly elevated (Fig. 
91 
 
3.3 b), along with their ability to form tube-like structures in an in vitro 
Matrigel assay (Fig. 3.3 c). Together, these results illustrate that miR-148b is 
able to induce in vitro angiogenesis via enhancing HUVEC proliferation, 
migration and cell network formation. 
 
Figure 3.3| MiR-148b overexpression enhances proliferation and in vitro angiogenesis. a. 
EC proliferation was analysed by BrdU incorporation assay and expressed as a fold change in 
absorbance (n=3); b. ECIS migration assay using 8W2LE array reported as migration speed 
(µm/h) (n=3); c. Representative Matrigel assay pictures and d. quantification as total tubules 
length expressed as pixel density (n=3); Values are means±SEM *P<0.05; **P<0.01 vs control. 
Unpaired two-tailed Student’s t-test was applied. 
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3.3.5 Topical miR-148b delivery facilitates angiogenesis and promotes wound 
healing in vivo 
In order to determine whether overexpression of miR-148b is also able to 
induce angiogenic response in vivo, a model of mouse wound healing 
angiogenesis has been used due to the fact that this is an ideal model to analyse 
angiogenesis because of its easy accessibility to control and modulate the 
process (Eming et al., 2007). Notably, in the skin of the healthy mice miR-148b 
expression was reduced significantly 3 days after wound induction (Fig. 3.4 
a). Next, the topical delivery of miR-148b mimics, within Pluronic gel, 
increased miR-148b expression 7 days after injury (Fig. 3.4 b). Expression 
levels of both targets, TGFB2 and SMAD2, were considerably reduced in the 
wounds following the treatment with miR-148b mimics (Fig. 3.4 b). Moreover, 
miR-148b overexpression significantly accelerated wound closure (Fig. 3.4 c, 
d) and enhanced the wound perfusion detected by Doppler analysis (Fig. 3.4 
e). Finally, delivery of miR-148b mimics has also increased vascularization in 
the wound as shown by considerable enhancement of CD31 positive vessels 
(Fig. 3.4 f). Overall, these data indicate that miR-148b overexpression via 
topical miR mimics delivery is able to inhibit TGFB2 and SMAD2 expression 




Figure 3.4| MiR-148b facilitates angiogenesis and wound healing in vivo. a. qPCR showing 
expression of miR-148b at 3 and 7 days after wounding, relative to unwounded skin (n = 5); 
average Ct values: miR-148b (0 d: 29, 3 d: 31, 7 d: 30); b. qPCR showing relative gene expression 
of miR-148b, TGFB2 and SMAD2 in dermal wound after delivering of miR-148b mimic or 
control oligonucleotides for 5 days; average Ct values: miR-148b (pluronic: 27, control: 28, 
miR-148b mimic: 23), TGFB2 (pluronic: 25, control: 24, miR-148b mimic: 26), SMAD2 (pluronic: 
24, control: 23, miR-148b mimic: 27)  c. Representative images of control and miR-148b mimic 
treated wounds at 0 and 7 days post wound injury, scale bar=5mm; d. Level of wound closure 
expressed in percentage of wound area from the initial area (n=8); e. Representative colour 
laser Doppler images are taken at 5 days post wounds. Chart shows level of wounds perfusion 
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in mice (calculated as the ratio between treated and control blood flow; n=8 per group); f. 
Immunohistochemistry for CD31 (antibody dilution 1:50), α-SMA (antibody dilution 1:100) in 
miR-148b mimic-treated or control-treated skin wounds; scale bar=100μm (magnification 
400x); yellow line determine wound edge. Quantification of vessel density expressed as CD31 
positive vessels/mm2 (n=8); For miRNA qPCR U6 was used as a house-keeping control; For 
target gene qPCR 18s was used as a house-keeping control; Values are means±SEM *P<0.05; 


















Here, this chapter shows for the first time that miR-148b is a modulator of 
endothelial cells function and angiogenesis. Moreover, this chapter provides 
novel evidence that miR-148b is targeting the expression of TGFB2 and 
SMAD2 genes, which are part of one signalling cascade. Finally, these data 
elucidates for the first time that role of miR-148b in promoting the wound 
repair as well as in vivo angiogenesis. 
3.4.1 MiR-148b targets TGF-β pathway and upregulates in vitro angiogenesis  
There has been no scientific data in the literature to date discussing the role of 
miR-148b in endothelial cell biology. The high-throughput phenotypic screen 
carried out prior to this study has elucidated for the first time that miR-148b 
overexpression in HUVEC is able to induce cell proliferation. To follow up on 
the preliminary data, the migration and in vitro angiogenesis assays in this 
chapter have confirmed the proangiogenic properties of miR-148b. Recently, 
Yang et al. has carried out a similar high-throughput miRNA screen in order 
to identify miRNAs that could target the expression of Nox2 gene (Yang et al., 
2017), which is a strong inducer of reactive oxygen species (ROS) production 
in infarcted myocardium (Cave et al., 2006). Interestingly, the study has 
identified miR-148b along with miR-204 and miR-106b to be potent 
modulators of Nox2 expression in human macrophages (THP-1 cells). 
Moreover, all three miRNAs were able to decrease ROS production in the 
macrophages as well as reduce the secretion of pro-inflammatory cytokines 
(Yang et al., 2017). 
Further, the miRNA pathway analysis software has predicted miR-148b to 
potently modulate TGF-β cascade. The target validation experiments in this 
chapter have confirmed TGFB2 and SMAD2 to be direct miR-148b targets with 
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a strong regulation in HUVECs. These results can explain the increase in 
proliferation as well as in vitro angiogenesis because TGF-β pathway has been 
reported before to negatively regulate the proliferation of endothelial cells and 
angiogenesis via ALK5 activation (Goumans et al., 2002) and VEGF 
insensitivity (Viloria-Petit et al., 2013). In the analogous study, Dews et al. 
suggested that miR-17∼92 cluster, upregulated by c-Myc, is able to promote 
angiogenesis via blocking the expression of the components of TGF-β 
signalling cascade – TGFBR2 and SMAD4 (Dews et al., 2010). 
Interestingly, the downregulation levels of TGFB2 and SMAD2 in response to 
miR-148b overexpression are different: the expression of TGFB2 is completely 
silenced, whereas SMAD2 is only ~65% downregulated. This discrepancy can 
be explained by the fact that the interaction between miR-148b and TGFB2 
forms the 8mer, which is the exact match to the seed sequence of mature miR-
148b. On the other hand, miR-148b:SMAD2 is a 7mer with incomplete binding 
of miR-148b. As a result, the interaction between TGFB2 mRNA and miR-148b 
is stronger and downregulation is more significant than of SMAD2. It could 
also be speculated that TGFB2 is expressed in a higher abundance than 
SMAD2 mRNA resulting in “sponge out” effect on miR-148b.  
Importantly, miR-148b overexpression leads to consistent downregulation of 
other putative target genes, SMAD5, GADD45B, BCL2L11, p27, SNAI1, 
MEOX2, TNRC6A, AGO1, S1PR1 and a miR-148b host gene COPZ1. 
Interestingly, SMAD5 is involved in an antagonising pathway to the TGFβ2 
pathway. It is possible to speculate that the ability of miR-148b to modulate 
SMAD5 is part of the feedback mechanism to balance out the effect of TGFβ2-
SMAD2 downregulation. What is more, GADD45B, BCL2L11, p27, TNRC6A 
and S1PR1 are all antiangiogenic genes. It is therefore logical to assume that 
the strong pro-angiogenic effect of miR-148b is also partially attribute to 
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downregulation of this genes. Notably, AGO1 is involved in miRISC assemble 
and, thus, its silencing by miR-148b could also be a feedback negative 
mechanism to diminish the production of mature miR-148b-3p, when the 
levels of its precursor are too high. Similarly, miR-148b targeting of its host 
gene COPZ1 suggest another mechanism of automodulation to control miR-
148b levels in the cell. 
Overall, the in vitro part of this chapter demonstrated that miR-148b is able to 
enhance HUVEC proliferation, migration and angiogenesis in vitro, possibly 
by targeting specifically TGFβ2-ALK5-SMAD2/3 axe. 
3.4.2 Topical miR-148b delivery enhances in vivo angiogenesis and wound 
repair 
For this study, mouse wound healing model has been chosen for the in vivo 
experiments due to several practical reasons. Not only it is easily obtainable, 
but it also provides an accelerated model of healing, which can be easily 
managed and manipulated molecularly and genetically (Perez and Davis, 
2008). In the context of this chapter, the mouse wound healing model is 
particularly useful due to the fact that it minimizes the systemic off-target 
effects of miRNA therapy due to the topical local delivery directly on the 
wounds. Specifically, due to the fact that miR-148b overexpression was able to 
induce in vitro angiogenesis, the mouse wound repair method provides a well 
visualizable model for in vivo angiogenic response that can be modulated by 
miRNA mimic delivery. For the purpose of this chapter, a Pluronic F-127 
polymeric gel (Escobar-Chavez et al., 2006) is used as a delivery vehicle of 
miR-148b mimic and control oligonucleotides. Using this method, the data in 
this chapter demonstrates for the first time that the successful miR-148b 
mimics delivery on the wounds is able to target TGF-β pathway in vivo and 
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significantly enhance the dermal angiogenic response and accelerate the 
wound repair.  
It is clear now that miRNA are becoming important modulators of wound 
healing process (Sen and Roy, 2008). Interestingly, in 2006 it has been reported 
that Dicer is expressed in mouse skin and is required for dermal 
morphogenesis (Andl et al., 2006). There is a significant number of miRNAs 
that are expressed in the skin, the most abundant being miR-200, miR-19/20 
family and miR-199 (Yi et al., 2006). It is important to note that the wound 
repair process involves a number of stages: the inflammatory phase, the 
proliferation phase, which includes epithelisation, angiogenesis and 
granulation tissue formation, and remodelling phase characterized by the 
deposition of collagen that continues after wound closure. Specifically, within 
one hour of the injury the haemostasis process is taking place, which is 
characterized by clotting and vasoconstriction, acting simultaneously to 
prevent prolonged haemorrhage, followed by vasodilation phase that allows 
the migration of immune cells. After the first hour the inflammatory phase is 
initiated via migration of leukocytes to the wound site; it is characterized by 
phagocytosis of bacteria as well as wound debris and secretion of chemokines 
and cytokines, which attract fibroblasts and endothelial cells to the wound. 
Within one day of the injury the proliferative phase begins that can act up until 
one month post-injury. During this phase endothelial cells as well as fibroblast 
start to proliferate and secrete ECM accompanied by angiogenesis and 
granulation tissue formation. Finally, a remodelling stage is initiated by the 
contraction of the wound due to activation of myofibroblasts, followed by 




Notably, each stage in the wound healing process is characterized by 
expression of different genes and is regulated by different sets of miRNAs 
(Banerjee et al., 2011). Examples of miRNAs regulating the inflammatory 
phase of wound healing are: miR-105 modulating the expression of Toll-like 
receptor 2 (TLR2) (Benakanakere et al., 2009) as well as miR-146a and miR-
125b regulating TNF-α pathway (Sonkoly et al., 2008). The keratinocyte 
migration and proliferation during proliferation phase of wound healing is 
orchestrated by pro-migratory miR-205 and anti-proliferative miR-210 
targeting SHIP2 phosphatase (Yu et al., 2010) and transcription factor E2F3 
(Biswas et al., 2010), respectively. Moreover, recent study demonstrated that 
non-healing ulcers-associated miR-21 and miR-130a negatively regulate the 
granulation phase of the wound healing (Pastar et al., 2012) 
However, there is not much known about miRNAs regulating angiogenic 
phase of wound healing.  This chapter focused specifically on the angiogenic 
stage of the wound repair during the proliferation phase. MiR-148b was able 
to promote angiogenesis in vitro and in the wound, consistently, possibly by 
silencing the components of TGF-β pathway. 
Interestingly, it has been demonstrated that reduction of the translation of 
TGF-β in human epidermal keratinocytes resulted in increased secretion of 
pro-angiogenic VEGF (Riedel et al., 2007). Taking together the data from this 
chapter, it is therefore possible to speculate that by decreasing the expression 
of TGFB2 in the wound tissue, the keratinocytes become less subjected to TGF-
β2 stimulus and thereby start to secrete more VEGF, that in turn upregulates 
endothelial cell proliferation and migration even more, creating a feed-
forward positive loop of angiogenic response. 
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It is important to note that the findings in this chapter directly present the 
translational significance of the research carried out. The in vitro part of the 
investigation perfectly aligns with the mice study, sharing the same targets of 
miR-148b and the model of angiogenesis. Both the cellular angiogenic as well 
as mouse wound healing models prove that miR-148b is able to efficiently 
enhance angiogenesis and ultimately lead to the closure of the wounds, 
concluding the pre-clinical part of the study. One possible strategy for the 
clinical study would be to use miR-148b mimic delivery to enhance the closure 
of non-healing ulcers in diabetic patients. More work should be done at the ex 
vivo level to generate the proof-of-concept data that miR-148b topical delivery 
is able to induce wound closure in the skin from patients with diabetes. 
Importantly, this chapter provides a solid foundation for the initiation of 
human studies and opens up the avenue for possible therapeutic utilization of 
miR-148b. 
3.4.3 Limitations 
The main limitation of this chapter is the lack of direct link between TGFB2 
and SMAD2 silencing by miR-148b and enhancement of angiogenesis. It is 
clear from the data that miR-148b also targets other strong anti-angiogenic 
genes, downregulation of which, together with TGFB2 and SMAD2, could 
explain such a marginal pro-angiogenic effect of miR-148b. 
3.4.4 Conclusion 
This chapter introduces the novelty into the research field of miRNA, 
angiogenesis and wound healing. Specifically, the data in this chapter 
identifies a novel function of miR-148b to induce angiogenesis in endothelial 
cells in vitro and presents the evidence that in vivo topical delivery of miR-148b 
mimic in the mouse wound is able to facilitate faster wound closure and 
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perfusion via enhancing in vivo angiogenic response. This chapter also 
discusses a significance of these findings, particularly, in the setting of miRNA 
therapeutics and the possibility to use miR-148b as a potential therapeutic 
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Initially described as a passive barrier, the endothelium is now appreciated as 
a complex tissue with multiple functions, with endothelial cells acting as 
vascular transducers of physical and chemical stimuli within the circulation 
(Adams and Alitalo, 2007). It has been demonstrated numerously that 
endothelial cells exhibit high level of adaptation in response to external 
stimuli, as well as high plasticity which is an integral part of various 
developmental and pathological processes (Dejana et al., 2017). One type of 
plasticity is endothelial-to-mesenchymal transition (EndMT), which is a 
physiologically vital mechanism during development that can become 
pathological in the adult body. EndMT is characterized by the loss of 
endothelial-specific markers from the endothelial cells and the adaptation of a 
mesenchymal-like phenotype along with mesenchymal-specific molecular 
composition. In particular, vascular endothelial cadherin (VE-cadherin) and 
platelet-endothelial cell adhesion molecule 1 (PECAM-1, CD31) are being 
replaced by of α-SMA, vimentin, N-cadherin and extracellular matrix (ECM) 
proteins such as collagen type I and III (Piera-Velazquez and Jimenez, 2012).  
Moreover, cytoskeletal rearrangement is also observed in the cells enduring 
EndMT, which leads to a change in cell polarity giving them a stretched and 
more fibroblast-like morphology (Piera-Velazquez and Jimenez, 2012). The 
process of EndMT is vital during the embryonic stages of cardiac and 
pulmonary artery development (Arciniegas et al., 2005, Armstrong and 
Bischoff, 2004). However, the transition program is abnormal during post-
natal stages leading to a number of disorders such as growth and progression 
of tumours (Zeisberg et al., 2007a), fibrosis of the heart (Zeisberg et al., 2007b) 
and renal systems (Zeisberg et al., 2008). 
104 
 
Accumulating studies over the past few years have also revealed that 
activation of TGF-β pathway regulates endothelial cell phenotypic plasticity 
and its activation can lead to EndMT induction (Dejana et al., 2017). It is also 
well known that TGF-β signalling pathway is a crucial regulator of both 
normal and irregular vascular function (Goumans and Ten Dijke, 2017). 
During canonical activation of TGF-β pathway, TGF-β binds to the 
heteromeric receptor complex formed by the activin-like kinase 5 (ALK5, also 
known as TGF-β type I receptor, TGF-βR1) and the TGFβ type II receptor 
(TGF-βR2). Phosphorylation of ALK5 by the kinase TGF-βR2, activates its 
catalytic domain, facilitating the induction of the receptor-regulated Smad 
proteins (i.e. SMAD2 and SMAD3), which then translocate to the nucleus. 
Finally, nuclear-localized Smads modulate the transcription of specific target 
genes  (van Meeteren and ten Dijke, 2012). 
MicroRNAs are characterized as post-transcriptional gene silencers, which 
interact with their complementary mRNA transcripts (Ha and Kim, 2014). 
Their capacity to simultaneously knock down the expression of number of 
different mRNAs leads to efficient amplification of biological responses (Li 
and Rana, 2014). Recent investigations have described the important roles of 
miRNAs as therapeutic agents in regulating either physiological or 
pathological angiogenesis, particularly through the regulation of endothelial 
cell function (reviewed in (Caporali and Emanueli, 2011, Caporali and 
Emanueli, 2012)). 
Recently, a number of miRNAs have been identified as modulators of the 
elements of TGF-β/Smad signalling axis (Kurakula et al., 2015), and ultimately, 
as regulators of EndMT process (Ghosh et al., 2012a).  Despite the fact that the 
role of TGF-β signalling in modulating endothelial cell homeostasis and 
plasticity is now well known (van Meeteren and ten Dijke, 2012), there is not 
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much evidence on the mechanisms regulating the molecular cascade. The 
rational for this chapter came from the bioinformatic analysis using the 
miRNA target prediction tools, where it was found that miR-148b target genes 
are strongly enriched for the components of TGF-β pathway. Moreover, the 
data in previous chapter has confirmed that miR-148b directly targets the 
expression of TGFB2 and SMAD2 genes, which both are key members of TGF-
β signalling cascade as well as are potent inducers of EndMT. MiR-148b 
together with miR-148a and miR-152 comprise the miR-148/152 family (Chen 
et al., 2013). Abnormal expression of miR-148/152 family has been reported in 
tumours, but also in non-cancer diseases such as IgA nephropathy (Serino et 
al., 2012) and atherosclerotic lesions (Bidzhekov et al., 2012). Nevertheless, 
miR-148b has never been observed to modulate TGF-β pathway, nor to 
participate in EndMT. 
4.1.1 Hypothesis 
Taking in account the data generated from bioinformatic analysis as well as 
results from the previous chapter on miR-148b-specific regulation of TGFB2 
and SMAD2, the main goal of this chapter was to the hypothesis that: 
“Downregulation of miR-148b induces TGF-β signalling and facilitates 
EndMT” 
4.1.2 Aims 
The aims of this chapter were: 
1. Identify the effect of miR-148b inhibition on TGFB2 and SMAD2 expression 
2. Determine whether miR-148b downregulation changes HUVEC 
proliferation, migration and cellular network formation in vitro 
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3.  Determine if inhibition of miR-148b changes HUVEC morphology and/or 
induces EndMT in vitro 





















4.2.1 Cells and Cell Culture 
Human umbilical vein ECs (HUVECs; Lonza) were grown in EGM-2 
(comprising EBM-2 with growth factors and other supplements) with 2% 
Foetal Bovine Serum.   
4.2.2 miR-148b Target Analysis 
Computational prediction of miR-148b target genes was done using published 
algorithm TargetScan (www.targetscan.org). miRpath v.3 
(http://diana.imis.athena-innovation.gr/DianaTools/index.php?r=mirpath) 
was used to perform gene set enriched analysis of miR-148b target genes. The 
prediction is based on Targetscan parameters such as Context score and 
Conservation score. 
4.2.3 RNA Extraction and Quantitative Real-Time Analysis 
Total RNA was extracted using miReasy kit (Qiagen). Real-time quantification 
to measure miRNAs was performed with the TaqMan miRNA reverse 
transcription kit and miRNA assay (Life Technology) using Lightcycler 480 
(Roche). MiRNAs expression was normalized to the U6 small nucleolar RNA 
(snRU6). For mRNA analysis, cDNA was amplified by quantitative real-time 
PCR (qPCR) and normalized to 18S ribosomal RNA. Each reaction was 
performed in triplicate. Quantification was performed by the 2–ddCt method. 
qPCR was used to measure the expression of miR-148b (miR-148b-3p Thermo 
Fisher Scientific, Cat. #4426961), snRU6 (Thermo Fisher Scientific, Cat. 
#4331182), TGFB2, SMAD2, CD31, VE-Cadherin, COL1A1 and 18S rRNA. 
Primers are pre-designed from Sigma (KiCqStartTM Primers). 
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4.2.4 Cells transfection, transduction and functional assays 
Lipofectamine RNAiMAX (Thermo Fisher Scientific) was used to transfect 
HUVECs with LNA anti-miR-148b and LNA anti-miR control (75nM final 
concentration), according to the manufacturer's instructions. The following 
functional assays were performed: BrdU incorporation assay using Cell 
Proliferation colorimetric assay (Roche); migration assay and endothelial 
barrier function were performed using ECIS machine as described below. 
Matrigel assay with HUVECs was performed using BD Matrigel Basement 
Membrane Matrix (BD Biosciences). 
4.2.5 ECIS Assays 
Confluent HUVECs were transfected with LNA anti-miR-148b and LNA anti-
miR control and plated on the ECIS chip array (8W1E or 8W10E). The 
migration speed was calculated in μm/h, distance from cells to chip surface in 
α (Ω0.5cm) and capacitance of the plasma membrane is Cm (μF/cm2). 
4.2.6 Western-Blot analyses  
Proteins were extracted from cultured cells or muscles by using ice-cold buffer 
A (50mM Hepes, 150mM NaCl, 1mM EDTA, 1mM EGTA, 25mM NaF, 5mM 
NaPPi, 1%Triton, 1% NP40, 1 mM Na3VO4, 0,25% sodium deoxycholate, 
0.5mM Na-orthovanadate, 1 mM benzamidine, 0.1mM phenylmethylsulfonyl 
fluoride). Protein concentration was determined using the Bio-Rad Protein 
Assay Reagent (Bio-Rad Laboratories, UK). Detection of proteins by Western 
blot analyses was done following separation of whole cell extracts (20µg) on 
SDS-polyacrylamide gels. Proteins were transferred to nitrocellulose 
membranes and probed with the following antibodies: TGFβ2 (Abcam Ltd. 
ab36495, 1:1000), SMAD2 (SantaCruz Biotechnology, Santa Cruz, CA, USA; 
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#3102, 1:1000), CD31 (Abcam Ltd., 1:1000), VE-Cadherin (Abcam Ltd. ab33168, 
1:1000), COL1A1 (Abcam Ltd., ab138492, 1:200), β-actin (Abcam Ltd., ab16039, 
1:4000) HDAC3  (GeneTex GTX113303, 1:1000) and GAPDH (GeneTex, GT239, 
1:1000) (used as loading control). For detection, we used secondary antibodies 
conjugated to horseradish peroxidase which were rabbit anti-mouse (Abcam 
Ltd., ab97046, 1:5000) and goat anti-rabbit (Abcam Ltd., ab6721, 1:10000). 
Detection was developed by chemiluminescence reaction (ECL) (Immunoblot, 
Millipore, 23225). 
4.2.7 Immunofluorescence 
Cells were fixed using 4% paraformaldehyde in PBS at room temperature for 
15 min. For intracellular staining, fixed cells were permeabilized using 0.5% 
Triton X-100 in PBS (Sigma-Aldrich) or 0.1% Saponin in PBS at room 
temperature for 10 min. The blocking of specific antibody activity was 
performed using 3% bovine serum albumin (BSA) in PBS for 1 hour. Samples 
were incubated with antibodies to CD31 (Abcam Ltd., 1:50), VE-cadherin 
(Abcam Ltd. ab33168, 1:100) and COL1A1 (Abcam Ltd., ab138492, 1:100) in 
PBS containing 1% BSA at 4°C overnight. Samples were washed extensively 
with PBS and incubated with Alexa-Fluor-488-conjugated antibodies to rabbit 
IgG (Life Technologies, Carlsbad, CA, # A11070) and Alexa-Fluor-594-
conjugated antibodies to rabbit IgG (Life Technologies, Carlsbad, CA, 
#A11072) in DAPI with PBS with 1% BSA at room temperature for 1 h. Image 
analysis was performed on Zeiss LSM 780 confocal microscope. 
4.2.8 Animal experiments 
All experiments involving mice were performed in accordance with the 
guidance and the operation of Animals (Scientific Procedures) Act 1986 and 
prior approval of the UK Home Office and the University of Edinburgh ethic 
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committee. CD-1 female mice (7–10 weeks old) were randomly assigned a 
treatment group and anaesthetized with isofluorane. Two full-thickness 
excisional wounds were made to the shaved dorsal skin. Full-thickness 
excisional wounds were made by picking up a fold of skin and using a sterile, 
disposable 5-mm biopsy punch (Kai Industries), resulting in generation of one 
wound on each side of the midline. Control oligonucleotides (scramble 
sequence), anti-miR-148b (1 μg/wound) and SMAD2 siRNA (1 μg/wound) 
were delivered topically by pipette into the wound cavity immediately after 
wounding and every two days (20μl in a vehicle of 30% Pluronic F-127 gel [is 
liquid at 4°C but solidifies at body temperature]; Sigma Aldrich). Wounds 
were photographed using an Olympus camera on days 0, 2, 4, 6, and 7 after 
wounding. To this aim, two perpendicular diameters of  the  wound  were  
measured  by  using  a  Vernier caliper  and  wound  area  was  calculated  
using  a  standard  formula  for  the  area  of  an  ellipse  (semi-major  diameter  
X  semi-minor  diameter  X Pi). 
4.2.9 Histology 
At days 5 or 7 post-wounding, wounds were harvested and fixed in 10% 
buffered formalin (16h at 4oC, Sigma) for embedding in paraffin.  Sectioning 
was done through the wound beyond the midpoint and wound centres as 
identified by staining with Haematoxylin and Eosin (Sigma). Sections were 
deparaffinised, rehydrated and stained with rat anti-mouse polyclonal CD31 
(Abcam, ab28364, 1:50) and Cy3-conjugated α-vascular smooth actin (Sigma) 
all antibodies overnight at 4oC. 
4.2.10 Statistical analysis 
Comparisons between different conditions were assessed using 2-tailed 
Student’s t test. Differences among groups were elicited using ANOVA 
111 
 
statistical test followed by Bonferroni post-hoc analyses as appropriate. 
Continuous data are expressed as mean ± SD of three independent 
experiments, each performed in triplicate or quintuplicate. P value <0.05 was 


















4.3.1 MiR-148b silencing unlocks the expression of on TGFB2 and SMAD2 
In order to downregulate miR-148b expression, HUVECs were transfected 
with LNA anti-miR-148b and LNA anti-miR control oligos for 6 days. As a 
result, the anti-miR-148b transfection decreased the expression of miR-148b 
(Fig. 4.1 a). MiR-148b downregulation resulted in increase in the expression of 
its target genes TGFB2 and SMAD2, which was also confirmed by the western 
blot analysis (Fig. 4.1). Together, this data confirms that miR-148b knockdown 
is able to induce the components of TGF-β signalling pathway, TGFB2 and 
SMAD2. 
Figure 4.1| MiR-148b inhibition modulates the components of TGF-β signalling. a. qPCR 
showing miR-148b expression levels after anti-miR transfection; average Ct values: miR-148b 
(control: 28; anti-miR-148b: 29); b. qPCR showing relative gene expression of TGFB2 and c. 
SMAD2, after miR-148b inhibition (n=3); average Ct values: TGFB2 (control: 27; anti-miR-148b: 
25), SMAD2 (control: 24, anti-miR-148b: 21); HUVECs were transfected with LNA anti-miR-
148b or LNA anti-miR control oligonucleotides for 6 days; For miRNA qPCR U6 was used as 
a house-keeping control; For target gene qPCR 18s was used as a house-keeping control; 
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Values are means±SEM *P<0.05; **P<0.01 vs control. Unpaired two-tailed Student’s t-test was 
applied. 
4.3.2 MiR-148b downregulation reduces HUVEC proliferation and increases 
membrane capacitance while having to effect on in vitro angiogenesis 
Next, the downregulation of miR-148b expression was assessed in the context 
of regulating endothelial cell function. Firstly, the BrdU incorporation assay 
has demonstrated that HUVECs transfected with anti-miR-148b exhibit 
diminished cellular proliferation (Fig. 4.2 a). Interestingly, the inhibition of 
miR-148b expression had no effect on HUVEC migration (Fig. 4.2 b) and 
cellular network formation on Matrigel (Fig. 4.2 b). In order, to better 
understand the possible morphological change that miR-148b downregulation 
could have on HUVECs, the cells were subjected to a very high-sensitivity 
membrane capacitance (Cm) assay, changes in which reflect structural 
changes in the plasma membrane and rearrangement of the cytoskeleton 
(Giaever and Keese, 1991a). Strikingly, downregulation of miR-148b elevated 
membrane capacitance of HUVECs, which is reflects on the morphological 
change (Fig. 4.2 d). Overall, these results demonstrate that miR-148b inhibition 
causes the decrease in endothelial cell proliferation, has no effect on in vitro 







Figure 4.2| MiR-148b inhibition differentially modulates endothelial cell function and 
leads to the structural change of endothelial cells. a. EC proliferation was analyzed by BrdU 
incorporation assay and expressed as a fold change in absorbance (n=3); b. ECIS migration 
assay reported as migration speed on 8W2LE array (µm/h) (n=3); c. Matrigel assay 
quantification as total tubules length and expressed as pixel density (n=3); d. Quantification 
of cell membrane capacitance in HUVECs knock-down for miR-148b or control expressed as 
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μF/cm2, 8W10E+ array was used  (n=5); Values are means±SEM *P<0.05; **P<0.01 vs control. 
Unpaired two-tailed Student’s t-test was applied. 
4.3.3 MiR-148b inhibition promotes EndMT in vitro 
Due to the fact that miR-148b downregulation increased cell membrane 
capacitance, and thus altered cellular structure, and enhanced TGF-β pathway, 
which is directly involved in EndMT, cells were analyzed for the expression 
of endothelial- and mesenchymal-specific markers. In particular, a significant 
decrease in gene expression of both endothelial markers, CD31 and VE-
Cadherin, was observed upon miR-148b downregulation (Fig. 4.3 a), further 
validated by reduction in the protein levels of both markers (Fig. 4.3 b). On the 
other hand, HUVEC exhibiting low miR-148b levels started to highly express 
pro-mesenchymal COL1A1 (Fig. 4.3 a, b). Furthermore, immunofluorescence 
staining revealed that control-treated HUVECs display a typically 
rounded/cobblestone morphology that was lost in anti-miR-148b treated cells. 
Anti-miR-148b treatment also resulted in a pronounced decrease in CD31 and 
VE-cadherin and increase in COL1A1 immunoreactivity (Fig. 4.3 c). Taken 
together, this data shows that loss of miR-148b function facilitates to EndMT 






Figure 4.3| MiR-148b downregulation induces EndMT program. a. qPCR showing relative 
gene expression of CD31, VE-Cadherin and COL1A1 after anti-miR-148b transfection; average 
Ct values: CD31 (control: 21; anti-miR-148b: 22), VE-Cadherin (control: 20; anti-miR-148b: 22), 
COL1A1 (control: 38; anti-miR-148: 34);  the dotted line represents the relative gene expression 
in HUVECs transfected with control anti-miR (n=3); b. Western blot analysis of TGFB2 
(antibody dilution 1:1000), SMAD2 (antibody dilution 1:1000), CD31 (antibody dilution 
1:1000), VE-Cadherin (antibody dilution 1:1000) and COL1A1 (antibody dilution 1:200); β-
actin is used as a loading control (1:4000) (n=3); c. Immunofluorescence images showing 
localization of CD31 (1:50), VE-Cadherin (1:100) and COL1A1 (1:100) in anti-miR-148b or 
control transfected cells (n=3); scale bar=50μm; For target gene qPCR 18s was used as a house-
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keeping control; Values are means±SEM *P<0.05; **P<0.01 vs control. Unpaired two-tailed 
Student’s t-test was applied. 
4.3.4 In vivo inhibition of miR-148b induces EndMT in the wound and impairs 
wound closure 
In order to understand whether miR-148b downregulation also induces 
EndMT in vivo, again a mouse model of wound healing has been employed. 
Specifically, a Pluronic gel was used as a delivery vehicle for the control and 
anti-miR-148b oligonucleotides onto the dermal wounds. Delivery of anti-
miR-148b, or control oligonucleotides immediately after wounding, and every 
two days thereafter, resulted in increased expression of TGFB2 and SMAD2 
target genes mRNA in the wounds (Fig. 4.4 a). Macroscopic analysis showed 
that wound closure was significantly attenuated in anti-miR-148b-treated 
wounds (Fig. 4.4 c, d). Nevertheless, inhibition of miR-148b did not have any 
effect on the wound perfusion as shown by Doppler analysis (Fig. 4.4 e). In 
order to test for the presence of EndMT in the wound edge, wounds were 
stained with CD31 and fibroblast-specific protein-1 (FSP-1) antibodies. 
Confocal analysis has demonstrated that, while control-oligonucleotide-
treated wounds contained only CD31-positive vessels, the wounds treated 
with anti-miR-148b-treated were comprised of CD31-FSP-1 double-positive 
vessels, consistent with the occurrence of EndMT (Fig. 4.5 a, b). Furthermore, 
the delivery of anti-miR-148b has led to the strong increase in FSP-1 single-
positive cells in the wounds (Fig. 4.5 c). Next, in order to confirm that loss-of-
miR-148b-mediated EndMT occurs through TGF-β2-SMAD2 axis, a siRNA for 
SMAD2 was used to silence SMAD2 in the anti-miR-148b treated wounds. The 
resulting SMAD2 knockdown (Fig. 4.4 b) was able to rescue the anti-miR-148b-
attenuated wound closure to the control level (Fig. 4.4 c, d) without changing 
the perfusion (Fig. 4.4 e). Moreover, silencing of SMAD2 reduced the 
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percentage of vessels positive for both CD31 and FSP-1 and decreased the total 
number of FSP-1 positive cells in the wounds treated with anti-miR-148b (Fig. 
4.5 a, b and c). Together, this data demonstrates that inhibition of miR-148b in 
vivo is able to attenuate wound healing and facilitate EndMT on the wound 
edge via SMAD2 upregulation. 
 
Figure 4.4| Inhibition of miR-148b delays wound closure and has no effect on perfusion. 
Dermal wounds were treated with control-oligonucleotides and anti-miR-148b or SMAD2 
siRNA for 7 days. a. qPCR showing relative expression of miR-148b, TGFB2 and SMAD2 
(n=5); average Ct values: miR-148b (pluronic: 27; control: 28; anti-miR-148b: 30), TGFB2 
(pluronic: 25; control: 27; anti-miR-148b: 24), SMAD2 (pluronic: 26; control: 27; anti-miR-148: 
25) b. qPCR showing relative SMAD2 expression in dermal wounds treated (n=5); average 
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Ct values: SMAD2 (pluronic: 26; control: 27; anti-miR-148b: 25; anti-miR-148b+siSMAD2: 28) 
c. Representative images of treated wounds at 0 and 7 days post wound injury, scale 
bar=5mm; d. Level of wound closure expressed in percentage of wound area from the initial 
wound area (n=8); e. Representative colour laser Doppler images are taken at 5 days post 
wounds. Chart shows level of wounds perfusion in mice (calculated as the ratio between 
treated and control blood flow; n=8 per group). For miRNA qPCR U6 was used as a house-
keeping control; For target gene qPCR 18s was used as a house-keeping control; Values are 
means±SEM. *P<0.05; **P<0.01 vs control; #P<0.05 vs anti-miR-148b. Unpaired two-tailed 
Student’s t-test and one-way ANOVA statistical test followed by Bonferroni post-hoc 
analyses were applied. 
Figure 4.5| Inhibition of miR-148b induces EndMT in a mouse model of wound healing. 
Dermal wounds were treated with control-oligonucleotides and anti-miR-148b or SMAD2 
siRNA for 7 days. a. Immunohistochemistry localization of CD31 (1:50) and FSP-1 (1:50) in 
the wound vessels; scale bar=25μm (magnification 630x) (n=8); b. Quantification of 
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CD31/FSP-1 double positive vessels and c. FSP-1 positive vessels in the wounds; n=8 per 
each group; Values are means±SEM. *P<0.05; **P<0.01 vs control. #P<0.05 vs anti-miR-148b 
Unpaired two-tailed Student’s t-test and one-way ANOVA statistical test followed by 



















The data presented in this chapter shows for the first time that downregulation 
of miR-148b is able to affect endothelial cell plasticity. Specifically, this chapter 
provides novel evidence that miR-148b inhibition upregulates the expression 
of TGFB2 and SMAD2 genes, thus activating TGF-β signalling cascade and 
leading to EndMT program. Finally, these findings provide the evidence that 
in vivo silencing of miR-148b expression causes poor wound repair in mice due 
to induction of EndMT. 
4.4.1 MiR-148b inhibition promotes EndMT on the cellular level while having 
no effect on in vitro angiogenesis 
Based on the data from the previous chapter, where it has been demonstrated 
that miR-148b overexpression boosts endothelial cell proliferation the in vitro 
angiogenic response, it was expected that inhibition of miR-148b would 
attenuate angiogenesis in vitro. Nevertheless, the findings in this chapter 
showed that miR-148b knockdown is sufficient to decrease endothelial cell 
proliferation without affecting endothelial cell migration and cellular network 
formation. Notably, this data separates miR-148b effect on cellular 
proliferation and angiogenic response, which occurred simultaneously in the 
previous chapter. To elucidate the effect of miR-148b inhibition on the cellular 
level, an ECIS model has been employed, which is able to pick up sensitive 
changes in cellular electrical impedance parameters (Giaever and Keese, 
1991b). The use of ECIS model in endothelial cells has been described before 
and changes in impedance have been attributed to the endothelial function 
and morphology (Szulcek et al., 2014). After applying this model to the cells 
transfected with anti-miR-148b, it was found that one of the impedance 
parameters, cell membrane capacitance (Cm), was significantly increased. 
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Based on the fact that different cell types exhibit different values of Cm 
(Giaever and Keese, 1991b), it has been concluded that miR-148b 
downregulation exerts a phenotypic change on HUVECs. Interestingly, it has 
been recently reported that increase in cell membrane capacitance occurs 
during cellular differentiation (Qi et al., 2015). 
Furthermore, miR-148b silencing upregulated its target genes, TGFB2 and 
SMAD2, which are central components of TGF-β signalling cascade. 
Activation of this pathway has been numerously reporter to play a key role in 
inducing EndMT program (Dejana et al., 2017). Together with increase in 
membrane capacitance, activation of TGF-β signalling, reduction of 
endothelial-specific markers, CD31 and VE-Cadherin and upregulation of 
fibroblast-specific COL1A1, this chapter demonstrates for the first time that 
miR-148b downregulation promotes EndMT program. 
Interestingly, since Ghosh et al. has reported the first evidence of miRNA 
involvement in EndMT (Ghosh et al., 2012b), miRNAs are now known to 
modulate EndMT through different mechanisms. In vitro and in vivo studies 
demonstrated that decreased FGF signalling leads to reduction in let-7 
expression and initiation of TGF-β-dependent EndMT (Chen et al., 2012). 
Recently, miR-20a was shown to target multiple genes in TGF-β signalling 
such as ALK5, TGFBR2 and SARA, thereby negatively regulating EndMT. The 
expression of miR-20a, which is normally downregulated during EndMT, is 
rescued by FGF2 (Correia et al., 2016). The study also specifies that miR-20a 
regulates EndMT on the receptor level. On the other hand, this chapter shows 
that miR-148b modulates the transition program on receptor (targeting 
TGFB2) and signal transduction levels (targeting SMAD2). Contrary to the 
previous studies, Kumarswamy et al. showed that miR-21 upregulation in 
response to TGF-β2 treatment is able to induce EndMT via silencing 
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phosphatase and tensin homolog (PTEN) in endothelial cells, resulting in 
activation of the Akt-pathway (Kumarswamy et al., 2012). Opposite to the 
results from this chapter, downregulation of miR-21 leads to inhibition of 
EndMT and partial restoration of pro-endothelial phenotype, which is a 
consequence of PTEN upregulation and reduction in Akt signalling. In 
agreement with this study, a recent investigation reported that TGF-β-induced 
miR-27b overexpression causes EndMT via silencing Elk1 in mouse pancreatic 
microvascular endothelial cells. Interestingly, it was also found that one of 
miR-27b target genes is VAV3, a regulator of actin remodeling, which is also 
modulated by another EndMT-promoting miRNA, miR-31, suggesting a 
potential combinatorial regulation (Suzuki et al., 2017). This important point 
is also true in the context of this chapter as SMAD2 is also a target of EndMT-
facilitating miR-20a, which could potentially act in a synergic manner with 
miR-148b. 
Up until now, here has been no scientific evidence to date discussing the role 
of miR-148b in endothelial cell plasticity and EndMT. The data in this chapter 
provides novel evidence on a new regulatory player in induction of EndMT 
program in vitro. Together with other miRNAs such as let-7, miR-20a and 
others, miR-148b may constitute a larger post-transcriptional regulatory 
network modulating endothelial cell plasticity. 
4.4.2 MiR-148b inhibition attenuates wound repair by inducing EndMT in 
mice wounds 
Due to the successful utilization of mouse wound healing angiogenesis model 
in the previous chapter, the same approach was used in this chapter. As 
previously described, the Pluronic gel delivery system is sufficient to deliver 
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anti-miR-148b oligos in mouse wounds, thus leading to poor wound closure 
and induction of EndMT program. 
The occurrence of EndMT postnatally has been associated with different types 
of fibrotic disease such as that in kidney (Zeisberg et al., 2008) and heart 
(Zeisberg et al., 2007c), both of which are associated with excessive collagen 
expression and deposition. Previous studies reported the importance of 
EndMT in dermal fibrosis, showing that delay in wound closure is associated 
with excessive collagen deposition (Manetti et al., 2017a). 
This chapter has demonstrated for the first time that induction of EndMT in 
response to miR-148b downregulation has a detrimental influence on skin 
wound healing. Following delivery of anti-miR-148b to the wounds, EndMT 
accounted for around 20% of skin vessels that were undergoing mesenchymal 
transition. This is highly important as cells going through transition program 
can be expected to secrete large amounts of collagen and other ECM proteins, 
which could contribute to fibrosis. In addition, the acquisition of mesenchymal 
phenotype by the dermal endothelial cells is likely to lead to endothelial 
dysfunction, seen through decreased cellular migration or dysregulation of 
inflammatory cell recruitment. The data in this chapter also elucidates the 
mechanism of EndMT induction in the current model, which is mainly based 
on activation of SMAD2 as demonstrated by the reduction of EndMT in vivo 
using siRNA for SMAD2.  
Interestingly, the downregulation of miR-148b did not affect wound 
perfusion, which is supported by in vitro data showing that miR-148b 
inhibition does not attenuate angiogenesis. The uninvolvement of 
angiogenesis further confirms that the impairment of wound repair is a result 
of endothelial cells switching to mesenchymal cell lineage. The argument that 
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wound healing is attenuated due to possible excess of collagen deposition 
following EndMT induction in the wounds is supported by findings that 
fibrosis and TGF-β pathway activation are central causes of the pathology of 
scleroderma (Varga, 2002a), which is a disorder characterized by thickened 
skin and poor wound healing (Moran, 2014). Due to the fact that not only does 
miR-148b inhibition activate TGF-β pathway in vivo, but also leads to wound 
repair impairment and EndMT, it is therefore plausible to speculate that miR-
148b downregulation could play role in the pathology of scleroderma. It has 
been recently demonstrated that it is possible to treat scleroderma using 
miRNA therapy approach. In particular, a topical antagomir approach has 
been utilized to downregulate miR-155 levels in mice, which resulted in 
decreased fibrosis, skin thickening and activated fibroblasts, which are the 
hallmarks of scleroderma (Yan et al., 2016). Furthermore, it has been shown 
before that TGF-β pathway is upregulated in skin scars (Xie et al., 2008, Scott 
et al., 1995, Wang et al., 2000), which are also characterized by increased 
deposition of ECM proteins (Gauglitz et al., 2011). In line with similarities with 
the model of wound healing in this chapter it is possible to speculate that 
decreased levels of miR-148b could be a characteristic of scarring, due to its 
effects on TGF-β cascade upregulation and poor wound repair. Moreover, it 
has been demonstrated that by diminishing TGF-β signalling using antisense 
oligonucleotide approach it is possible to decrease the scarring in the adult 
wounds (Choi et al., 1996). Combining the data from both chapters it is logical 
to assume that topical modulation of miR-148b in the skin could revert the 
detrimental scarring. 
Overall, the data presented in this chapter supports the involvement of miR-
148b in skin wound healing and induction of EndMT in vivo. These findings 
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also open up new avenues for miR-148b-based therapies for disorders such as 
scleroderma and scarring. 
4.4.3 Limitations 
One limitation of this chapter is a technical challenge in quantifying the 
secreted COL1A1 due to the fact that it is insoluble. This data would be a good 
indication of the fibrotic potential of anti-miR-148b. Another limitation is 
inability of the in vivo model to detect the cells which have completely lost the 
endothelial phenotype and became mesenchymal. The lineage (endothelial) 
tracing mice would be able to solve this challenge. 
4.4.4 Conclusion 
The chapter provides new data on the molecular mechanism of EndMT, 
linking it’s induction to the previously unreported miR-148b in endothelial cell 
biology. In particular, the results presented in this chapter elucidate the 
important function of miR-148b on the differentiation of endothelial cells, 
where its downregulation can lead to the mesenchymal switch, governed by 
upregulation of TGFB2 and SMAD2 expression. The induction of EndMT in 
vivo and its detrimental effect on wound healing process further confirms the 



























Endothelial-to-mesenchymal transition (EndMT) is a process by which 
endothelial cells (ECs) significantly lose endothelial features and gain 
mesenchymal fibroblast-like phenotype, which is characterized by elevated 
expression of α-SMA, vimentin, N-cadherin and acquisition of “spindle-
shaped” cellular morphology due to cytoskeleton rearrangement (Medici and 
Kalluri, 2012). In addition to its important role during embryogenesis, such as 
cardiac and pulmonary artery development (Armstrong and Bischoff, 2004, 
Arciniegas et al., 2005), EndMT also occurs in adult organism in response to 
pathological stimuli, such as inflammation, leading to pathologies such as 
cardiac (Zeisberg et al., 2007b) and renal fibrosis (Zeisberg et al., 2008), 
vascular remodelling (Cooley et al., 2014) and atherosclerosis (Evrard et al., 
2016). 
Inflammation is maintained by specific plasma molecules, mediators of 
inflammation, which act as propagators of the inflammatory response by local 
as well as systemic action. Inflammatory mediators largely consist of pro-
inflammatory cytokines, such as interleukin-1 beta (IL-1b) and tumor necrosis 
factor alpha (TNF-a), growth factors, reactive oxygen species (ROS) as well as 
bacterial endotoxins. Importantly, it has been demonstrated that mediators of 
inflammation are able to induce endothelial cell differentiation into activated 
fibroblasts, thus linking inflammation to EndMT (Pérez et al., 2017). Data 
reported in the mid-1980s showed that human umbilical vein endothelial cells 
(HUVECs), cultured in the activated peripheral blood mononuclear leukocyte 
supernatants, underwent morphological changes, producing mesenchymal-
like morphology instead of the typical endothelial cobblestone appearance 
(Montesano et al., 1984). It is believed that inflammatory cytokines induce 
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EndMT program in endothelial cells via activation of NF-κB transcription 
factor, however the precise mechanism is still not understood. 
Non-coding microRNAs are post-transcriptional repressors of gene 
expression and are often dysregulated in pathological processes (Quiat and 
Olson, 2013). MiRNAs are able to exert diverse functions on endothelial cells, 
including the regulation of proliferation, migration and in vitro angiogenesis 
(Wu et al., 2009). Moreover, recent studies on endothelial cell plasticity have 
shown that miRNAs can also play a key role in the modulation of EndMT 
(Chen et al., 2012, Cao et al., 2014). Interestingly, Chen et al. has demonstrated 
that inflammatory cytokines are able to induce the EndMT program in 
HUVECs via indirect reduction of let-7 miRNA expression and activation of 
the TGF-β signalling (Chen et al., 2012). 
In the previous chapter it has been found that miR-148b holds the capacity to 
modulate TGF-β signalling and its downregulation leads to the induction of 
EndMT. Due to the profound phenotypic effect of miR-148b on endothelial cell 
function and phenotype the following chapter will focus on the mechanism of 
regulation of miR-148b expression. 
5.1.1 Hypothesis 
In light of the findings from the previous chapter on induction of TGF-β 
signalling and EndMT in response of miR-148b downregulation and the 
published literature stating that inflammation is a link between two processes, 
the main goal of this chapter was to the hypothesis that: 






The aims of this chapter were: 
1.    Identify pro-inflammatory stimuli regulating miR-148b expression 
2.    Determine whether induction of inflammation can facilitate EndMT 
3.  Determine whether exogenous modulation of miR-148b expression can 


















5.2.1 Cells and Cell Culture 
Human umbilical vein ECs (HUVECs; Lonza) were grown in EGM-2 
(comprising EBM-2 with growth factors and other supplements) with 2% 
Foetal Bovine Serum.  Confluent HUVECs were treated with 10 ng/ml TNF-α, 
IL-1β, TGF-β2 (PeproTech); medium and cytokines were changed every two 
days. SB 431542 (Tocris) has been used at the dose of 10μM. 
5.2.2 Cells transfection, transduction and functional assays 
Lipofectamine RNAiMAX (Thermo Fisher Scientific) was used to transfect 
HUVECs treated with TNF-α/IL-1β with miR-148b mimic, mimic control 
(25nM final concentration), siRNA SMAD2 and siRNA control (10nm final 
concentration) according to the manufacturer's instructions.  
5.2.3 RNA Extraction and Quantitative Real-Time Analysis 
Total RNA was extracted using miReasy kit (Qiagen). Real-time quantification 
to measure miRNAs was performed with the TaqMan miRNA reverse 
transcription kit and miRNA assay (Life Technology) using Lightcycler 480 
(Roche). MiRNAs expression was normalized to the U6 small nucleolar RNA 
(snRU6). For mRNA analysis, cDNA was amplified by quantitative real-time 
PCR (qPCR) and normalized to 18S ribosomal RNA. Each reaction was 
performed in triplicate. Quantification was performed by the 2–ddCt method. 
qPCR was used to measure the expression of miR-148b (miR-148b-3p Thermo 
Fisher Scientific, Cat. #4426961), snRU6 (Thermo Fisher Scientific, Cat. 
#4331182), TGFB2, SMAD2, CD31, VE-Cadherin, COL1A1 and 18S rRNA. 
Primers are pre-designed from Sigma (KiCqStartTM Primers). 
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5.2.4 Western-Blot analyses  
Proteins were extracted from cultured cells or muscles by using ice-cold buffer 
A (50mM Hepes, 150mM NaCl, 1mM EDTA, 1mM EGTA, 25mM NaF, 5mM 
NaPPi, 1%Triton, 1% NP40, 1 mM Na3VO4, 0,25% sodium deoxycholate, 
0.5mM Na-orthovanadate, 1 mM benzamidine, 0.1mM phenylmethylsulfonyl 
fluoride). Protein concentration was determined using the Bio-Rad Protein 
Assay Reagent (Bio-Rad Laboratories, UK). Detection of proteins by Western 
blot analyses was done following separation of whole cell extracts (20µg) on 
SDS-polyacrylamide gels. Proteins were transferred to nitrocellulose 
membranes and probed with the following antibodies: TGFβ2 (Abcam Ltd. 
ab36495, 1:1000), SMAD2 (SantaCruz Biotechnology, Santa Cruz, CA, USA; 
#3102, 1:1000), CD31 (Abcam Ltd., 1:1000), VE-Cadherin (Abcam Ltd. ab33168, 
1:1000), COL1A1 (Abcam Ltd., ab138492, 1:200), β-actin (Abcam Ltd., ab16039, 
1:4000) (used as loading control). For detection, we used secondary antibodies 
conjugated to horseradish peroxidase which were rabbit anti-mouse (Abcam 
Ltd., ab97046, 1:5000) and goat anti-rabbit (Abcam Ltd., ab6721, 1:10000). 
Detection was developed by chemiluminescence reaction (ECL) (Immunoblot, 
Millipore, 23225). 
5.2.5 Immunofluorescence 
Cells were fixed using 4% paraformaldehyde in PBS at room temperature for 
15 min. For intracellular staining, fixed cells were permeabilized using 0.5% 
Triton X-100 in PBS (Sigma-Aldrich) or 0.1% Saponin in PBS at room 
temperature for 10 min. The blocking of specific antibody activity was 
performed using 3% bovine serum albumin (BSA) in PBS for 1 hour. Samples 
were incubated with antibodies to CD31 (Abcam Ltd., 1:50), VE-cadherin 
(Abcam Ltd. ab33168, 1:100) and COL1A1 (Abcam Ltd., ab138492, 1:100) in 
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PBS containing 1% BSA at 4°C overnight. Samples were washed extensively 
with PBS and incubated with Alexa-Fluor-488-conjugated antibodies to rabbit 
IgG (Life Technologies, Carlsbad, CA, # A11070) and Alexa-Fluor-594-
conjugated antibodies to rabbit IgG (Life Technologies, Carlsbad, CA, 
#A11072) in DAPI with PBS with 1% BSA at room temperature for 1 h. Image 
analysis was performed on Zeiss LSM 780 confocal microscope. 
5.2.6 ELISA assay 
Cell culture medium collected from HUVECs stimulated with TNF-α and IL-
1β 6 days after stimulation. Then, the culture medium medium was collected 
and a commercially available sandwich ELISA kit (R&D Systems #DB250) was 
used to measure the secretion of TGF-β2 in the medium. The absorbance 
(450 nm) for each sample was analyzed by a microplate reader Infinite® 
M1000 PRO (Tecan) and was interpolated with a standard curve. 
5.2.7 Statistical analysis 
Comparisons between different conditions were assessed using 2-tailed 
Student’s t test. Differences among groups were elicited using ANOVA 
statistical test followed by Bonferroni post-hoc analyses as appropriate. 
Continuous data are expressed as mean ± SD of three independent 
experiments, each performed in triplicate or quintuplicate. P value <0.05 was 








5.3.1 Combination of TNF-α, IL-1β reduce miR-148b expression in vitro 
In order to investigate whether cytokine treatment is able to affect the 
expression of miR-148b, HUVECs were treated for 6 days with the following 
cytokines: TNF-α, IL-1β, TGF-β1, TGF-β2 and a combination of TNF-α/IL-1β. 
The single delivery of cytokines did not exert any significant effects on miR-
148b expression (Fig. 5.1 a-d). Interestingly, the combination of TNF-α and IL-
1β pro-inflammatory cytokines has led to the inhibition of miR-148b 
expression 3 days post-treatment with the sharpest decrease after 6 days (Fig. 
5.1 e). This data shows that only the simultaneous stimulation of HUVECs 







Figure 5.1| The combination of pro-inflammatory cytokines downregulates the expression 
of miR-148b. qPCR showing relative miR-148b expression after treatment of HUVECs with 10 
ng/ml of: a. TNF-α (average Ct values of all time points 28); b. IL-1β (average Ct values of  
time points 28 (4-8h) and 29 (24h-6 days)); c. TGF-β1 (average Ct values of 4h, 3 days and 6 
days 32, 8 h-24 h - 31); d. TGF-β2 (average Ct values of all time points 31) and e. TNF-α/ IL-1β 
(average Ct values of 4-24 h – 30; 3 days: 31; 6 days: 32) for 6 days; the dotted line represents 
relative miR-148b expression in vehicle treated HUVECs (n=3): U6 was used as a house-
keeping control in the qPCR; Values are means±SEM *P<0.05 vs control. Unpaired two-tailed 
Student’s t-test was applied. 
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5.3.2 TNF-α/IL-1β-induced inflammation promotes EndMT 
To test if inflammation, induced by the combination of TNF-α and IL-1β, is 
able to promote EndMT, stimulated HUVECs were analysed for the panel of 
transition markers employed in the previous chapter. Specifically, the 
expression of TGFB2 and SMAD2, which are also miR-148b targets, was 
significantly increased at mRNA and protein levels, accompanied by the 
increase in TGF-β2 secretion (Fig. 5.2 a-c). Notably, the level of phosphorylated 
SMAD2 (p-SMAD2), which represent the activated variant of the protein, 
increased markedly following cytokine stimulation (Fig. 5.2 b). Moreover, 
consistent with an induction of EndMT, both mRNA and protein expression 
of the endothelial-specific markers, CD31 and VE-Cadherin, were decreased 
after cytokines stimulation, while COL1A1 was markedly elevated (Fig 5.2 a, 
b). These findings were further confirmed by immunofluorescence staining of 
HUVECs showing the reduction in CD31 and VE-Cadherin and increase in 
COL1A1 immunoreactivity (Fig. 5.2 d). Together, this data demonstrates that 
chronic inflammation facilitated by TNF-α/IL-1β stimulation induces EndMT. 
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Figure 5.2| Chronic inflammation induces EndMT in vitro. HUVECs were stimulated with 
a combination of TNF-α and IL-1β for 6 days.  a. qPCR showing relative expression of TGFB2 
(average Ct: vehicle: 27; TNF-α/IL-1β: 25), SMAD2 (average Ct: vehicle: 27; TNF-α/IL-1β: 26), 
CD31 (average Ct: vehicle: 22; TNF-α/IL-1β: 24), VE-cadherin (average Ct: vehicle: 23; TNF-
α/IL-1β: 24) and COL1A1 (average Ct: vehicle: 37; TNF-α/IL-1β: 40); the dotted line represents 
the relative gene expression in vehicle treated HUVECs (n=3); b. Western blot analysis of 
TGFB2, p-SMAD2, SMAD2, CD31, VE-Cadherin and COL1A1; β-actin was used as a loading 
control; c. Quantification of TGF-β2 ELISA experiment expressed in TGF-β2 concentration 
(ng/mL) in TNF-α/IL-1β treated samples vs the control; d. Immunofluorescence images 
showing localization of CD31 (1:50), VE-Cadherin (1:100) and COL1A1 (1:100) in TNF-α/IL-1β 
treated cells; scale bar=50μm (magnification 40x); 18s was used as a house-keeping control in 
the qPCR;  Values are means±SEM. *P<0.05; **P<0.01 vs vehicle. Unpaired two-tailed Student’s 
t-test was applied. 
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5.3.3 MiR-148b gain-of-function inhibits EndMT and maintains endothelial 
phenotype after cytokine treatment 
The next question to address was whether exogenous overexpression of miR-
148b could preserve the endothelial phenotype of HUVECs and attenuate 
EndMT induced by inflammation. To do that, HUVECs were simultaneously 
transfected with miR-148b mimic and stimulated with TNF-α and IL-1β. 
Firstly, a strong increase in miR-148b levels was observed in cells with miR-
148b gain-of-function (Fig. 5.3 a) in collaboration with decrease in its targets, 
TGFB2 and SMAD2, which were elevated in response to inflammation (Fig. 5.3 
a, b). Importantly, miR-148b gain-of-function was sufficient to block SMAD2 
phosphorylation (Fig. 5.3 b), thus preventing the activation of pro-EndMT 
signalling. The secretion of TGF-β2 was also markedly attenuated by the cells 
transfected with miR-148b mimic (Fig. 5.3 c). Importantly, miR-148b gain-of-
function was sufficient to rescue the endothelial phenotype of HUVECs, as 
shown by the increased CD31 and VE-Cadherin and reduced COL1A1 
expression and immunofluorescence signals (Fig. 5.3 a, b, d). Together, these 
findings demonstrate that miR-148b overexpression in the HUVEC model of 




Figure 5.3| MiR-148b gain-of-function inhibits cytokines-induced EndMT. HUVECs were 
transfected with miR-148b mimic stimulated with a combination of TNF-α and IL-1β for 6 
days.  a. qPCR showing relative expression of miR-148b (average Ct: vehicle: 28; TNF-α/IL-1β 
+ control: 27; TNF-α/IL-1β + miR-148b mimic: 22), TGFB2 (average Ct: vehicle: 27; TNF-α/IL-
1β + control: 26; TNF-α/IL-1β + miR-148b mimic: 27), SMAD2 (average Ct: vehicle: 26; TNF-
α/IL-1β + control: 25; TNF-α/IL-1β + miR-148b mimic: 26), CD31 (average Ct: vehicle: 23; TNF-
α/IL-1β + control: 24; TNF-α/IL-1β + miR-148b mimic: 22), VE-cadherin (average Ct: vehicle: 23; 
TNF-α/IL-1β + control: 24; TNF-α/IL-1β + miR-148b mimic: 22) and COL1A1 (average Ct: 
vehicle: 35; TNF-α/IL-1β + control: 33; TNF-α/IL-1β + miR-148b mimic: 34); the dotted line 
represents the relative gene expression in vehicle treated HUVECs (n=3); b. Western blot 
analysis of TGFB2, p-SMAD2, SMAD2, CD31, VE-Cadherin and COL1A1; GAPDH was used 
as a loading control instead of β-actin due to the fact that it was constant; c. Quantification of 
TGFβ2 ELISA experiment expressed in TGFβ2 concentration (ng/mL) in miR-148b gain-of-
function and/or TNFα/IL-1β treated samples vs the control; d. Immunofluorescence images 
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showing localization of CD31 (1:50), VE-Cadherin (1:100) and COL1A1 (1:100) in miR-148b or 
control transfected HUVECS and/or treated with TNF-α/IL-1β; scale bar=50μm (magnification 
40x) (n=3). For miRNA qPCR U6 was used as a house-keeping control; For target gene qPCR 
18s was used as a house-keeping control; Values are means±SEM. *P<0.05; **P<0.01 vs vehicle 
and/or TNFα/IL-1β together with control mimic. Unpaired two-tailed Student’s t-test was 
applied. 
5.3.4 Inflammation-induced EndMT occurs partially via SMAD2 
In order to better understand the involvement of miR-148b target genes in the 
mechanism of inflammation-induced EndMT, two methods of TGF-β pathway 
interference were employed: an inhibitor of receptor kinase ALK5, SB431542 
and siRNA for SMAD2. Interestingly, treatment of HUVECs, stimulated with 
inflammatory cytokines, was not sufficient to completely prevent SMAD2 
phosphorylation and, thus, did not increase the expression of endothelial-
specific markers CD31 and VE-Cadherin (Fig. 5.4 a, b). Conversely, SMAD2 
silencing in HUVECs treated with TNF-α/IL-1β increased the expression of 
CD31 and VE-Cadherin (Fig. 5.4 c). Further, SMAD2 knockdown as well as 
increase in CD31 and VE-Cadherin and reduction in COL1A1 were confirmed 
at protein level (Fig. 5.4 d). Finally, immunocytochemistry validated a partial 
increase in CD31 and VE-Cadherin and a significant decrease in COL1A1 in 
stimulated HUVECs with SMAD2 knockdown (Fig. 5.4 e). Together, this data 
demonstrates that SMAD2 silencing is able to partially preserve the 
endothelial phenotype, suggesting that EndMT induced by chronic 





Figure 5.4| SMAD2 silencing partially inhibits cytokines-induced EndMT. HUVECs were 
treated with ALK5 inhibitor SB431542 or transfected with SMAD2 siRNA and stimulated with 
a combination of TNF-α and IL-1β for 6 days.  a. qPCR showing relative expression CD31 and 
VE-Cadherin following treatment with ALK5 inhibitor SB431542 and/or TNFα/IL-1β (average 
Cts are constant for all conditions 23-24); the dotted line represents the relative gene 
expression in vehicle treated HUVECs (n=3); b. Western blot analysis of p-SMAD2 (1:1000) 
and SMAD2 (1:1000) following treatment with ALK5 inhibitor SB431542 and/or TNFα/IL-1β; 
β-actin (1:4000) is used as a loading control; c. qPCR showing relative expression CD31 and 
VE-Cadherin following transfection with SMAD2 siRNA and/or TNFα/IL-1β (average Cts for 
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CD31 24 vs 23; VE-Cadherin: 25 vs 23); the dotted line represents the relative gene expression 
in vehicle treated HUVECs (n=3); d. Western blot analysis of SMAD2 (1:1000), CD31 (1:1000), 
VE-Cadherin (1:1000) and COL1A1 (1:1000) following transfection with SMAD2 siRNA and/or 
TNFα/IL-1β; HDAC3 (1:500) is used as a loading control instead of β-actin because the latter 
for changing; e. Immunofluorescence images showing localization of CD31 (1:50), VE-
Cadherin (1:100) and COL1A1 (1:100) in SMAD2 siRNA or control transfected HUVECS 
and/or treated with TNF-α/IL-1β, scale bar=50μm (magnification 400x); 18s was used as a 
house-keeping control in the qPCR; Values are means±SEM. *P<0.05 vs TNFα/IL-1β treated 


















The data presented in this chapter demonstrates for the first time the role of 
miR-148b as a mediator between inflammation and EndMT. Specifically, this 
chapter shows that chronic inflammation, induced by TNF-α and IL-1β, 
reduces the expression of miR-148b, thus causing the initiation of EndMT 
program. The chapter further confirms this data by providing the evidence 
that miR-148b gain-of-function is able to restore the endothelial phenotype 
post-stimulation with inflammatory cytokines. Finally, the results in the 
current chapter confirm the inflammation-miR-148b-TGF-β-EndMT axis, 
where the inflammation-induced transition program occurs via SMAD2-
dependent mechanism. 
5.4.1 Chronic inflammation induces EndMT via miR-148b downregulation 
One of the first studies describing the inflammation-dependent regulation of 
miRNA expression came from Chen et al., demonstrating the importance of 
let-7 miRNA in EndMT (Chen et al., 2012). Specifically, the investigation has 
proposed a novel model of EndMT, where inflammation induced by IFN-γ, 
TNF-α and IL-1β leads to suppression of FGF signalling, which in turn 
decreases let-7 expression, thus promoting transition program (Chen et al., 
2012). Notably, this chapter discusses the model of chronic inflammation 
induced by the combination of TNF-α and IL-1β cytokines for 6 days. As in 
the study before, induction of inflammation targets the expression of miR-148b 
and leads to EndMT due to resulting overexpression of SMAD2. It is important 
to note that in addition to the upregulation of TGFB2 and SMAD2 expression, 
the inflammatory environment also led to the marginal increase in TGF-β2 
secretion, suggesting the possible autocrine as well as paracrine feed-forward 
loop of EndMT regulation. 
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Furthermore, the model of EndMT discussed in this chapter has been 
supported by another study, demonstrating the potency of different cytokines 
to induce the transition program in human intestinal microvascular 
endothelial cells (HIMEC) (Rieder et al., 2011). Specifically, it has been shown 
that only the combination of inflammatory cytokines such as TNF-α and IL-1β 
was able to exert the strongest EndMT phenotype, with a slight enhancement 
by the addition of TGF-β1 (Rieder et al., 2011). Importantly, this supports the 
data presented in this chapter that the strongest downregulation of miR-148b 
was observed when combining both TNF-α and IL-1β. Due to the fact that 
TGF-β1 and TGF-β2 were not able to affect miR-148b expression, it can be 
speculated that miR-148b-modulated EndMT is inflammation dependent. 
Moreover, the investigation also pointed out that the chronic treatment of 
endothelial cells with TNF-α, IL-1β and TGF-β1 resulted into marginal 
increase in collagen 1 expression and intestinal fibrosis (Rieder et al., 2011). 
Due to the fact that inflammation-induced EndMT via miR-148b 
downregulation led to strong enhancement of COL1A1 in the current model, 
it is possible to speculate that reduction of miR-148b by chronic inflammation 
could be a source of EndMT in different fibrotic pathologies. 
5.4.2 MiR-148b gain-of-function attenuates EndMT induced by chronic 
inflammation via SMAD2 silencing 
One of the pioneering studies in the involvement of miRNA in EndMT has 
demonstrated that inhibition of miR-21 in TGF-β-induced model of transition 
is sufficient to partially block EndMT (Kumarswamy et al., 2012). Later, 
another investigation has shown that miR-20a gain-of-function exerts a 
protective anti-EndMT effect on endothelial cells, comparable to FGF2 
stimulation (Correia et al., 2016). In agreement with the study above, miR-148b 
gain-of-function in the model presented in this chapter, efficiently abrogated 
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EndMT and rescued the endothelial phenotype. Importantly, due to the fact 
that EndMT was inhibited in response to simultaneous miR-148b 
overexpression and induction of inflammation, it therefore suggests that miR-
148b is able to block EndMT initiation step. Moreover, the reduction of TGF-
β2 secretion after miR-148b gain-of-function demonstrates that miR-148b can 
block the potential autocrine and paracrine EndMT regulation. Taking 
together the decrease in SMAD2 and TGFB2 gene expression as well as 
inhibition of TGF-β2 release, it is reasonable to assign miR-148b a role of potent 
negative regulator of EndMT. Additionally, Correia et al. demonstrates that 
miR-20a blocks EndMT through different levels: targeting the expression of 
SMADs, ALK5, TGFBR2 and SARA (Correia et al., 2016). Concordantly, 
Targetscan miRNA target prediction analysis shows that other players in TGF-
β pathway, such as TGFBRAP1 and SMURF2, are putative miR-148b target 
genes, suggesting that miR-148b prevents EndMT by potently targeting 
different stages of TGF-β signalling.  
The study above suggests that the mechanism of EndMT inhibition is achieved 
due to combinatorial silencing of several genes in TGF-β pathway by miR-20a 
(Correia et al., 2016). The data in this chapter has shown that the effect of miR-
148b-induced block of EndMT is achieved mainly through SMAD2 silencing. 
In particular, inhibition of TGF-βR1 was not sufficient to block EndMT and 
rescue the endothelial phenotype in response to inflammatory cytokines. As 
was shown by subsequent western blot analysis the ALK5 inhibitor was not 
able to prevent phosphorylation of SMAD2 significantly, and the remaining 
p-SMAD2 levels were sufficient to induce the EndMT program. It can also be 
speculated, that in the current model of chronic inflammation, SMAD2 is being 
alternatively phosphorylated. Specifically, it has been reported before that 
Toll-Like Receptor 4 (TLR4) signalling is able to induce SMAD2 
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phosphorylation in the presence of activated TGF-β pathway (Bhattacharyya 
et al., 2013). Notably, mammalian TLRs share the same cytoplasmic domains 
with IL-1 receptor family and, thus, exert similar cascades of signal 
transduction (Lin and Yeh, 2005). Moreover, it has been demonstrated that 
TNF-α signalling can activate SMAD2 phosphorylation by itself during 
epithelial-to-mesenchymal transition (Camara and Jarai, 2010). Taking into 
account these findings, it is possible to speculate that both TNF-α and IL-1β 
can induce ALK5-independent SMAD2 phosphorylation, which facilitates 
EndMT even in the presence of TGF-βR1 inhibitor. 
5.4.3 Limitations 
The main limitation in this chapter is the activity of the cytokines. In particular, 
TGF-β cytokines need to be activated by MMPs because the inactive form will 
not have any downstream effects. Other inflammatory cytokines are fragile 
and the activity may be decreasing over time. Another technical limitation is 
the fact that coating the coverslips with fibronectin increases the matrix 
stiffness leading to change in cell behaviour, such as increase in proliferation 
and fibrosis, which could contribute to the increase in collagen. 
5.4.4 Conclusion 
The important novelty of this chapter is the introduction of the link between 
inflammation, miR-148b and EndMT. The chapter proposes a model, where a 
physiological inflammatory stimuli, such as TNF-α and IL-1β, lead to 
reduction of miR-148b, thus facilitating EndMT program. Notably, this data 
demonstrates that pharmacological overexpression of miR-148b using mimics 
is sufficient to block the physiological induction of EndMT preserving the 
endothelial integrity. This chapter provides further mechanistic evidence, 
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showing that SMAD2 is at least partially responsible for induction of EndMT 




















CHAPTER 6: CONCLUSIONS 










6.1 GENERAL DISCUSSION AND CONCLUSIONS 
This thesis has explored and demonstrated for the first time that miR-148b 
plays a vital role in determining endothelial cell function and plasticity via 
targeting and regulating the TGF-β pathway. Overexpression of miR-148b 
reduces the expression of TGFB2 and SMAD2 and facilitates the acquisition of 
a pro-endothelial cell phenotype, enhancing EC proliferation, migration as 
well as in vitro angiogenesis. The topical in vivo delivery of miR-148b mimics 
onto injured skin significantly induces dermal angiogenesis and leads to a 
faster wound healing process. On the other hand, the silencing of endogenous 
miR-148b turns on the EndMT program in the endothelial cells via 
upregulation of TGFB2 and SMAD2. The effect of the pharmacological miR-
148b inhibition can be phenocopied by the physiological inflammatory stimuli 
such as TNF-α and IL-1β. Ultimately, miR-148b loss-of-function in vivo leads 
to induction of dermal EndMT attenuating the wound closure. 
Importantly, the work presented in this thesis demonstrated the correlation 
between in vitro and in vivo functions of miR-148b. The increase in endothelial 
cell proliferation, migration and in vitro angiogenic response has been 
validated in cellular HUVEC model and could be possibly attributed to the 
interference with TGFB2 and SMAD2 expression. This data is also backed up 
by the previous literature stating that the TGF-β/ALK5 pathway inhibits 
endothelial cell migration and proliferation (Goumans et al., 2002), which can 
explain the enhancing effects of miR-148b on endothelial cell function. The 
proangiogenic effects of miR-148b overexpression are replicated in the in vivo 
model of wound healing angiogenesis. It is important to note that in the 
current model, following the wound induction, the peak of neovascularization 
occurs between days 4 and 8 after skin puncture. Therefore, the angiogenic 
response can be studied during this timeframe (Simons et al., 2015). In this 
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work, not only did miR-148b upregulation lead to the increase in in vivo 
angiogenesis and wound perfusion, but also markedly accelerated the wound 
closure in mice. It is proposed in this work that accelerated wound healing 
occurred due to miR-148b-induced TGF-β pathway inhibition, mainly due to 
SMAD2 downregulation, as shown experimentally. Indeed, in accordance 
with this thesis, it has been demonstrated in the literature that SMAD3 
antisense oligonucleotides accelerated wound healing and reduced scarring in 
a mouse excisional wound model (Hong et al., 2008). It has been shown 
previously that 1-3 days after skin injury, there is a strong inflammatory 
response happening in the wound, characterized by high levels of cytokines, 
including TNF-α and IL-1β (Reinke and Sorg, 2012). Taking into account that 
TNF-α/IL-1β treatment reduces miR-148b expression in vitro, it is therefore 
possible to assume that miR-148b downregulation 3 days after skin injury is 
due to physiological inflammatory response in the wound. Interestingly, 7 
days after wounding, miR-148b levels go up in the skin, which correlates well 
with the proliferation stage of the wound healing that occurs after 3-10 days 
(Reinke and Sorg, 2012). Overall, this thesis has demonstrated that exogenous 
delivery of miR-148b mimics is able to initiate angiogenesis and faster wound 
perfusion, thus accelerating the wound healing process. 
The next part of this thesis was exploring miR-148b loss-of-function to 
understand its role in endothelial biology further. One of the key messages of 
the thesis is that miR-148b downregulation leads to the induction of EndMT. 
Moreover, this work has dissected the mechanism of miR-148b-dependent 
EndMT induction both in vitro and in vivo, showing that the effect is achieved 
through activation of TGF-β signalling, mostly via SMAD2 upregulation. 
Importantly, this investigation presented a pioneering data of EndMT 
occurrence in the in vivo model of wound healing due to miR-148b inhibition. 
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Previous studies reported the importance of EndMT in dermal fibrosis, 
showing that delay in wound closure is associated with excessive collagen 
deposition (Manetti et al., 2017b). The data in this thesis has demonstrated that 
miR-148b silencing in the skin results in expression of the fibroblast-specific 
FSP-1 marker in 30% of skin vessels. These findings are clinically relevant 
because upon transition, the cells in these FSP-1 positive vessels can be 
expected to secrete large amounts of collagen and other ECM proteins, which 
could contribute to fibrotic skin disease. However, the current acute model of 
wound healing is not suitable for exploring the differences in fibrosis due to 
the fact that fibrotic response is initiated in the skin after 10 days post 
wounding (Patel et al., 2018). Under normal physiological conditions, the 
deposition of ECM proteins is a transient process, which is terminated once a 
sufficient amount of matrix is accumulated in the wound bed (Faler et al., 
2006). The silencing of miR-148b leads to the over-activation of TGF-β in the 
wound, potentially enhancing the probability of development of fibrotic 
disease. One such disease is scleroderma, characterized by pathological skin 
fibrosis, poor wound closure and enhanced TGF-β signalling (Maeda et al., 
2016, Varga, 2002b). 
Clearly, EndMT has established itself to play an important role in different 
pathologies, such as atherosclerosis (Evrard et al., 2016), vein graft failure 
(Chen et al., 2012) and contributes significantly to tissue fibrosis, including 
cardiac and kidney fibrosis (Zeisberg et al., 2007b, Zeisberg et al., 2008, 
Zeisberg et al., 2007a). Nevertheless, there are studies suggesting that tissue 
fibrosis originates primarily from the activation and proliferation of the 
myofibroblasts and only 10% comes from EndMT (LeBleu et al., 2013). More 
studies are needed to identify the significance of EndMT in human physiology. 
However, it is safe to say that during complex diseases, including tissue 
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fibrosis, a number of different pathological processes are occurring 
simultaneously, inducing each other in a feed-forward loop. 
Importantly, the effects of miR-148b downregulation by anti-miR-148b, such 
as induction of TGF-β signalling and EndMT were phenocopied by 
physiological inflammatory stimuli, TNF-α and IL-1β. In a number of studies 
it has been shown that TNF-α and IL-1β can trigger EndMT through NF-κB 
translocation to the nucleus (Rieder et al., 2011, Mahler et al., 2013). In the 
model proposed in this thesis, TNF-α/IL-1β-mediated NF-κB activation might 
function directly on miR-148b expression or on miR-148b maturation from pri- 
or pre-miR-148b, thus boosting the TGF-β cascade and inducing the EndMT 
program. Using the rescue experiment, this thesis confirmed that TNF-α/IL-
1β-mediated EndMT occurs via miR-148b downregulation and partially via 
SMAD2 signalling.  Interestingly, the TGF-βR1 (ALK5) inhibitor was not able 
to prevent SMAD2 phosphorylation and block EndMT. This thesis has that, in 
this model, SMAD2 is partially phosphorylated via ALK5-independent 
mechanism, such as TLR4 signalling, TNF-α-dependent phosphorylation or 
by Mps1, which is a component of the mitotic spindle checkpoint that is 
functional during oxidative stress (Zhu et al., 2007, Yu et al., 2016). The fact 
that miR-148b gain-of-function is able to prevent the transition program and 
can preserve the endothelial phenotype confirms that miR-148b is a key player 
in TNF-α/IL-1β-induced EndMT. Interestingly in a recent study it has been 
shown that the serum from Kawasaki disease patients, which is rich in 
inflammatory cytokines, reduces the expression of miR-483 and induces 
EndMT. Moreover, in agreement with this thesis, miR-483 gain-of-function 
was able to rescue the endothelial phenotype and suppress EndMT (He et al., 
2017). Overall, the final results chapter identified the way miR-148b is 
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regulated under physiological inflammatory conditions, leading to the 
pathological EndMT. 
6.1 Future work 
Potential future experiments in the in vitro part of the study would be carried 
out to elucidate the mechanism of EndMT induced by the inflammatory 
cytokines. It has been shown in this work that 6 days treatment with TNF-α/IL-
1β is able to downregulate miR-148b, which in turn promotes the transition 
program. It is therefore important to understand the signalling cascade that 
occurs in between cytokine binding to their receptors and miR-148b 
downregulation. The most likely possibility is that TNF-α and IL-1β, upon 
interaction with their membrane receptors, induce NF-kB translocation to the 
nucleus, which then leads to miR-148b downregulation. To do this, HUVECs 
would be transfected with siRNA NF-kB and the treated with TNF-α/IL-1β for 
6 days. If, after that, the EndMT is prevented, it would show that miR-148b 
downregulation is NF-kB-dependent. 
The current data shows that TNF-α/IL-1β stimulation downregulates miR-
148b. However, it is unclear whether the cytokines decreases the transcription 
of miR-148b or maturation step. It has been reported before that p-SMAD2/3 
is able to interact directly with Dicer and promote maturation of miRNA 
(Garcia et al., 2015). In the model presented in the thesis there is high level of 
SMAD2 phosphorylation. Thus, it is important to test whether p-SMAD2 is 
able to affect miR-148b maturation. To do that the qPCR should be carried on 
the RNA extract from stimulated HUVECs with primers targeting pri-miR-
148b, which is a primary transcript form of miR-148b, and compare the 
expression with the control cells. This will show if there is a difference in miR-
148b transcription. To understand whether the cytokines affect the maturation 
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of miR-148b, the northern blot can be carried out to compare the levels of pre-
miR-148b and mature miR-148b between stimulated and control HUVECs 
after transfection with pre-miR-148b. The possible increase in pre-miR-148b in 
stimulated cells vs control could mean that the maturation step is blocked after 
cytokine treatment. 
Next interesting in vitro experiment would be to understand whether the 
transition in our model is complete or reversible. To do this, HUVECs should 
be treated with cytokines for 6 days and then, at day 6, the medium should be 
changed to complete endothelium growth medium. At the selected time 
points, cells should be harvested and tested for the EndMT markers, which 
would show whether HUVECs differentiated completely into mesenchymal 
cells or the effect is reversible. Another variation of this experiment would be 
to transfect TNF-α/IL-1β-stimulated cells with miR-148b mimic after 6 days of 
treatment and not at day 0. The results from this experiment would also 
suggest whether miR-148b can block EndMT initiation or progression. 
Interestingly, Correia et al. has carried out a similar study, where endothelial 
cells, undergoing TGF-β-induced EndMT, were transfected with miR-20a at 
day 0 and after 72 hours post-treatment. Specifically, it has been found that 
miR-20a can only have an effect, when introduced at day 0, where it can limit 
the number of cells acquiring mesenchymal phenotype (Correia et al., 2016). 
Further, it’s essential to determine the physiological stimuli, which can induce 
the expression of miR-148b in the endothelial cells. There are a number of 
studies demonstrating that FGF is able to attenuate EndMT and rescue the 
endothelial phenotype (Chen et al., 2012, Correia et al., 2016). It is, therefore, 
reasonable to test whether HUVEC stimulation with FGF would upregulate 
miR-148b. It is well known that FGF promotes endothelial cell proliferation 
and is a strong inducer of angiogenesis (Ucuzian et al., 2010, Seghezzi et al., 
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1998). It is therefore interesting to see if miR-148b silencing using anti-miR in 
the stimulated HUVECs with FGF would attenuate pre-angiogenic effects of 
FGF. In that case, it would mean that FGF is acting via miR-148b dependent 
pathway. 
In this study, it has been demonstrated that miR-148b targets two key 
members of TGF-β pathway, TGFB2 and SMAD2. This shows that miR-148b is 
able to regulate the cascade at different levels. It would be interesting to see 
what other genes within TGF-β signalling can be modulated by miR-148b. For 
this, a specific TGF-β signalling array can be used to see which genes in the 
pathway are downregulated by miR-148b mimic. Indeed, TargetScan and 
MirPath analyses predict different components of TGF-β pathway, such as 
TGFBRAP1, GDF6, BMPR1B and others, to be miR-148b target genes. The 
whole miR-148b regulatory network could be identified by carrying out Ago2 
pulldown and then doing RNA sequencing to find all RNA molecules, which 
are bound to miR-148b-3p. 
In the in vivo part of the study there are two main experiments that could be 
carried out in the future. As mentioned previously, the wound healing model 
in this thesis is not long enough to see the fibrotic response. Therefore, it would 
be interesting to prolong the model and compare the collagen levels between 
control and anti-miR-148b treated wounds at later time points. Another output 
of wound healing process is scar formation. Notably, it has been reported that 
EndMT contributes to scar formation in the wounds (Patel et al., 2018). It 
would, thus, be interesting to investigate whether anti-miR-148b treatment 
would enhance the scarring in the wound. On the other hand, it is possible to 
assume that miR-148b mimic delivery would decrease the scar formation due 
to enhanced regenerative response. 
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Finally, it has been reported that angiogenesis is attenuated in the diabetic 
non-healing ulcers (Okonkwo and DiPietro, 2017, Drinkwater et al., 2002). 
Currently, there is no efficient treatment for this detrimental condition, which 
can ultimately lead to severe complications, including leg amputations. It is 
therefore important to understand whether miR-148b treatment could 
improve the closure of diabetic non-healing wounds. For this, an ex vivo model 
of wounding on the skin of diabetic patients can be employed, where miR-
148b mimics would be delivered to the induced wounds. The possible positive 
results from this study could initiate Phase I clinical trials, investigating the 
safety of miR-148-based therapy, preparing for the later efficacy studies. 
Current challenges with miRNA-based therapies include possible off-target 
effects, especially when miRNA therapeutics are delivered systemically. With 
this method, the pathological off-target effects are minimized due to a 
localized topical delivery directly to the wounds. 
Potentially, it might be also possible to use miR-148b-based therapy within 
other disease models such as myocardial infarction. After acute myocardial 
infarction, a significant ischemic injury occurs in the myocardium, which 
determines the size of the infarct. The restoration of the coronary blood flow 
using the stent implantation or coronary artery bypass surgery improves the 
outcome of the patients. However, the ischemic post-MI heart exerts 
microvascular rarefaction and dysfunction, which impairs the perfusion of the 
whole myocardium (Cochain et al., 2013). Thus, a pro-angiogenic therapy 
post-MI would be beneficial to restore the blood supply of the myocardium. 
In this context miR-148b-based therapeutics could prove to be effective in the 
perfusion of the infarcted myocardium. In order to remove the possible 
pathological system off-target effects, miR-148b oligos could be delivered 
locally during the angioplasty, either in free form or coupled to nanoparticles. 
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At the moment, the UK priority patent application has been filed to protect the 
intellectual property generated in this thesis. The technology of miR-148b-
based gene therapy could be licenced out to RNA delivery companies such as 
miRagen Therapeutics and Regulus Therapeutics, which can take this 
technology further, generating potential treatments and introducing them into 
clinical practice. 
Overall, the work presented in this thesis has identified the new role of miR-
148b in endothelial cell biology, emphasising its proangiogenic properties, 
which accelerate the wound healing process. Inhibition of miR-148b has been 
shown to have a detrimental effect on endothelium, promoting EndMT and 
attenuating the wound closure. The data from this study can be used further 
to generate miR-148b-based therapy for promoting wound repair, reducing 
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